

International ERS/ATS guidelines on definition, evaluation

European Respiratory Journal

43, 343-373

DOI: [10.1183/09031936.00202013](https://doi.org/10.1183/09031936.00202013)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Giving Asthma Support to Patients (GASP): a novel online asthma education, monitoring, assessment and management tool. <i>Journal of Primary Health Care</i> , 2014, 6, 238.	0.2	5
2	Lymphotoxin $\hat{I}^2$ Receptor Signaling Induces IL-8 Production in Human Bronchial Epithelial Cells. <i>PLoS ONE</i> , 2014, 9, e114791.	1.1	16
3	Severe Asthma. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2014, 111, 847-55.	0.6	79
4	Recent advances in chronotherapy for the management of asthma. <i>ChronoPhysiology and Therapy</i> , 0, , 125.	0.5	8
5	The Effects of Bronchiectasis on Asthma Exacerbation. <i>Tuberculosis and Respiratory Diseases</i> , 2014, 77, 209.	0.7	40
6	Targeting Immune Pathways for Therapy in Asthma and Chronic Obstructive Pulmonary Disease. <i>Annals of the American Thoracic Society</i> , 2014, 11, S322-S328.	1.5	85
7	Gene Expression in Relation to Exhaled Nitric Oxide Identifies Novel Asthma Phenotypes with Unique Biomolecular Pathways. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 190, 1363-1372.	2.5	162
9	Severe Asthma. <i>Annals of the American Thoracic Society</i> , 2014, 11, 996-997.	1.5	10
10	Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. <i>European Respiratory Journal</i> , 2014, 44, 267-267.	3.1	4
11	Interventional Pulmonology in the Pediatric Population. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2014, 35, 751-762.	0.8	5
13	Long-acting anticholinergic agents in patients with uncontrolled asthma: a systematic review and meta-analysis. <i>International Journal of Tuberculosis and Lung Disease</i> , 2014, 18, 1421-1430.	0.6	12
14	Magnetic Resonance Imaging of Inflammation in Subjects with Allergic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 620-622.	2.5	1
15	Destination Airway: Tracking Granulocytes in Asthma. <i>EBioMedicine</i> , 2014, 1, 105-106.	2.7	1
16	Interleukin-22 exacerbates airway inflammation induced by short-term exposure to cigarette smoke in mice. <i>Acta Pharmacologica Sinica</i> , 2014, 35, 1393-1401.	2.8	8
17	Severe Asthma: Pragmatic Clinical Lumping and Time for Investigational Splitting. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2014, 189, 619-620.	2.5	2
18	Animal Models of Allergic Airways Disease: Where Are We and Where to Next?. <i>Journal of Cellular Biochemistry</i> , 2014, 115, 2055-2064.	1.2	42
19	Developing and Emerging Clinical Asthma Phenotypes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 671-680.	2.0	86
20	Heterogeneity of phenotypes in severe asthmatics. The Belgian Severe Asthma Registry (BSAR). <i>Respiratory Medicine</i> , 2014, 108, 1723-1732.	1.3	215

#	ARTICLE	IF	CITATIONS
21	Breathing exercises for asthma. <i>Breathe</i> , 2014, 10, 312-322.	0.6	29
22	Central Hypoadrenalism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4027-4036.	1.8	80
23	Laryngeal botoxification for severe asthma. <i>Respirology</i> , 2014, 19, 467-468.	1.3	3
24	Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 1198-1204.	2.7	89
25	Asthma: pathogenesis and novel drugs for treatment. <i>BMJ, The</i> , 2014, 349, g5517-g5517.	3.0	189
26	Treatment adherence in asthmatic patients: The last frontier?. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 134, 1269-1270.	1.5	10
27	Hot tub Legionella pneumonia outbreak. <i>European Respiratory Journal</i> , 2014, 44, 1379-1381.	3.1	6
28	Airway and systemic eosinophilia in asthma: does site matter?. <i>European Respiratory Journal</i> , 2014, 44, 14-16.	3.1	5
30	Bronchial asthma: is personalized therapy on the horizon?. <i>Allergo Journal International</i> , 2014, 23, 246-251.	0.9	5
31	Weekly low-dose methotrexate for reduction of Global Initiative for Asthma Step 5 treatment in severe refractory asthma: study protocol for a randomized controlled trial. <i>Trials</i> , 2014, 15, 492.	0.7	5
32	Bronchial thermoplasty: a new therapeutic option for the treatment of severe, uncontrolled asthma in adults. <i>European Respiratory Review</i> , 2014, 23, 510-518.	3.0	62
33	Asthma: still a promising future?. <i>European Respiratory Review</i> , 2014, 23, 405-407.	3.0	25
34	Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. <i>European Respiratory Journal</i> , 2014, 44, 266-266.	3.1	0
35	Comment on: International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. <i>European Respiratory Journal</i> , 2014, 44, 267-268.	3.1	16
36	Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. <i>European Respiratory Journal</i> , 2014, 44, 1098-1099.	3.1	19
37	Trustworthy guidelines on severe asthma thanks to the ERS and ATS. <i>European Respiratory Journal</i> , 2014, 43, 315-318.	3.1	10
38	Defining Phenotypes in Asthma: A Step Towards Personalized Medicine. <i>Drugs</i> , 2014, 74, 719-728.	4.9	67
39	International European Respiratory Society/American Thoracic Society guidelines on severe asthma. <i>European Respiratory Journal</i> , 2014, 44, 1377-1378.	3.1	17

#	ARTICLE	IF	CITATIONS
40	Thermoplastie bronchique dans l'asthme. Revue Des Maladies Respiratoires Actualites, 2014, 6, 516-519.	0.0	0
41	Anticholinergics/Antimuscarinic Drugs in Asthma. Current Allergy and Asthma Reports, 2014, 14, 484.	2.4	13
43	Critical Review of Bronchial Thermoplasty: Where Should It Fit into Asthma Therapy?. Current Allergy and Asthma Reports, 2014, 14, 470.	2.4	9
44	International European Respiratory Society/American Thoracic Society guidelines on severe asthma. European Respiratory Journal, 2014, 44, 1378-1379.	3.1	33
46	Mujer de 51 años que consulta por tos, pitos y disnea. Medicine, 2014, 11, 3918.e1-3918.e3.	0.0	0
47	Targeted omics and systems medicine: personalising care. Lancet Respiratory Medicine, 2014, 2, 785-787.	5.2	20
48	The role of mepolizumab in atopic and nonatopic severe asthma with persistent eosinophilia. European Respiratory Journal, 2014, 44, 239-241.	3.1	70
49	Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. European Respiratory Journal, 2014, 44, 97-108.	3.1	171
50	Importance of concomitant local and systemic eosinophilia in uncontrolled asthma. European Respiratory Journal, 2014, 44, 1096-1098.	3.1	2
51	Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. New England Journal of Medicine, 2014, 371, 1189-1197.	13.9	1,331
52	MicroRNA: Potential biomarkers and therapeutic targets for allergic asthma?. Annals of Medicine, 2014, 46, 633-639.	1.5	21
53	Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma. New England Journal of Medicine, 2014, 371, 1198-1207.	13.9	1,807
54	Chloride channel blockade relaxes airway smooth muscle and potentiates relaxation by $\beta_2$ -agonists. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2014, 307, L273-L282.	1.3	17
55	Adjuvant-dependent regulation of interleukin-17 expressing $\gamma\delta$ T cells and inhibition of Th2 responses in allergic airways disease. Respiratory Research, 2014, 15, 90.	1.4	31
56	Severe Asthma in Children. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 489-500.	2.0	140
57	Prevalence of severe childhood asthma according to the WHO. Respiratory Medicine, 2014, 108, 1234-1237.	1.3	62
58	25-Hydroxyvitamin D3-Deficiency Enhances Oxidative Stress and Corticosteroid Resistance in Severe Asthma Exacerbation. PLoS ONE, 2014, 9, e111599.	1.1	78
59	Defining severe asthma – an approach to find new therapies. European Clinical Respiratory Journal, 2014, 1, 24356.	0.7	3

#	ARTICLE	IF	CITATIONS
60	Bronchial Thermoplasty. <i>Chest</i> , 2014, 146, 17-21.	0.4	34
61	Is the Eosinophil a Leading Villain in Lung Function Decline?. <i>Chest</i> , 2015, 148, 844-846.	0.4	6
63	Unraveling the Pathophysiology of the Asthma-COPD Overlap Syndrome. <i>Chest</i> , 2015, 148, 313-320.	0.4	45
64	Epigenome-modifying tools in asthma. <i>Epigenomics</i> , 2015, 7, 1017-1032.	1.0	49
65	Severe asthma: Epidemiology, burden of illness, and heterogeneity. <i>Allergy and Asthma Proceedings</i> , 2015, 36, 418-424.	1.0	72
66	STRATOS 1 and 2: considerations in clinical trial design for a fully human monoclonal antibody in severe asthma. <i>Clinical Investigation</i> , 2015, 5, 701-711.	0.0	15
67	The GINA asthma strategy report: what's new for primary care?. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15050.	1.1	61
68	Why aren't we doing better in asthma: time for personalised medicine?. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 15004.	1.1	42
69	A historical perspective: Are inhaled corticoids sufficient to control asthma?. <i>Journal of Translational Internal Medicine</i> , 2015, 3, 113-115.	1.0	2
70	Severe asthma in childhood. <i>Italian Journal of Pediatrics</i> , 2015, 41, .	1.0	0
71	Asthma attacks: how can we reduce the risks?. <i>Npj Primary Care Respiratory Medicine</i> , 2015, 25, 14105.	1.1	4
72	Allergic asthma. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 216-222.	0.1	0
73	“Difficult Asthma” Not as Easy as You Think. <i>Chest</i> , 2015, 148, 843-844.	0.4	5
76	Vocal cord dysfunction: asking the right questions. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1374-1375.	1.4	2
77	Induced sputum supernatant bioactive lipid mediators can identify subtypes of asthma. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1779-1789.	1.4	27
78	Trans-basement membrane migration of eosinophils induced by LPS-stimulated neutrophils from human peripheral blood <i>in vitro</i> . <i>ERJ Open Research</i> , 2015, 1, 00003-2015.	1.1	17
79	Reducing asthma attacks in patients with severe asthma: The role of bronchial thermoplasty. <i>Allergy and Asthma Proceedings</i> , 2015, 36, 242-250.	1.0	6
80	Bronchial thermoplasty: Where there is smoke, there is fire. <i>Allergy and Asthma Proceedings</i> , 2015, 36, 251-255.	1.0	10

#	ARTICLE	IF	CITATIONS
81	Anxiety but not depression symptoms are associated with greater perceived dyspnea in asthma during bronchoconstriction. <i>Allergy and Asthma Proceedings</i> , 2015, 36, 447-457.	1.0	23
82	Work-Related Asthma. <i>Journal of Occupational and Environmental Medicine</i> , 2015, 57, e121-e129.	0.9	18
83	Addressing the challenges of severe asthma. <i>Allergy and Asthma Proceedings</i> , 2015, 36, 237-239.	1.0	5
84	The past, present, and future of monoclonal antibodies to IL-5 and eosinophilic asthma: a review. <i>Journal of Asthma and Allergy</i> , 2015, 8, 125.	1.5	34
85	Profile of lebrikizumab and its potential in the treatment of asthma. <i>Journal of Asthma and Allergy</i> , 2015, 8, 87.	1.5	15
86	Clinical characteristics of children and adolescents with severe therapy-resistant asthma in Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 2015, 41, 343-350.	0.4	12
87	Unrecognised psychopathology in patients with difficult asthma: major mental and personality disorders. <i>BJPsych Open</i> , 2015, 1, 14-17.	0.3	5
88	Indications for the use of bronchial thermoplasty in severe asthma. <i>South African Medical Journal</i> , 2015, 105, 808.	0.2	0
89	Association of Sand Dust Particles with Pulmonary Function and Respiratory Symptoms in Adult Patients with Asthma in Western Japan Using Light Detection and Ranging: A Panel Study. <i>International Journal of Environmental Research and Public Health</i> , 2015, 12, 13038-13052.	1.2	17
90	Chronic Comorbidities Contribute to the Burden and Costs of Persistent Asthma. <i>Mediators of Inflammation</i> , 2015, 2015, 1-7.	1.4	30
91	Analysis of a Panel of 48 Cytokines in BAL Fluids Specifically Identifies IL-8 Levels as the Only Cytokine that Distinguishes Controlled Asthma from Uncontrolled Asthma, and Correlates Inversely with FEV1. <i>PLoS ONE</i> , 2015, 10, e0126035.	1.1	82
92	Positioning new pharmacotherapies for COPD. <i>International Journal of COPD</i> , 2015, 10, 1427.	0.9	24
93	Six-minute walk test and respiratory muscle strength in patients with uncontrolled severe asthma: a pilot study. <i>Jornal Brasileiro De Pneumologia</i> , 2015, 41, 211-218.	0.4	7
94	Airway<math>\alpha</math>-Defensin-1 Protein Is Elevated in COPD and Severe Asthma. <i>Mediators of Inflammation</i> , 2015, 2015, 1-8.	1.4	23
95	Recommendations for the use of bronchial thermoplasty in the management of severe asthma. <i>South African Medical Journal</i> , 2015, 105, 726.	0.2	3
96	The revised 2014 GINA strategy report. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 1-7.	1.2	116
97	Usefulness of Noninvasive Methods for the Study of Bronchial Inflammation in the Control of Patients with Asthma. <i>International Archives of Allergy and Immunology</i> , 2015, 166, 1-12.	0.9	17
98	Lung abscess as a complication of bronchial thermoplasty. <i>Journal of Asthma</i> , 2015, 52, 740-742.	0.9	16

#	ARTICLE	IF	CITATIONS
99	Asthma control and exacerbations in patients with severe asthma treated with omalizumab in Portugal. <i>Revista Portuguesa De Pneumologia</i> , 2015, 21, 327-333.	0.7	8
100	The discovery and development of omalizumab for the treatment of asthma. <i>Expert Opinion on Drug Discovery</i> , 2015, 10, 1033-1042.	2.5	64
101	Are the antimicrobial properties of macrolides required for their therapeutic efficacy in chronic neutrophilic airway diseases?. <i>Thorax</i> , 2015, 70, 401-403.	2.7	8
102	Innate immunity is a key factor for the resolution of inflammation in asthma. <i>European Respiratory Review</i> , 2015, 24, 141-153.	3.0	46
103	Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 135-145.	1.0	39
104	Real-life long-term omalizumab therapy in children with severe allergic asthma. <i>European Respiratory Journal</i> , 2015, 46, 856-859.	3.1	97
105	A potential immunopathogenic role for reduced IL-35 expression in allergic asthma. <i>Journal of Asthma</i> , 2015, 52, 763-771.	0.9	21
106	Steps to better understand severe asthma in adults. <i>The Prescriber</i> , 2015, 26, 29-33.	0.1	8
107	Predicting asthma morbidity in children using proposed markers of Th2aC type inflammation. <i>Pediatric Allergy and Immunology</i> , 2015, 26, 772-779.	1.1	52
108	Adjusting prednisone using blood eosinophils reduces exacerbations and improves asthma control in difficult patients with asthma. <i>Respirology</i> , 2015, 20, 1282-1284.	1.3	33
109	Guidance on handheld inhalers in asthma and COPD guidelines: An update. <i>Respiratory Medicine</i> , 2015, 109, 1592-1593.	1.3	6
111	Dedicated Severe Asthma Services Improve Health-care Use and Quality of Life. <i>Chest</i> , 2015, 148, 870-876.	0.4	100
112	Systematic Review on the Definition of Allergic Diseases in Children: The MeDALL Study. <i>International Archives of Allergy and Immunology</i> , 2015, 168, 110-121.	0.9	18
113	Low interleukin (IL)-18 levels in sputum supernatants of patients with severe refractory asthma. <i>Respiratory Medicine</i> , 2015, 109, 580-587.	1.3	11
115	What goes up must come down: biomarkers and novel biologicals in severe asthma. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1162-1169.	1.4	25
116	Toll-like receptor 9 dependent interferon- $\gamma$ release is impaired in severe asthma but is not associated with exacerbation frequency. <i>Immunobiology</i> , 2015, 220, 859-864.	0.8	9
117	Normativa sobre asma grave no controlada. <i>Archivos De Bronconeumologia</i> , 2015, 51, 235-246.	0.4	30
118	Heterogeneity in mechanisms influencing glucocorticoid sensitivity: The need for a systems biology approach to treatment of glucocorticoid-resistant inflammation. , 2015, 150, 81-93.		29

#	ARTICLE	IF	CITATIONS
119	Phenotype of asthmatics with increased airway <i>S</i> -nitrosoglutathione reductase activity. <i>European Respiratory Journal</i> , 2015, 45, 87-97.	3.1	26
120	Nasal IL-17F is related to bronchial IL-17F/neutrophilia and exacerbations in stable atopic severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 236-240.	2.7	52
121	Serum Apolipoprotein A-I and Large High-Density Lipoprotein Particles Are Positively Correlated with FEV <sub>1</sub> in Atopic Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 990-1000.	2.5	66
122	Nasal lavage is better than blood count in predicting sputum eosinophilia. <i>Clinical and Experimental Allergy</i> , 2015, 45, 1006-1008.	1.4	3
123	The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 36-43.	1.0	26
124	Modern methods for endoscopic treatment of obstructive pulmonary diseases. <i>Journal of Asthma</i> , 2015, 52, 920-925.	0.9	2
125	Misdiagnosis Among Frequent Exacerbators of Clinically Diagnosed Asthma and COPD in Absence of Confirmation of Airflow Obstruction. <i>Lung</i> , 2015, 193, 505-512.	1.4	28
126	A Nonmuscle Myosin Light Chain Kinase-Dependent Gene Signature in Peripheral Blood Mononuclear Cells is Linked to Human Asthma Severity and Exacerbation Status. <i>Pulmonary Circulation</i> , 2015, 5, 335-338.	0.8	9
127	Bronchial thermoplasty in asthma: current perspectives. <i>Journal of Asthma and Allergy</i> , 2015, 8, 39.	1.5	23
128	Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. <i>Lancet Respiratory Medicine</i> , 2015, 3, 692-701.	5.2	318
129	Contrôle de l'asthme : quels objectifs réalistes?. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 164-167.	0.0	0
130	Cysteine oxidation impairs systemic glucocorticoid responsiveness in children with difficult-to-treat asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 454-461.e9.	1.5	20
131	Airway Inflammation after Bronchial Thermoplasty for Severe Asthma. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1302-1309.	1.5	82
132	Eosinophilia in Pulmonary Disorders. <i>Immunology and Allergy Clinics of North America</i> , 2015, 35, 477-492.	0.7	17
134	ASMA SEVERA EN ADULTOS: ENFOQUE DIAGNÓSTICO Y TRATAMIENTO. <i>Revista Médica Clínica Las Condes</i> , 2015, 26, 267-275.	0.2	2
135	Ring in the new. <i>Thorax</i> , 2015, 70, 403-403.	2.7	0
136	Severe Asthma in School-Age Children: Evaluation and Phenotypic Advances. <i>Current Allergy and Asthma Reports</i> , 2015, 15, 20.	2.4	15
137	Corticosteroid insensitive alveolar macrophages from asthma patients; synergistic interaction with a p38 mitogen-activated protein kinase (MAPK) inhibitor. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 756-766.	1.1	24



#	ARTICLE	IF	CITATIONS
138	Intranasal administration of CpG oligodeoxynucleotides reduces lower airway inflammation in a murine model of combined allergic rhinitis and asthma syndrome. <i>International Immunopharmacology</i> , 2015, 28, 390-398.	1.7	19
139	Respiratory Disorders Related to Smoking Tobacco. <i>Progress in Respiratory Research</i> , 0, , 72-84.	0.1	0
140	Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. <i>European Respiratory Journal</i> , 2015, 46, 688-696.	3.1	137
141	Little orphan asthmas?. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 903-904.	1.5	2
142	Combining the Mannitol Test and FeNO in the Assessment of Poorly Controlled Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2015, 3, 553-559.	2.0	9
143	Biomarkers and inhaled corticosteroid responsiveness in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 884-885.	1.5	5
144	Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. <i>Lancet Respiratory Medicine</i> , the, 2015, 3, 290-300.	5.2	202
145	Computed Tomography Assessment of Airways Throughout Bronchial Tree Demonstrates Airway Narrowing in Severe Asthma. <i>Academic Radiology</i> , 2015, 22, 734-742.	1.3	15
146	Distinct endotypes of steroid-resistant asthma characterized by IL-17A <sup>high</sup> and IFN- $\gamma$ <sup>high</sup> immunophenotypes: Potential benefits of calcitriol. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 628-637.e4.	1.5	170
147	Guidelines for Severe Uncontrolled Asthma. <i>Archivos De Bronconeumologia</i> , 2015, 51, 235-246.	0.4	17
148	No evidence for altered intracellular calcium-handling in airway smooth muscle cells from human subjects with asthma. <i>BMC Pulmonary Medicine</i> , 2015, 15, 12.	0.8	7
149	Recurrent lung atelectasis from fibrin plugs as a very early complication of bronchial thermoplasty: a case report. <i>Multidisciplinary Respiratory Medicine</i> , 2015, 10, 9.	0.6	27
150	Pharmacological approach to treating eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss). <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 505-515.	0.5	0
151	The ambition of the European Respiratory Journal: chapter 3. <i>European Respiratory Journal</i> , 2015, 45, 1-6.	3.1	11
152	The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and Meta-analysis. <i>Lung</i> , 2015, 193, 477-486.	1.4	12
153	Eosinophilic granulomatosis with polyangiitis (Churgâ€“Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management. <i>European Journal of Internal Medicine</i> , 2015, 26, 545-553.	1.0	371
154	Tiotropium RespimatÂ®: A Review of Its Use in Asthma Poorly Controlled with Inhaled Corticosteroids and Long-Acting $\beta$ 2-Adrenergic Agonists. <i>Drugs</i> , 2015, 75, 809-816.	4.9	7
155	Mepolizumab for eosinophilic severe asthma: recent studies. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 909-914.	1.4	11

#	ARTICLE	IF	CITATIONS
156	Microbiota in Allergy and Asthma and the Emerging Relationship with the Gut Microbiome. <i>Cell Host and Microbe</i> , 2015, 17, 592-602.	5.1	327
157	What about Targeting Smooth Muscle Remodeling in Severe Asthma?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 6-8.	2.5	3
158	Asthma-COPD overlap 2015: now we are six. <i>Thorax</i> , 2015, 70, 683-691.	2.7	176
159	Therapeutic implications of "neutrophilic asthma"™. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 33-38.	1.2	39
160	Near-Fatal Asthma in the Elderly. <i>Dimensions of Critical Care Nursing</i> , 2015, 34, 26-32.	0.4	4
161	Managing severe asthma in adults. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 8-15.	1.2	24
162	Translational value of animal models of asthma: Challenges and promises. <i>European Journal of Pharmacology</i> , 2015, 759, 272-277.	1.7	45
163	Antifungals in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 48-54.	1.2	17
164	Severe asthma in childhood. <i>Current Opinion in Pulmonary Medicine</i> , 2015, 21, 16-21.	1.2	7
165	Clinical phenotypes of asthma should link up with disease mechanisms. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 56-62.	1.1	26
166	The prevalence of severe refractory asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 896-902.	1.5	582
167	ERS guidelines, statements and technical standards published in the <i>ERJ</i> in 2014: a year in review. <i>European Respiratory Journal</i> , 2015, 45, 863-866.	3.1	10
168	Psychological aspects in asthma: do psychological factors affect asthma management?. <i>Asthma Research and Practice</i> , 2015, 1, 7.	1.2	49
169	Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. <i>European Respiratory Journal</i> , 2015, 46, 1308-1321.	3.1	434
170	The Asthma-COPD Overlap Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 1241-1249.	13.9	489
171	Update on reslizumab for eosinophilic asthma. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1531-1539.	1.4	20
172	The burden of severe asthma in childhood and adolescence: results from the paediatric U-BIOPRED cohorts. <i>European Respiratory Journal</i> , 2015, 46, 1322-1333.	3.1	179
173	Prise en charge de l'asthme non contrôlé: du diagnostic au traitement. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 200-206.	0.0	0

#	ARTICLE	IF	CITATIONS
174	The quest for the grail: multidimensional efforts for understanding and targeting severe asthma. <i>European Respiratory Journal</i> , 2015, 46, 1227-1231.	3.1	8
175	Biomarkers of asthma and allergic airway diseases. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 115, 335-340.	0.5	26
176	Phenotypes of severe asthma among children and adolescents in Brazil: a prospective study. <i>BMC Pulmonary Medicine</i> , 2015, 15, 36.	0.8	10
177	Novel imaging approaches in adult asthma and their clinical potential. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1147-1162.	1.3	6
178	The need to differentiate between adults and children when treating severe asthma. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 419-428.	1.0	13
179	Control of asthma in real life: still a valuable goal?. <i>European Respiratory Review</i> , 2015, 24, 361-369.	3.0	43
180	Distinct Phenotypes of Cigarette Smokers Identified by Cluster Analysis of Patients with Severe Asthma. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1771-1780.	1.5	15
181	Roflumilast for asthma: Efficacy findings in non-placebo-controlled comparator and dosing studies. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 35, S11-S19.	1.1	21
182	Update on the current methods for the diagnosis and treatment of severe childhood asthma. <i>Expert Review of Respiratory Medicine</i> , 2015, 9, 769-777.	1.0	6
183	The airway microbiome in patients with severe asthma: Associations with disease features and severity. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 874-884.	1.5	395
184	Drug therapies in severe asthma – the era of stratified medicine. <i>Clinical Medicine</i> , 2015, 15, 452-456.	0.8	11
185	Clinical asthma phenotypes in the real world: opportunities and challenges. <i>Breathe</i> , 2015, 11, 186-193.	0.6	26
186	Treatment of severe asthma: entering the era of targeted therapy. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1713-1725.	1.4	13
187	Omalizumab therapy for children and adolescents with severe allergic asthma. <i>Expert Review of Clinical Immunology</i> , 2015, 11, 1309-1319.	1.3	4
188	Targeting the interleukin pathway in the treatment of asthma. <i>Lancet, The</i> , 2015, 386, 1086-1096.	6.3	230
189	Calcium Channel Blocker Reduces Airway Remodeling – Or Does It?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 863-864.	2.5	4
190	New and future strategies to improve asthma control in children. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 136, 848-859.	1.5	80
191	GINA 2015: the latest iteration of a magnificent journey. <i>European Respiratory Journal</i> , 2015, 46, 579-582.	3.1	16

#	ARTICLE	IF	CITATIONS
192	Clinically relevant subgroups in COPD and asthma. <i>European Respiratory Review</i> , 2015, 24, 283-298.	3.0	35
193	A summary of the new GINA strategy: a roadmap to asthma control. <i>European Respiratory Journal</i> , 2015, 46, 622-639.	3.1	636
195	Should lung biopsies be performed in patients with severe asthma?. <i>European Respiratory Review</i> , 2015, 24, 525-539.	3.0	19
196	European Resuscitation Council Guidelines for Resuscitation 2015. <i>Resuscitation</i> , 2015, 95, 148-201.	1.3	696
197	Biomarkers and severe asthma: a critical appraisal. <i>Clinical and Molecular Allergy</i> , 2015, 13, 20.	0.8	49
198	Pathobiology of Severe Asthma. <i>Annual Review of Pathology: Mechanisms of Disease</i> , 2015, 10, 511-545.	9.6	100
199	Phenotype of asthma related with high serum periostin levels. <i>Allergology International</i> , 2015, 64, 175-180.	1.4	102
200	New insights into the treatment of severe asthma in children. <i>Paediatric Respiratory Reviews</i> , 2015, 16, 167-173.	1.2	6
201	Indoor fungal diversity and asthma: A meta-analysis and systematic review of risk factors. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 110-122.	1.5	240
202	Current concepts of severe asthma. <i>Journal of Clinical Investigation</i> , 2016, 126, 2394-2403.	3.9	188
203	Long-term safety of tiotropium delivered by Respimat <sup>®</sup> SoftMist <sup>®</sup> Inhaler: patient selection and special considerations. <i>Therapeutics and Clinical Risk Management</i> , 2016, Volume 12, 1433-1444.	0.9	4
204	Challenges in the management of severe allergic asthma in the elderly. <i>Journal of Asthma and Allergy</i> , 2016, 9, 55.	1.5	2
205	Tratamiento del asma severo con Omalizumab: experiencia pediátrica en Chile y revisión de la literatura. <i>Revista Chilena De Enfermedades Respiratorias</i> , 2016, 32, 160-168.	0.1	0
206	Severe Asthma: Moving from Phenotype to Endotype Classification with Updates on Treatment. <i>Journal of Nursing &amp; Care</i> , 2016, 05, .	0.1	0
207	IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. <i>Journal of Immunology Research</i> , 2016, 2016, 1-12.	0.9	77
208	How Effective and Safe Is Bronchial Thermoplasty in "Real Life" Asthmatics Compared to Those Enrolled in Randomized Clinical Trials?. <i>BioMed Research International</i> , 2016, 2016, 1-3.	0.9	6
209	Importance of fractional exhaled nitric oxide in the differentiation of asthma&ndash;COPD overlap syndrome, asthma, and COPD. <i>International Journal of COPD</i> , 2016, Volume 11, 2385-2390.	0.9	43
210	Association between severe asthma and changes in the stomatognathic system. <i>Jornal Brasileiro De Pneumologia</i> , 2016, 42, 423-428.	0.4	10

#	ARTICLE	IF	CITATIONS
211	Delivery of RNAi Therapeutics to the Airwaysâ€”From Bench to Bedside. <i>Molecules</i> , 2016, 21, 1249.	1.7	54
212	Allergic Fungal Airway Disease. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2016, 26, 344-354.	0.6	76
213	Economic Burden of Illness Among Patients with Severe Asthma in a Managed Care Setting. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2016, 22, 848-861.	0.5	68
214	A review of omalizumab for the management of severe asthma. <i>Drug Design, Development and Therapy</i> , 2016, Volume 10, 2369-2378.	2.0	22
215	Clinical usefulness of mepolizumab in severe eosinophilic asthma. <i>Therapeutics and Clinical Risk Management</i> , 2016, 12, 907.	0.9	19
216	Biomarkers in the Management of Difficult Asthma. <i>Current Topics in Medicinal Chemistry</i> , 2016, 16, 1561-1573.	1.0	45
217	Role of T2 inflammation biomarkers in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 59-68.	1.2	65
218	Staphylococcal enterotoxin IgE sensitization in lateâ€”onset severe eosinophilic asthma in the elderly. <i>Clinical and Experimental Allergy</i> , 2016, 46, 411-421.	1.4	62
219	Airway Microbiota and the Implications of Dysbiosis in Asthma. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 52.	2.4	48
220	Asthma phenotypes and endotypes. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 3-9.	1.2	52
221	Infection and inflammation in induced sputum from preschool children with chronic airways diseases. <i>Pediatric Pulmonology</i> , 2016, 51, 778-786.	1.0	46
222	Pathogenesis and prevention strategies of severe asthma exacerbations in children. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 25-31.	1.2	13
223	Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. <i>Shock</i> , 2016, 46, 239-248.	1.0	259
224	Biomarkers and asthma management. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 210-217.	1.1	11
225	Effect of Antiâ€”IL-13 Treatment on Airway Dimensions in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 118-120.	2.5	13
226	Eosinophilic bioactivities in severe asthma. <i>World Allergy Organization Journal</i> , 2016, 9, 21.	1.6	66
227	Profile of difficult to treat asthma patients referred for systematic assessment. <i>Respiratory Medicine</i> , 2016, 117, 166-173.	1.3	47
228	Moving towards precision care for childhood asthma. <i>Current Opinion in Pediatrics</i> , 2016, 28, 331-338.	1.0	12

#	ARTICLE	IF	CITATIONS
229	Asthma control and exacerbations. <i>Current Opinion in Pulmonary Medicine</i> , 2016, 22, 32-37.	1.2	15
230	Toward better management of rare and orphan pulmonary diseases. <i>European Respiratory Journal</i> , 2016, 47, 1334-1335.	3.1	5
232	Asthma heterogeneity and severity. <i>World Allergy Organization Journal</i> , 2016, 9, 41.	1.6	73
233	Targeting immunoglobulin E in non-atopic asthma: crossing the red line?. <i>European Respiratory Journal</i> , 2016, 48, 1538-1540.	3.1	4
234	Asthma attacks: should we nail our colours to the mast (cell)?. <i>European Respiratory Journal</i> , 2016, 48, 1261-1264.	3.1	2
235	Assessment of work-related asthma prevalence, control and severity: protocol of a field study. <i>BMC Public Health</i> , 2016, 16, 1164.	1.2	5
236	Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study). <i>BMJ Open</i> , 2016, 6, e011857.	0.8	61
237	Management of difficult to treat severe asthma—what's the evidence?. <i>Drug and Therapeutics Bulletin</i> , 2016, 54, 126-129.	0.3	1
238	Simulation of Forced Expiration in a Biophysical Model, With Homogeneous and Clustered Bronchoconstriction. <i>Journal of Biomechanical Engineering</i> , 2016, 138, 061008.	0.6	9
239	Severe asthma: anti-IgE or anti-IL-5?. <i>European Clinical Respiratory Journal</i> , 2016, 3, 31813.	0.7	22
240	Step 4: stick or twist? A review of asthma therapy. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000143.	1.2	3
241	Asthma phenotypes in children and stratified pharmacological treatment regimens. <i>Expert Review of Clinical Pharmacology</i> , 2016, 10, 1-11.	1.3	7
243	Observational Study of Methotrexate in the Treatment of Bronchiolitis Obliterans Syndrome. <i>Transplantation Proceedings</i> , 2016, 48, 3387-3392.	0.3	9
244	Therapeutic interventions in severe asthma. <i>World Allergy Organization Journal</i> , 2016, 9, 40.	1.6	38
245	Fatal asthma; is it still an epidemic?. <i>World Allergy Organization Journal</i> , 2016, 9, 42.	1.6	27
247	Severe asthma and asthma-chronic obstructive pulmonary disease syndrome. <i>Lancet, The</i> , 2016, 388, 2741-2742.	6.3	2
248	Serum progranulin as an indicator of neutrophilic airway inflammation and asthma severity. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 646-650.	0.5	15
249	L'asthme sévère, une maladie difficile. <i>Revue Des Maladies Respiratoires Actualites</i> , 2016, 8, 226-230.	0.0	0

#	ARTICLE	IF	CITATIONS
250	Increased circulating IL-9-producing CD8+ T cells are associated with eosinophilia and high FeNO in allergic asthmatics. <i>Experimental and Therapeutic Medicine</i> , 2016, 12, 4055-4060.	0.8	8
251	Comparison of Costs and Clinical Outcomes Between Hospital and Outpatient Administration of Omalizumab in Patients With Severe Uncontrolled Asthma. <i>Archivos De Bronconeumologia</i> , 2016, 52, 211-216.	0.4	2
252	The enigmatic role of IL-22 in asthma. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 619-623.	1.0	3
253	The management of asthma in the phenotype and biomarker era: The proposal of a new diagnostic-therapeutic model. <i>Journal of Asthma</i> , 2016, 53, 665-667.	0.9	8
255	Case reports “When bronchial obstruction in the young adult is not asthma and inhalers do not help. <i>Journal of Asthma</i> , 2016, 53, 660-664.	0.9	0
256	Asthme s’vire: quels pneumallergènes?. <i>Revue Francaise D’allergologie</i> , 2016, 56, 163-164.	0.1	1
257	Future treatment for asthma. <i>European Respiratory Review</i> , 2016, 25, 77-92.	3.0	17
258	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. <i>European Respiratory Journal</i> , 2016, 47, 1028-1033.	3.1	50
259	Assessment of corticosteroid response in pediatric patients with severe asthma by using a multidomain approach. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 413-420.e6.	1.5	63
260	Asthmatic granulomatosis. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 581-582.	0.5	0
261	Asthma-COPD Overlap Syndrome (ACOS): Single disease entity or not? Could exhaled nitric oxide be a useful biomarker for the differentiation of ACOS, asthma and COPD?. <i>Medical Hypotheses</i> , 2016, 91, 20-23.	0.8	21
262	Toll-Like Receptor 7-Targeted Therapy in Respiratory Disease. <i>Transfusion Medicine and Hemotherapy</i> , 2016, 43, 114-119.	0.7	15
263	Could relative abundance of airway lipoxins be the clue to restore corticosteroid sensitivity in severe asthma?. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1807-1808.	1.5	1
264	Variability in Asthma Inflammatory Phenotype in Induced Sputum. Frequency and Causes. <i>Archivos De Bronconeumologia</i> , 2016, 52, 76-81.	0.4	10
265	Mepolizumab for the reduction of exacerbations in severe eosinophilic asthma. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 607-617.	1.0	8
266	The cytokine interleukin-26 as a biomarker in pediatric asthma. <i>Respiratory Research</i> , 2016, 17, 32.	1.4	31
267	Toward precision medicine and health: Opportunities and challenges in allergic diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1289-1300.	1.5	75
268	Asthma inflammatory phenotypes show differential microRNA expression in sputum. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1433-1446.	1.5	168

#	ARTICLE	IF	CITATIONS
269	Utility of Induced Sputum in Routine Clinical Practice. <i>Archivos De Bronconeumologia</i> , 2016, 52, 250-255.	0.4	2
270	Airway smooth muscle enlargement is associated with protease-activated receptor 2/ligand overexpression in patients with difficult-to-control severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 729-739.e11.	1.5	26
271	Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting $\beta_2$ agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. <i>Lancet, The</i> , 2016, 388, 31-44.	6.3	760
272	Dupilumab: a potential new treatment for severe asthma. <i>Lancet, The</i> , 2016, 388, 3-4.	6.3	17
273	What lies beyond Asthma Control Test: Suggestions for clinical practice. <i>Journal of Asthma</i> , 2016, 53, 559-562.	0.9	5
274	Herbal medicine for adults with asthma: A systematic review. <i>Journal of Asthma</i> , 2016, 53, 650-659.	0.9	43
275	Lebrikizumab in the treatment of asthma. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 847-852.	1.4	5
277	Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. <i>Lancet Respiratory Medicine,the</i> , 2016, 4, 549-556.	5.2	433
278	Respiratory clinical guidelines inform ward-based nurses' clinical skills and knowledge required for evidence-based care. <i>Breathe</i> , 2016, 12, 257-266.	0.6	3
279	Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg's/Strauss). <i>European Respiratory Journal</i> , 2016, 48, 1429-1441.	3.1	102
280	New sociology for better understanding severe eosinophilic asthma: introducing the SOCS family. <i>European Respiratory Journal</i> , 2016, 48, 608-610.	3.1	2
281	Benralizumab, an anti-interleukin-5 receptor $\beta_2$ monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016, 388, 2128-2141.	6.3	1,070
282	Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting $\beta_2$ -agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2016, 388, 2115-2127.	6.3	1,050
283	Biomarkers of Airway Type-2 Inflammation and Integrating Complex Phenotypes to Endotypes in Asthma. <i>Current Allergy and Asthma Reports</i> , 2016, 16, 71.	2.4	12
284	Anti-IL-5 for Severe Asthma. <i>Chest</i> , 2016, 150, 766-768.	0.4	13
285	Asthma and Hypogammaglobulinemia: an Asthma Phenotype with Low Type 2 Inflammation. <i>Journal of Clinical Immunology</i> , 2016, 36, 810-817.	2.0	16
286	Effects of older age and age of asthma onset on clinical and inflammatory variables in severe refractory asthma. <i>Respiratory Medicine</i> , 2016, 118, 46-52.	1.3	12
287	Prostaglandin D 2 receptor antagonism: a novel therapeutic option for eosinophilic asthma?. <i>Lancet Respiratory Medicine,the</i> , 2016, 4, 676-677.	5.2	7



#	ARTICLE	IF	CITATIONS
288	Comorbidities in difficult asthma are independent risk factors for frequent exacerbations, poor control and diminished quality of life. <i>Respirology</i> , 2016, 21, 1384-1390.	1.3	148
289	Predictors of future exacerbation risk in patients with asthma. <i>Postgraduate Medicine</i> , 2016, 128, 687-692.	0.9	11
290	Sex differences in asthma and gastroesophageal reflux disease incidence among the World Trade Center Health Program General Responder Cohort. <i>American Journal of Industrial Medicine</i> , 2016, 59, 815-822.	1.0	3
291	Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1335-1344.	2.7	93
292	Asthma phenotyping: a necessity for improved therapeutic precision and new targeted therapies. <i>Journal of Internal Medicine</i> , 2016, 279, 192-204.	2.7	130
293	Asthma phenotyping: noninvasive biomarkers suitable for bedside science are the next step to implement precision medicine. <i>Journal of Internal Medicine</i> , 2016, 279, 205-207.	2.7	9
294	Elucidating novel disease mechanisms in severe asthma. <i>Clinical and Translational Immunology</i> , 2016, 5, e91.	1.7	28
295	Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry. <i>Internal Medicine Journal</i> , 2016, 46, 1054-1062.	0.5	68
297	Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study. <i>Clinical Therapeutics</i> , 2016, 38, 2058-2070.e1.	1.1	228
298	Evaluation of exhaled nitric oxide's ability to predict methacholine challenge in adults with nonobstructive spirometry. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 117, 365-369.e1.	0.5	6
299	Step-down treatment from medium-dosage of budesonide/formoterol in controlled asthma. <i>Respiratory Medicine</i> , 2016, 119, 1-6.	1.3	14
300	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	1.4	47
301	Predictors of frequent exacerbations in (ex)smoking and never smoking adults with severe asthma. <i>Respiratory Medicine</i> , 2016, 118, 122-127.	1.3	21
302	Measures to reduce maintenance therapy with oral corticosteroid in adults with severe asthma. <i>Allergy and Asthma Proceedings</i> , 2016, 37, 125-139.	1.0	9
303	Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. <i>Clinical and Experimental Allergy</i> , 2016, 46, 1407-1415.	1.4	29
304	Role of Sleep Apnea and Gastroesophageal Reflux in Severe Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 461-471.	0.7	13
305	Diagnosis and management of asthma – Statement on the 2015 GINA Guidelines. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 541-554.	1.0	93
306	Dysfunctional breathing and reaching one's physiological limit as causes of exercise-induced dyspnoea. <i>Breathe</i> , 2016, 12, 120-129.	0.6	58

#	ARTICLE	IF	CITATIONS
307	Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation. <i>Pulmonary Pharmacology and Therapeutics</i> , 2016, 40, 52-68.	1.1	25
308	Biomarkers in Severe Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 547-557.	0.7	40
309	Imaging of Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 529-545.	0.7	13
310	Traditional Therapies for Severe Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 581-608.	0.7	5
311	Emerging Biologics in Severe Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 609-623.	0.7	9
312	Prostaglandin D2 receptor antagonists in early development as potential therapeutic options for asthma. <i>Expert Opinion on Investigational Drugs</i> , 2016, 25, 1083-1092.	1.9	32
313	Association Between Insomnia and Asthma Burden in the Severe Asthma Research Program (SARP) III. <i>Chest</i> , 2016, 150, 1242-1250.	0.4	51
314	Asthma-related deaths. <i>Multidisciplinary Respiratory Medicine</i> , 2016, 11, 37.	0.6	100
315	Glucocorticoids. <i>Handbook of Experimental Pharmacology</i> , 2016, 237, 171-196.	0.9	90
317	Identifying biomarkers for asthma diagnosis using targeted metabolomics approaches. <i>Respiratory Medicine</i> , 2016, 121, 59-66.	1.3	34
318	Mast cells are associated with exacerbations and eosinophilia in children with severe asthma. <i>European Respiratory Journal</i> , 2016, 48, 1320-1328.	3.1	31
319	Perioperative Evaluation of Patients with Pulmonary Conditions Undergoing Non-Cardiothoracic Surgery. <i>Health Services Insights</i> , 2016, 9s1, HSI.S40541.	0.6	23
320	Emerging Biological Therapies in Severe Eosinophilic Asthma. <i>Pulmonary Therapy</i> , 2016, 2, 153-169.	1.1	0
321	Severe Asthma: Challenges and Precision Approaches to Therapy. <i>Pulmonary Therapy</i> , 2016, 2, 139-152.	1.1	1
323	Evaluation of the use of Swedish integrated electronic health records and register health care data as support clinical trials in severe asthma: the PACEHR study. <i>Respiratory Research</i> , 2016, 17, 152.	1.4	6
324	Antioxidant supplementation and exhaled nitric oxide in children with asthma. <i>Allergy and Asthma Proceedings</i> , 2016, 37, 8-13.	1.0	30
325	Neutrophil extracellular traps are associated with inflammation in chronic airway disease. <i>Respirology</i> , 2016, 21, 467-475.	1.3	150
326	Temperature-controlled laminar airflow in severe asthma for exacerbation reduction (The LASER) Tj ETQq1 1 0.784314 rgBT /Overlock	0.7	5

#	ARTICLE	IF	CITATIONS
327	Epidemiology and Pulmonary Physiology of Severe Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2016, 36, 425-438.	0.7	14
328	Plasma interleukin-6 concentrations, metabolic dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. <i>Lancet Respiratory Medicine</i> , 2016, 4, 574-584.	5.2	375
329	Inhaled therapy in asthma. <i>Medicina Clínica (English Edition)</i> , 2016, 146, 316-323.	0.1	4
330	Mepolizumab: A New Class of Treatment for Adolescents with Severe Persistent Asthma. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2016, 29, 49-52.	0.3	2
331	Reduced epithelial suppressor of cytokine signalling 1 in severe eosinophilic asthma. <i>European Respiratory Journal</i> , 2016, 48, 715-725.	3.1	24
332	Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma. <i>Lancet Respiratory Medicine</i> , 2016, 4, 585-592.	5.2	53
333	How to manage a child with difficult asthma?. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 873-879.	1.0	9
334	Trans-Basement Membrane Migration of Eosinophils Induced By LPS-Stimulated Neutrophils from Human Peripheral Blood in Vitro. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, AB167.	1.5	0
336	Novel strategies for the treatment of asthma. <i>Allergo Journal International</i> , 2016, 25, 11-17.	0.9	26
337	An outreaching model of tertiary difficult asthma care reduces adverse asthma outcomes and healthcare utilisation costs. <i>European Respiratory Journal</i> , 2016, 47, 1857-1860.	3.1	5
338	Asthma Management for Children. <i>Advances in Pediatrics</i> , 2016, 63, 103-126.	0.5	9
339	Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. <i>BMC Pulmonary Medicine</i> , 2016, 16, 28.	0.8	17
340	CXC chemokine superfamily induced by Interferon- $\gamma$ in asthma: a cross-sectional observational study. <i>Asthma Research and Practice</i> , 2016, 2, 6.	1.2	20
341	Severe asthma features in children: a case-control online survey. <i>Italian Journal of Pediatrics</i> , 2016, 42, 9.	1.0	41
342	Allergic disease and <i>Staphylococcus aureus</i> carriage in adolescents in the Arctic region of Norway. <i>Pediatric Allergy and Immunology</i> , 2016, 27, 728-735.	1.1	20
343	Relaxing effect of a new ruthenium complex nitric oxide donor on airway smooth muscle of an experimental model of asthma in rats. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 221-229.	0.9	14
344	Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1472-1479.	2.7	76
345	Consensus-based approach for severe paediatric asthma in routine clinical practice. <i>Anales De Pediatría (English Edition)</i> , 2016, 84, 122.e1-122.e11.	0.1	1

#	ARTICLE	IF	CITATIONS
346	Severe Asthma in Children: Lessons Learned and Future Directions. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 11-19.	2.0	62
347	A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. <i>European Respiratory Journal</i> , 2016, 47, 490-498.	3.1	110
348	Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 29-38.	1.0	27
349	Challenges in the pharmacological treatment of geriatric asthma. <i>Expert Review of Clinical Pharmacology</i> , 2016, 9, 917-926.	1.3	11
350	Clinical correlates of lung ventilation defects in asthmatic children. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 789-796.e7.	1.5	43
351	Comparación de costes y resultados clínicos entre la administración hospitalaria o ambulatoria de omalizumab, en pacientes con asma grave no controlada. <i>Archivos De Bronconeumología</i> , 2016, 52, 211-216.	0.4	9
352	Airway lipoxin A4/formyl peptide receptor 2 lipoxin receptor levels in pediatric patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1796-1806.	1.5	29
353	A Novel CD4 <sup>+</sup> T Cell-Dependent Murine Model of <i>Pneumocystis</i> -driven Asthma-like Pathology. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 807-820.	2.5	37
354	Advances in Bronchial Thermoplasty. <i>Chest</i> , 2016, 150, 694-704.	0.4	20
355	Emerging monoclonal antibodies as targeted innovative therapeutic approaches to asthma. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 99, 38-48.	2.3	44
356	Staphylococcal enterotoxin-specific IgE: a biomarker for a distinct phenotype of severe asthma?. <i>Clinical and Experimental Allergy</i> , 2016, 46, 387-389.	1.4	5
357	Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 142-149.e8.	1.5	49
358	Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. <i>Thorax</i> , 2016, 71, 339-346.	2.7	257
359	Activin-A is overexpressed in severe asthma and is implicated in angiogenic processes. <i>European Respiratory Journal</i> , 2016, 47, 769-782.	3.1	30
360	Treatable traits: toward precision medicine of chronic airway diseases. <i>European Respiratory Journal</i> , 2016, 47, 410-419.	3.1	746
361	Blood eosinophils: the Holy Grail for asthma phenotyping?. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 90-91.	0.5	2
362	Measuring total IgE is useful in detecting exacerbations in patients with allergic bronchopulmonary aspergillosis receiving omalizumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2016, 4, 361-363.	2.0	5
365	The potential of methylxanthine-based therapies in pediatric respiratory tract diseases. <i>Respiratory Medicine</i> , 2016, 112, 1-9.	1.3	45

#	ARTICLE	IF	CITATIONS
366	Targeting the JAK-STAT pathway in the treatment of $\text{IL-17A}^{\text{hi}}$ severe asthma. <i>Future Medicinal Chemistry</i> , 2016, 8, 405-419.	1.1	32
367	Utilidad del esputo inducido en la práctica clínica habitual. <i>Archivos De Bronconeumologia</i> , 2016, 52, 250-255.	0.4	3
368	Diagnosis and investigation in the severe asthma clinic. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 491-503.	1.0	21
369	Bronchial thermoplasty: a review of the evidence. <i>Annals of Allergy, Asthma and Immunology</i> , 2016, 116, 92-98.	0.5	25
370	Atopic endotype in childhood. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 844-851.e4.	1.5	40
372	Targeted anti-inflammatory therapeutics in asthma and chronic obstructive lung disease. <i>Translational Research</i> , 2016, 167, 192-203.	2.2	100
373	Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study. <i>Journal of Asthma</i> , 2016, 53, 201-206.	0.9	50
374	Refractory Childhood Asthma. , 2016, , 343-353.e5.		0
375	Variabilidad del fenotipo inflamatorio del asma en el esputo inducido. Frecuencia y causas. <i>Archivos De Bronconeumologia</i> , 2016, 52, 76-81.	0.4	6
377	Biomarkers Guided Treatment Strategies in Adult Patients with Asthma: Ready for the Clinical Field?. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2017, 65, 1-9.	1.0	10
378	Office spirometry correlates with laboratory spirometry in patients with symptomatic asthma and COPD. <i>Clinical Respiratory Journal</i> , 2017, 11, 805-811.	0.6	15
379	Transcriptional profiling identifies the long noncoding RNA plasmacytoma variant translocation (lncRNA PLVT) in allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 780-789.	1.5	95
380	Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma. <i>Allergology International</i> , 2017, 66, 445-451.	1.4	31
381	Is allergic sensitization relevant in severe asthma? Which allergens may be culprits?. <i>World Allergy Organization Journal</i> , 2017, 10, 2.	1.6	28
382	Aspirin tolerance in patients with nonsteroidal anti-inflammatory drug-exacerbated respiratory disease following treatment with omalizumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 842-845.	2.0	16
383	Tiotropium for the treatment of asthma in adolescents. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 305-312.	0.9	9
384	Intraepithelial neutrophils in pediatric severe asthma are associated with better lung function. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1819-1829.e11.	1.5	96
385	Dysregulation of lipidomic profile and antiviral immunity in response to hyaluronan in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1379-1383.	1.5	42

#	ARTICLE	IF	CITATIONS
386	Targeted Therapy for Severe Asthma: Identifying the Right Patients. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 235-247.	1.6	5
387	The level of diagnostic assessment in severe asthma: A nationwide real-life study. <i>Respiratory Medicine</i> , 2017, 124, 21-29.	1.3	22
388	Development of a peptide conjugate vaccine for inducing therapeutic anti-IgE antibodies. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 429-434.	1.4	6
389	Clinical trial research in focus: do trials prepare us to deliver precision medicine in those with severe asthma?. <i>Lancet Respiratory Medicine</i> , 2017, 5, 92-95.	5.2	4
390	Airway Hyperresponsiveness in Asthma: Measurement and Clinical Relevance. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 649-659.e2.	2.0	68
391	Airway and serum biochemical correlates of refractory neutrophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1004-1014.e13.	1.5	43
392	The current and future role of biomarkers in type 2 cytokine-mediated asthma management. <i>Clinical and Experimental Allergy</i> , 2017, 47, 148-160.	1.4	66
393	Procedural and short-term safety of bronchial thermoplasty in clinical practice: evidence from a national registry and Hospital Episode Statistics. <i>Journal of Asthma</i> , 2017, 54, 872-879.	0.9	29
394	Dupilumab for the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2017, 26, 357-366.	1.9	47
395	Personalised Medicine for Asthma and Chronic Obstructive Pulmonary Disease. <i>Respiration</i> , 2017, 93, 153-161.	1.2	25
396	Quantitative computed tomographic imaging-based clustering differentiates asthmatic subgroups with distinctive clinical phenotypes. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 690-700.e8.	1.5	79
397	Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, S1-S14.	2.0	57
398	Bronchial thermoplasty in severe asthma in Australia. <i>Internal Medicine Journal</i> , 2017, 47, 536-541.	0.5	16
399	ASMA SEVERA PROBLEMAÁTICA EN PEDIATRÃA. <i>Revista MÃ©dica ClÃnica Las Condes</i> , 2017, 28, 45-54.	0.2	0
400	Omalizumab in severe asthma: Evaluation of the clinical impact after its withdrawal. <i>Revista Portuguesa De Pneumologia</i> , 2017, 23, 108-109.	0.7	0
401	Advances in mechanisms and management of chronic cough: The Ninth London International Cough Symposium 2016. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 47, 2-8.	1.1	20
403	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing â€“ Executive summary. <i>Alergologia Polska - Polish Journal of Allergology</i> , 2017, 4, 2-6.	0.0	1
404	Asma (a excepciÃ³n del asma aguda). <i>EMC - Tratado De Medicina</i> , 2017, 21, 1-9.	0.0	0

#	ARTICLE	IF	CITATIONS
405	Toward Predicting Individual Risk in Asthma Using Daily Home Monitoring of Resistance. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 265-267.	2.5	15
406	Adaptation of a difficult-to-manage asthma programme for implementation in the Dutch context: a modified e-Delphi. Npj Primary Care Respiratory Medicine, 2017, 27, 16086.	1.1	13
407	Asthma or asthmaâ€COPD overlap syndrome? â€“ Reply. Respiriology, 2017, 22, 612-613.	1.3	1
408	The relationship between the Leicester cough questionnaire, eosinophilic airway inflammation and asthma patient related outcomes in severe adult asthma. Respiratory Research, 2017, 18, 44.	1.4	16
409	Patient Characteristics and Individualization of Biologic Therapy. Immunology and Allergy Clinics of North America, 2017, 37, 261-281.	0.7	0
410	Natural killer cellâ€mediated inflammation resolution is disabled in severe asthma. Science Immunology, 2017, 2, .	5.6	76
411	A Structured Approach to Specialist-referred Difficult Asthma Patients Improves Control of Comorbidities and Enhances Asthma Outcomes. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 956-964.e3.	2.0	56
412	Phenotype-Driven Therapeutics in Severe Asthma. Current Allergy and Asthma Reports, 2017, 17, 10.	2.4	36
413	Targeting patients with asthma for omalizumab therapy: choosing the right patient to get the best value for money. Therapeutic Advances in Chronic Disease, 2017, 8, 31-45.	1.1	7
414	Predicting Asthma Exacerbations from a Drop of Blood. Clinical Chemistry, 2017, 63, 799-801.	1.5	1
415	Can biomarkers help us hit targets in difficultâ€toâ€treat asthma?. Respiriology, 2017, 22, 430-442.	1.3	36
416	Asthma Yardstick. Annals of Allergy, Asthma and Immunology, 2017, 118, 133-142.e3.	0.5	26
417	T-helper cell type 2 (Th2) and non-Th2 molecular phenotypes of asthma using sputum transcriptomics in U-BIOPRED. European Respiratory Journal, 2017, 49, 1602135.	3.1	283
418	Asma (al di fuori dellâ€™asma acuto). EMC - AKOS - Trattato Di Medicina, 2017, 19, 1-9.	0.0	0
420	Sinus Computed Tomographic Findings in Adult Smokers and Nonsmokers with Asthma. Analysis of Clinical Indices and Biomarkers. Annals of the American Thoracic Society, 2017, 14, 332-341.	1.5	48
421	Severe asthma: phenotyping to endotyping or vice versa?. European Respiratory Journal, 2017, 49, 1700053.	3.1	14
422	IntÃ©rÃ©t du test de contrÃ©le de lâ€™asthme (ACT) dans la prise en charge des patients asthmatiques Ã Casablanca. Revue Francaise D'allergologie, 2017, 57, 109-112.	0.1	0
423	Disease Burden of Mild Asthma: Findings from a Cross-Sectional Real-World Survey. Advances in Therapy, 2017, 34, 1109-1127.	1.3	36

#	ARTICLE	IF	CITATIONS
424	Mouse models of severe asthma: Understanding the mechanisms of steroid resistance, tissue remodelling and disease exacerbation. <i>Respirology</i> , 2017, 22, 874-885.	1.3	54
425	Altered fatty acid metabolism and reduced stearyl-coenzyme a desaturase activity in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1744-1752.	2.7	29
426	Clinical phenotypes in asthma during childhood. <i>Clinical and Experimental Allergy</i> , 2017, 47, 848-855.	1.4	68
427	Interferon- $\gamma$ for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center Retrospective Observational Cohort Study. <i>Journal of Rheumatology</i> , 2017, 44, 806-814.	1.0	20
428	The association between serum periostin and a type 2 helper airway composite index in optimally treated asthmatics. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1129-1131.e3.	2.0	3
429	Responsiveness to oral prednisolone in severe asthma is related to the degree of eosinophilic airway inflammation. <i>Clinical and Experimental Allergy</i> , 2017, 47, 890-899.	1.4	25
430	Allergic sinusitis and severe asthma caused by occupational exposure to locust bean gum: Case report. <i>American Journal of Industrial Medicine</i> , 2017, 60, 658-663.	1.0	4
431	Emerging Therapies in Severe Eosinophilic Asthma. <i>Archivos De Bronconeumologia</i> , 2017, 53, 233-234.	0.4	0
432	Cationic CaMKII Inhibiting Nanoparticles Prevent Allergic Asthma. <i>Molecular Pharmaceutics</i> , 2017, 14, 2166-2175.	2.3	22
433	Precision medicine in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 254-260.	1.2	8
434	Severe eosinophilic asthma: a roadmap to consensus. <i>European Respiratory Journal</i> , 2017, 49, 1700634.	3.1	143
435	Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1431-1444.	1.5	130
436	Prospects for new and emerging therapeutics in severe asthma: the role of biologics. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 505-512.	1.0	7
437	Associations in asthma between quantitative computed tomography and bronchial biopsy-derived airway remodelling. <i>European Respiratory Journal</i> , 2017, 49, 1601507.	3.1	32
438	Severe asthma: Current management, targeted therapies and future directions – A roundtable report. <i>Respirology</i> , 2017, 22, 53-60.	1.3	50
439	Severe asthma: Can we fix it? Prologue to seeking innovative solutions for severe asthma. <i>Respirology</i> , 2017, 22, 19-20.	1.3	4
440	Clinical potential for imaging in patients with asthma and other lung disorders. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 21-28.	1.5	8
441	Childhood severe asthma: New insights on remodelling and biomarkers. <i>Paediatric Respiratory Reviews</i> , 2017, 24, 11-13.	1.2	17



#	ARTICLE	IF	CITATIONS
442	Defining asthma and assessing asthma outcomes using electronic health record data: a systematic scoping review. <i>European Respiratory Journal</i> , 2017, 49, 1700204.	3.1	42
443	Association of the miR-196a2, miR-146a, and miR-499 Polymorphisms with Asthma Phenotypes in a Korean Population. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 547-554.	1.6	24
444	Lung function parameters in omalizumab responder patients: An interesting tool?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1953-1961.	2.7	28
445	Influence of chronic azithromycin treatment on the composition of the oropharyngeal microbial community in patients with severe asthma. <i>BMC Microbiology</i> , 2017, 17, 109.	1.3	26
446	Novel targets of omalizumab in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 56-61.	1.2	15
447	Management of severe asthma: targeting the airways, comorbidities and risk factors. <i>Internal Medicine Journal</i> , 2017, 47, 623-631.	0.5	30
448	Oral Glucocorticoidâ€™Sparing Effect of Benralizumab in Severe Asthma. <i>New England Journal of Medicine</i> , 2017, 376, 2448-2458.	13.9	779
449	Update in Asthma 2016. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 548-557.	2.5	5
450	Infection-mediated asthma: etiology, mechanisms and treatment options, with focus on Chlamydia pneumoniae and macrolides. <i>Respiratory Research</i> , 2017, 18, 98.	1.4	52
451	<scp>S</scp>i<scp>MA</scp>: A simplified migration assay for analyzing neutrophil migration. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2017, 91, 675-685.	1.1	16
452	The asthma-plus syndrome. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 513-515.	1.0	3
453	The future of asthma research and development: a roadmap from the European Asthma Research and Innovation Partnership (EARIP). <i>European Respiratory Journal</i> , 2017, 49, 1602295.	3.1	18
454	Allergic and Noninvasive Infectious Pulmonary Aspergillosis Syndromes. <i>Clinics in Chest Medicine</i> , 2017, 38, 521-534.	0.8	33
455	Interleukin-5 Inhibitors for Severe Asthma: Rationale and Future Outlook. <i>BioDrugs</i> , 2017, 31, 93-103.	2.2	20
456	Metabolomics analysis identifies different metabotypes of asthma severity. <i>European Respiratory Journal</i> , 2017, 49, 1601740.	3.1	143
457	Saturated Fatty Acid Increases Lung Macrophages and Augments House Dust Mite-Induced Airway Inflammation in Mice Fed with High-Fat Diet. <i>Inflammation</i> , 2017, 40, 1072-1086.	1.7	61
458	Effect of alfacalcidol on the pulmonary function of adult asthmatic patients: A randomized trial. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 557-563.	0.5	13
459	Exercise for Multimorbid Patients in Primary Care: One Prescription for All?. <i>Sports Medicine</i> , 2017, 47, 2143-2153.	3.1	12

#	ARTICLE	IF	CITATIONS
460	Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 390-400.	5.2	432
461	Novel Biomarkers in Severe Asthma. <i>Archivos De Bronconeumologia</i> , 2017, 53, 175-176.	0.4	1
462	Nuevos biomarcadores del asma grave. <i>Archivos De Bronconeumologia</i> , 2017, 53, 175-176.	0.4	4
463	Emerging Therapies in Severe Eosinophilic Asthma. <i>Archivos De Bronconeumologia</i> , 2017, 53, 233-234.	0.4	0
464	A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN- $\beta$ and IFN- $\gamma$ ) and Type 2 Inflammation (IL-5 and IL-13). <i>EBioMedicine</i> , 2017, 19, 128-138.	2.7	102
465	Airway microbial dysbiosis in asthmatic patients: A target for prevention and treatment?. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1071-1081.	1.5	124
466	Long-term future risk of severe exacerbations: Distinct 5-year trajectories of problematic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1398-1405.	2.7	36
467	Is asthma associated with cognitive impairments? A meta-analytic review. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2017, 39, 965-978.	0.8	71
468	Asthma management: A new phenotype-based approach using presence of eosinophilia and allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1279-1287.	2.7	40
469	Comorbidities in severe asthma: Clinical impact and management. <i>Respirology</i> , 2017, 22, 651-661.	1.3	172
470	Early computed tomography modifications following bronchial thermoplasty in patients with severe asthma. <i>European Respiratory Journal</i> , 2017, 49, 1601565.	3.1	39
471	Use of biologics in severe food allergies. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 232-238.	1.1	24
472	Clinical management of severe therapy-resistant asthma. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 1-8.	1.0	17
473	Identifying rare diseases using electronic medical records: the example of allergic bronchopulmonary aspergillosis. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 785-791.	0.9	12
474	hMSCs suppress neutrophil-dominant airway inflammation in a murine model of asthma. <i>Experimental and Molecular Medicine</i> , 2017, 49, e288-e288.	3.2	28
475	Novel monoclonal treatments in severe asthma. <i>Journal of Asthma</i> , 2017, 54, 991-1011.	0.9	9
476	Immunologic regulatory effects of human umbilical cord blood-derived mesenchymal stem cells in a murine ovalbumin asthma model. <i>Clinical and Experimental Allergy</i> , 2017, 47, 937-945.	1.4	26
477	Activin-A co-opts IRF4 and AhR signaling to induce human regulatory T cells that restrain asthmatic responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2017, 114, E2891-E2900.	3.3	52

#	ARTICLE	IF	CITATIONS
478	Physical activity, airway resistance and small airway dysfunction in severe asthma. <i>European Respiratory Journal</i> , 2017, 49, 1601827.	3.1	44
479	Perspectives on the International Classification of Diseases, 11th Revision, developments in allergy clinical practice in the United States. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 118, 127-132.	0.5	10
480	Fungal Sensitization Is Associated with Increased Risk of Life-Threatening Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1025-1031.e2.	2.0	38
481	Comparative effectiveness of mepolizumab and omalizumab in severe asthma: An indirect treatment comparison. <i>Respiratory Medicine</i> , 2017, 123, 140-148.	1.3	46
482	Revisiting <sc>T</sc>ype 2â€high and <sc>T</sc>ype 2â€low airway inflammation in asthma: current knowledge and therapeutic implications. <i>Clinical and Experimental Allergy</i> , 2017, 47, 161-175.	1.4	287
483	A Severe Asthma Disease Signature from Gene Expression Profiling of Peripheral Blood from U-BIOPRED Cohorts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1311-1320.	2.5	152
484	Identification of IL-17F/frequent exacerbator endotype in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 395-406.	1.5	118
485	Diagnosing eosinophilic asthma using a multivariate prediction model based on blood granulocyte responsiveness. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1202-1211.	2.7	21
486	Severe and non-severe asthma in the community: A large electronic database analysis. <i>Respiratory Medicine</i> , 2017, 123, 131-139.	1.3	27
487	Efficacy of long-term omalizumab therapy in patients with severe asthma. <i>Respiratory Investigation</i> , 2017, 55, 114-120.	0.9	4
488	Parental Snoring and Environmental Pollutants, but Not Aeroallergen Sensitization, Are Associated with Childhood Snoring in a Birth Cohort. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2017, 30, 31-38.	0.3	8
489	Effectiveness of Shin'iseihaito in Asthmatic Patients with Upper Airway Diseases: A Retrospective Cohort Study. <i>Journal of Alternative and Complementary Medicine</i> , 2017, 23, 121-125.	2.1	2
490	Effects of Age and Disease Severity on Systemic Corticosteroid Responses in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 195, 1439-1448.	2.5	87
491	Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1602298.	3.1	44
492	Monoclonal Antibody Therapy for Asthma. <i>Clinical Pulmonary Medicine</i> , 2017, 24, 250-257.	0.3	3
493	Cough and severe asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 47, 72-76.	1.1	9
494	Dupilumab for the treatment of asthma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1565-1572.	1.4	33
495	Personalised medicine in asthma: time for action. <i>European Respiratory Review</i> , 2017, 26, 170064.	3.0	32

#	ARTICLE	IF	CITATIONS
497	Impact of omalizumab in children from a middle-income country with severe therapy-resistant asthma: A real-life study. <i>Pediatric Pulmonology</i> , 2017, 52, 1408-1413.	1.0	33
499	Emerging interleukin receptor antagonists for the treatment of asthma. <i>Expert Opinion on Emerging Drugs</i> , 2017, 22, 275-283.	1.0	1
500	Sputum microbiota in severe asthma patients: Relationship to eosinophilic inflammation. <i>Respiratory Medicine</i> , 2017, 131, 192-198.	1.3	83
501	Acute Radiological Abnormalities after Bronchial Thermoplasty: A Prospective Cohort Trial. <i>Respiration</i> , 2017, 94, 258-262.	1.2	22
502	Severe therapy resistant asthma in children: translational approaches to uncover sub-phenotypes. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 867-874.	1.0	14
503	Stratification of eosinophilic asthma patients treated with reslizumab and GINA Step 4 or 5 therapy. <i>ERJ Open Research</i> , 2017, 3, 00004-2017.	1.1	17
504	Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 46, 88-98.	1.1	15
505	Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. <i>European Respiratory Journal</i> , 2017, 50, 1700017.	3.1	122
506	Predictive Biomarkers for Asthma Therapy. <i>Current Allergy and Asthma Reports</i> , 2017, 17, 69.	2.4	44
507	Prise en charge de lâ€™asthme Â«ÂsÃ©vÃ©reÂ» au BÃ©nin, un pays aux ressources limitÃ©es. <i>Revue Francaise D'allergologie</i> , 2017, 57, 413-417.	0.1	1
508	The role of upper airway pathology as a co-morbidity in severe asthma. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 855-865.	1.0	42
509	Asthma Phenotypes and Endotypes: Implications for Personalised Therapy. <i>BioDrugs</i> , 2017, 31, 393-408.	2.2	20
510	Immune monitoring for precision medicine in allergy and asthma. <i>Current Opinion in Immunology</i> , 2017, 48, 82-91.	2.4	15
511	â€œI have lost in every facet of my lifeâ€ the hidden burden of severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1700765.	3.1	128
512	ATS Core Curriculum 2017: Part II. Pediatric Pulmonary Medicine. <i>Annals of the American Thoracic Society</i> , 2017, 14, S165-S181.	1.5	3
513	An invisible disease: severe asthma is more than just â€œbad asthmaâ€. <i>European Respiratory Journal</i> , 2017, 50, 1701109.	3.1	15
514	Airway calibre variation is a major determinant of exhaled nitric oxide's ability to capture asthma control. <i>European Respiratory Journal</i> , 2017, 50, 1700392.	3.1	9
515	Tezepelumab in Adults with Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2017, 377, 936-946.	13.9	693

#	ARTICLE	IF	CITATIONS
516	Severe and Difficult-to-Treat Asthma in Adults. <i>New England Journal of Medicine</i> , 2017, 377, 965-976.	13.9	357
517	How effective is bronchial thermoplasty for severe asthma in clinical practice?. <i>European Respiratory Journal</i> , 2017, 50, 1701140.	3.1	10
518	Phenotypes Determined by Cluster Analysis in Moderate to Severe Bronchial Asthma. <i>Folia Medica</i> , 2017, 59, 165-173.	0.2	9
519	Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects. <i>Therapeutic Advances in Respiratory Disease</i> , 2017, 11, 311-325.	1.0	25
520	Cas clinique n° 6 : Un asthme avec obstruction bronchique persistante. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 43-48.	0.0	0
521	The pro-inflammatory cytokines, salivary cortisol and alpha-amylase are associated with generalized anxiety disorder (GAD) in patients with asthma. <i>Neuroscience Letters</i> , 2017, 656, 15-21.	1.0	13
522	Diagnosis and Management of Asthma in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 279.	3.8	158
523	Characteristics of asthmatics with detectable IL-32 <sup>β</sup> in induced sputum. <i>Respiratory Medicine</i> , 2017, 129, 85-90.	1.3	8
525	II. Topic Sessions. <i>Pediatric Pulmonology</i> , 2017, 52, S32-S93.	1.0	4
527	The role of imaging in the assessment of severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 97-102.	1.2	21
528	Role of biologics targeting type 2 airway inflammation in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 3-11.	1.2	28
529	Histologic Findings of Severe/Therapy-Resistant Asthma From Video-assisted Thoracoscopic Surgery Biopsies. <i>American Journal of Surgical Pathology</i> , 2017, 41, 182-188.	2.1	12
530	Appropriate selection for omalizumab treatment in patients with severe asthma?. <i>European Clinical Respiratory Journal</i> , 2017, 4, 1359477.	0.7	5
531	Characteristics of severe asthma with fungal sensitization. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 253-257.	0.5	75
532	Multidimensional assessment of severe asthma: A systematic review and meta-analysis. <i>Respirology</i> , 2017, 22, 1262-1275.	1.3	82
533	Care pathways for the selection of a biologic in severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1701782.	3.1	79
534	Mortality: a neglected outcome in AOCs-treated severe asthma. <i>European Respiratory Journal</i> , 2017, 50, 1701486.	3.1	40
536	Asthme : actualités sur les nouveaux traitements de l'asthme sévère. <i>Revue Des Maladies Respiratoires Actualites</i> , 2017, 9, 428-432.	0.0	0

#	ARTICLE	IF	CITATIONS
537	Current and new challenges in occupational lung diseases. <i>European Respiratory Review</i> , 2017, 26, 170080.	3.0	71
538	Asthma biomarkers in the age of biologics. <i>Allergy, Asthma and Clinical Immunology</i> , 2017, 13, 48.	0.9	68
539	The era of research collaborations: new models for working together. <i>European Respiratory Journal</i> , 2017, 49, 1601848.	3.1	11
540	Bronchial Thermoplasty in Severe Asthma. <i>Current Pulmonology Reports</i> , 2017, 6, 221-226.	0.5	0
541	Guiding principles for use of newer biologics and bronchial thermoplasty for patients with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 533-540.	0.5	33
542	Initiating or changing to a fixed-dose combination of Fluticasone propionate/Formoterol over Fluticasone propionate/Salmeterol: A real-life effectiveness and cost impact evaluation. <i>Respiratory Medicine</i> , 2017, 129, 199-206.	1.3	8
543	The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies. <i>Current Medical Research and Opinion</i> , 2017, 33, 1605-1613.	0.9	72
544	Mepolizumab for the treatment of severe eosinophilic asthma. <i>American Journal of Health-System Pharmacy</i> , 2017, 74, 963-969.	0.5	15
545	Mepolizumab efficacy in patients with severe eosinophilic asthma receiving different controller therapies. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1464-1466.e4.	1.5	16
547	Effect of nintedanib on airway inflammation and remodeling in a murine chronic asthma model. <i>Experimental Lung Research</i> , 2017, 43, 187-196.	0.5	28
548	Fibromyalgia as a cause of uncontrolled asthma: a caseâ€“control multicenter study. <i>Current Medical Research and Opinion</i> , 2017, 33, 2181-2186.	0.9	6
549	Management of Severe Asthma before Referral to the Severe Asthma Specialist. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 877-886.	2.0	24
550	Severe Asthma in Children. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 889-898.	2.0	87
551	Severe Asthma Phenotypes â€” How Should They Guide Evaluation and Treatment?. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 901-908.	2.0	100
552	A Systematic Approach to Evaluating Difficult to Control Asthma: A Little Goes a Long Way. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 965-966.	2.0	1
553	Nonpharmacologic Therapy for Severe Persistent Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 928-935.	2.0	23
554	The Many â€œBucketsâ€“of Severe Asthma: Moving Toward Personalized Management. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 936-937.	2.0	4
555	38-Year-Old Man With Asthma and Eosinophilia. <i>Mayo Clinic Proceedings</i> , 2017, 92, e111-e115.	1.4	1

#	ARTICLE	IF	CITATIONS
556	The Use of Mouse Asthma Models to Successfully Discover and Develop Novel Drugs. <i>International Archives of Allergy and Immunology</i> , 2017, 173, 61-70.	0.9	5
557	A case series evaluating the serological response of adult asthma patients to the 23-valent pneumococcal polysaccharide vaccine. <i>Allergy, Asthma and Clinical Immunology</i> , 2017, 13, 27.	0.9	7
558	Mechanisms and treatments for severe, steroid-resistant allergic airway disease and asthma. <i>Immunological Reviews</i> , 2017, 278, 41-62.	2.8	119
559	Age is associated with asthma phenotypes. <i>Respirology</i> , 2017, 22, 1558-1563.	1.3	19
560	SANI-Severe Asthma Network in Italy: a way forward to monitor severe asthma. <i>Clinical and Molecular Allergy</i> , 2017, 15, 9.	0.8	36
561	Small airways disease and severe asthma. <i>World Allergy Organization Journal</i> , 2017, 10, 20.	1.6	45
562	Point-of-care blood eosinophil count in a severe asthma clinic setting. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 16-20.	0.5	26
563	Development of allergic immunity in early life. <i>Immunological Reviews</i> , 2017, 278, 101-115.	2.8	20
564	High density lipoproteins and type 2 inflammatory biomarkers are negatively correlated in atopic asthmatics. <i>Journal of Lipid Research</i> , 2017, 58, 1713-1721.	2.0	26
565	Pathogenesis of asthma: implications for precision medicine. <i>Clinical Science</i> , 2017, 131, 1723-1735.	1.8	118
566	Abnormal vocal cord movement in patients with and without airway obstruction and asthma symptoms. <i>Clinical and Experimental Allergy</i> , 2017, 47, 200-207.	1.4	40
567	POINT: Will New Anti-eosinophilic Drugs Be Useful in Asthma Management? Yes. <i>Chest</i> , 2017, 151, 14-17.	0.4	5
568	Allergy in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 207-220.	2.7	96
569	Validation of the pediatric sleep questionnaire in children with asthma. <i>Pediatric Pulmonology</i> , 2017, 52, 382-389.	1.0	31
570	Activin A and follistatin in patients with asthma. Does severity make the difference?. <i>Respirology</i> , 2017, 22, 473-479.	1.3	7
571	U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1797-1807.	1.5	236
572	Asthma phenotypes in childhood. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 705-713.	1.3	30
573	Tumor progression locus 2 reduces severe allergic airway inflammation by inhibiting Ccl24 production in dendritic cells. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 655-666.e7.	1.5	11

#	ARTICLE	IF	CITATIONS
574	Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 302-313.	2.5	346
575	Effectiveness of bronchial thermoplasty in patients with severe refractory asthma: Clinical and histopathologic correlations. Journal of Allergy and Clinical Immunology, 2017, 139, 1176-1185.	1.5	175
576	Systemic Corticosteroid Responses in Children with Severe Asthma: Phenotypic and Endotypic Features. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 410-419.e4.	2.0	18
577	Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. Journal of Allergy and Clinical Immunology, 2017, 139, 1167-1175.e2.	1.5	78
578	An early innate response underlies severe influenza-induced exacerbations of asthma in a novel steroid-insensitive and anti-IL-5-responsive mouse model. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 737-753.	2.7	38
579	Validated questionnaires heighten detection of difficult asthma comorbidities. Journal of Asthma, 2017, 54, 294-299.	0.9	36
580	University and public health system partnership: A real-life intervention to improve asthma management. Journal of Asthma, 2017, 54, 411-418.	0.9	2
581	Use of biologics to treat acute exacerbations and manage disease in asthma, COPD and IPF. , 2017, 169, 1-12.		7
582	Neutrophil autophagy and extracellular DNA traps contribute to airway inflammation in severe asthma. Clinical and Experimental Allergy, 2017, 47, 57-70.	1.4	143
583	Airway and peripheral urokinase plasminogen activator receptor is elevated in asthma, and identifies a severe, nonatopic subset of patients. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 473-482.	2.7	18
584	High-resolution metabolomics to identify urine biomarkers in corticosteroid-resistant asthmatic children. Journal of Allergy and Clinical Immunology, 2017, 139, 1518-1524.e4.	1.5	37
585	Biologics in the treatment of severe asthma. Allergologia Et Immunopathologia, 2017, 45, 45-49.	1.0	8
586	Electronic monitoring of adherence to inhaled corticosteroids: an essential tool in identifying severe asthma in children. European Respiratory Journal, 2017, 50, 1700910.	3.1	81
587	Adherence in severe asthma: time to get it right. European Respiratory Journal, 2017, 50, 1702191.	3.1	17
588	Recognition and management of severe asthma: A Canadian Thoracic Society position statement. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 199-221.	0.2	42
589	Severe and uncontrolled asthma in China: a cross-sectional survey from the Australasian Severe Asthma Network. Journal of Thoracic Disease, 2017, 9, 1333-1344.	0.6	33
591	Pneumopneumologie. Revue Des Maladies Respiratoires Actualites, 2017, 9, S17-S22.	0.0	0
592	Improving adherence to asthma treatment through patient education. Independent Nurse, 2017, 2017, 17-20.	0.0	1



#	ARTICLE	IF	CITATIONS
594	Payer Perspective of the American Academy of Sleep Medicine Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia. <i>Journal of Clinical Sleep Medicine</i> , 2017, 13, 155-157.	1.4	15
595	An Update on Anti-IgE Therapy in Pediatric Respiratory Diseases. <i>Current Respiratory Medicine Reviews</i> , 2017, 13, 22-29.	0.1	29
596	Managing the pediatric patient with refractory asthma: a multidisciplinary approach. <i>Journal of Asthma and Allergy</i> , 2017, Volume10, 123-130.	1.5	48
597	Omalizumab in Children with Severe Allergic Asthma: The Italian Real- Life Experience. <i>Current Respiratory Medicine Reviews</i> , 2017, 13, 36-42.	0.1	57
598	Specific allergen immunotherapy for the treatment of allergic asthma: a review of current evidence. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2017, 27, 1-35.	0.6	20
599	Dupilumab in the management of moderate-to-severe asthma: the data so far. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1139-1149.	0.9	38
600	Effects of Airborne Particulate Matter on Respiratory Health in a Community near a Cement Factory in Chilanga, Zambia: Results from a Panel Study. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 1351.	1.2	34
601	Reslizumab and Eosinophilic Asthma: One Step Closer to Precision Medicine?. <i>Frontiers in Immunology</i> , 2017, 8, 242.	2.2	37
602	Chimeric Antigen Receptor-Redirected Regulatory T Cells Suppress Experimental Allergic Airway Inflammation, a Model of Asthma. <i>Frontiers in Immunology</i> , 2017, 8, 1125.	2.2	66
603	Asthma Endotypes and an Overview of Targeted Therapy for Asthma. <i>Frontiers in Medicine</i> , 2017, 4, 158.	1.2	190
604	Mechanisms Mediating Pediatric Severe Asthma and Potential Novel Therapies. <i>Frontiers in Pediatrics</i> , 2017, 5, 154.	0.9	20
605	Effect of Pregnancy on Quantitative Medication Use and Relation to Exacerbations in Asthma. <i>BioMed Research International</i> , 2017, 2017, 1-15.	0.9	16
607	Sensitization to <i>Aspergillus</i> species is associated with frequent exacerbations in severe asthma. <i>Journal of Asthma and Allergy</i> , 2017, Volume10, 131-140.	1.5	61
608	Positioning of Long-Acting Muscarinic Antagonists in the Management of Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2017, 9, 386.	1.1	19
609	Progression to Uncontrolled Severe Asthma: A Novel Risk Equation. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 44-50.	0.5	1
610	ALX receptor ligands define a biochemical endotype for severe asthma. <i>JCI Insight</i> , 2017, 2, .	2.3	29
611	Targeted therapy for chronic respiratory disease: a new paradigm. <i>Medical Journal of Australia</i> , 2017, 206, 136-140.	0.8	7
612	Inhaled Corticosteroid-Containing Treatment Escalation and Outcomes for Patients with Asthma in a U.S. Health Care Organization. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 1149-1159.	0.5	10

#	ARTICLE	IF	CITATIONS
613	Bronchial thermoplasty: activations predict response. <i>Respiratory Research</i> , 2017, 18, 134.	1.4	44
614	Reduced suppressive effect of $\hat{I}^{22}$ -adrenoceptor agonist on fibrocyte function in severe asthma. <i>Respiratory Research</i> , 2017, 18, 194.	1.4	3
615	Corticosteroid plus $\hat{I}^{22}$ -agonist in a single inhaler as reliever therapy in intermittent and mild asthma: a proof-of-concept systematic review and meta-analysis. <i>Respiratory Research</i> , 2017, 18, 203.	1.4	16
616	Exhaled breath condensate metabolome clusters for endotype discovery in asthma. <i>Journal of Translational Medicine</i> , 2017, 15, 262.	1.8	44
617	Advances in paediatrics in 2016: current practices and challenges in allergy, autoimmune diseases, cardiology, endocrinology, gastroenterology, infectious diseases, neonatology, nephrology, neurology, nutrition, pulmonology. <i>Italian Journal of Pediatrics</i> , 2017, 43, 80.	1.0	2
618	Lung function in severe pediatric asthma: a longitudinal study in children and adolescents in Brazil. <i>Clinical and Translational Allergy</i> , 2017, 7, 48.	1.4	8
619	Choosing wisely: The Canadian Thoracic Society's list of six things that physicians and patients should question. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2017, 1, 54-61.	0.2	3
620	Clinical and Economic Burden of Elevated Blood Eosinophils in Patients With and Without Uncontrolled Asthma. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, 85-91.	0.5	19
621	Thermal ablation for asthma: current status and technique. <i>Journal of Thoracic Disease</i> , 2017, 9, S104-S109.	0.6	6
622	Does co-payment for inhaler devices affect therapy adherence and disease outcomes? A historical, matched cohort study. <i>Journal of Pragmatic and Observational Research</i> , 2017, Volume 8, 31-41.	1.1	3
624	Is it severe asthma or asthma with severe comorbidities?. <i>Journal of Asthma and Allergy</i> , 2017, Volume 10, 303-305.	1.5	16
625	Role of Periostin in Uncontrolled Asthma in Children (DADO study). <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2017, 27, 291-298.	0.6	16
626	Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?. <i>Journal of Asthma and Allergy</i> , 2017, Volume10, 237-247.	1.5	23
627	Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study. <i>International Journal of Molecular Sciences</i> , 2017, 18, 521.	1.8	14
628	Sputum Inflammatory Mediators Are Increased in <i>Aspergillus fumigatus</i> Culture-Positive Asthmatics. <i>Allergy, Asthma and Immunology Research</i> , 2017, 9, 177.	1.1	12
629	Role and challenges of severe asthma services: insights from the UK registry. <i>Minerva Medica</i> , 2017, 108, 13-17.	0.3	4
630	Robotic assisted excision of type I choledochal cyst with Roux-en-y hepaticojejunostomy reconstruction. <i>Hepatobiliary Surgery and Nutrition</i> , 2017, 6, 397-400.	0.7	7
631	Are specialized pro-resolving mediators promising therapeutic agents for severe bronchial asthma?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4266-4269.	0.6	8

#	ARTICLE	IF	CITATIONS
632	Severe asthma and asthma-COPD overlap: a double agent or identical twins?. <i>Journal of Thoracic Disease</i> , 2017, 9, 4798-4805.	0.6	10
633	Current Management of Severe Refractory Asthma in Italy: Analysis of Real-World Data. <i>Global &amp; Regional Health Technology Assessment</i> , 2017, 4, grhta.5000273.	0.2	3
634	Endobronchial thermoplasty for asthma. <i>Journal of Visualized Surgery</i> , 2017, 3, 127-127.	0.2	1
635	Peripheral whole blood lncRNA expression analysis in patients with eosinophilic asthma. <i>Medicine (United States)</i> , 2018, 97, e9817.	0.4	33
636	Novel therapies for severe asthma in children and adults. <i>Breathe</i> , 2018, 14, 59-62.	0.6	3
637	Models of care for severe asthma. <i>Respirology</i> , 2018, 23, 652-653.	1.3	1
638	Bronchial thermoplasty as a treatment for severe asthma: controversies, progress and uncertainties. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 269-282.	1.0	12
639	Nonadherence in the era of severe asthma biologics and thermoplasty. <i>European Respiratory Journal</i> , 2018, 51, 1701836.	3.1	85
640	An algorithmic approach for the treatment of severe uncontrolled asthma. <i>ERJ Open Research</i> , 2018, 4, 00125-2017.	1.1	58
641	Complex association patterns for inflammatory mediators in induced sputum from subjects with asthma. <i>Clinical and Experimental Allergy</i> , 2018, 48, 787-797.	1.4	49
642	Bronchial Thermoplasty: A Review of the Evidence. <i>Clinical Pulmonary Medicine</i> , 2018, 25, 39-45.	0.3	1
643	Bronchiectasis in severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 409-413.	0.5	51
644	Diesel exhaust particles up-regulate interleukin-17A expression via ROS/NF- $\kappa$ B in airway epithelium. <i>Biochemical Pharmacology</i> , 2018, 151, 1-8.	2.0	24
645	Inhaled corticosteroids and asthma control in adult-onset asthma: 12-year follow-up study. <i>Respiratory Medicine</i> , 2018, 137, 70-76.	1.3	19
646	Bronchial Thermoplasty in Severe Asthma: Best Practice Recommendations from an Expert Panel. <i>Respiration</i> , 2018, 95, 289-300.	1.2	38
647	Pruning of the Pulmonary Vasculature in Asthma. The Severe Asthma Research Program (SARP) Cohort. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 39-50.	2.5	51
648	Effects of Educated Monocytes with Xenogeneic Mesenchymal Stem Cell-Derived Conditioned Medium in a Mouse Model of Chronic Asthma. <i>Immunological Investigations</i> , 2018, 47, 504-520.	1.0	14
649	Working while unwell: Workplace impairment in people with severe asthma. <i>Clinical and Experimental Allergy</i> , 2018, 48, 650-662.	1.4	57

#	ARTICLE	IF	CITATIONS
650	Aryl hydrocarbon receptor activation by diesel exhaust particles mediates epithelium-derived cytokines expression in severe allergic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2192-2204.	2.7	71
651	CpG-ODNs and Budesonide Act Synergistically to Improve Allergic Responses in Combined Allergic Rhinitis and Asthma Syndrome Induced by Chronic Exposure to Ovalbumin by Modulating the TSLP-DC-OX40L Axis. <i>Inflammation</i> , 2018, 41, 1304-1320.	1.7	17
653	New biologics for allergic diseases. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 285-296.	1.3	18
654	Diagnosis and Management of Asthma – The Swiss Guidelines. <i>Respiration</i> , 2018, 95, 364-380.	1.2	46
655	Choosing wisely in the era of biologics for asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 345-346.	0.5	1
656	Airway epithelial phosphoinositide 3-kinase- $\gamma$ contributes to the modulation of fungi-induced innate immune response. <i>Thorax</i> , 2018, 73, 758-768.	2.7	19
657	Relationship of Inhaled Corticosteroid Adherence to Asthma Exacerbations in Patients with Moderate-to-Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1989-1998.e3.	2.0	44
658	The pediatric asthma yardstick. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 559-579.e11.	0.5	33
659	Sputum proteomics and airway cell transcripts of current and ex-smokers with severe asthma in U-BIOPRED: an exploratory analysis. <i>European Respiratory Journal</i> , 2018, 51, 1702173.	3.1	67
660	DNA methylation modules in airway smooth muscle are associated with asthma severity. <i>European Respiratory Journal</i> , 2018, 51, 1701068.	3.1	25
661	A century of ‘intrinsic asthma’. <i>Allergo Journal International</i> , 2018, 27, 215-219.	0.9	9
662	Nuevas opciones terapéuticas en asma. <i>Medicina Clínica</i> , 2018, 151, 16-17.	0.3	0
663	Basophil Membrane Expression of Epithelial Cytokine Receptors in Patients with Severe Asthma. <i>International Archives of Allergy and Immunology</i> , 2018, 175, 171-176.	0.9	21
664	Dissecting Asthma Transcriptomics: Does Site Matter?. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2018, 58, 144-146.	1.4	2
665	Emerging Concepts in Evidence-Based Asthma Management. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 082-90.	0.8	1
666	Impedance Oscillometry: Emerging Role in the Management of Chronic Respiratory Disease. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 3.	2.4	8
667	Biomarkers and asthma management: analysis and potential applications. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 96-108.	1.1	21
668	Bronchial Thermoplasty. , 2018, , 511-523.		0

#	ARTICLE	IF	CITATIONS
669	Interleukin-17A and vascular remodelling in severe asthma; lack of evidence for a direct role. <i>Clinical and Experimental Allergy</i> , 2018, 48, 365-378.	1.4	12
670	Vasoactive intestinal peptide inhibits airway smooth muscle cell proliferation in a mouse model of asthma via the ERK1/2 signaling pathway. <i>Experimental Cell Research</i> , 2018, 364, 168-174.	1.2	19
671	Allergic asthma is associated with increased risk of infections requiring antibiotics. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 169-176.e1.	0.5	19
672	Airway Inflammation and Inflammatory Biomarkers. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 056-063.	0.8	25
673	Diagnosis and Management of Severe Asthma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 091-099.	0.8	23
674	Current and future challenges in pediatric severe asthma. <i>Current Medical Research and Opinion</i> , 2018, 34, 943-944.	0.9	11
675	Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 504-511.e4.	0.5	94
676	Towards targeting resolution pathways of airway inflammation in asthma. , 2018, 186, 98-113.		76
677	The impact of gender on asthma in the daily clinical practice. <i>Postgraduate Medicine</i> , 2018, 130, 271-273.	0.9	15
678	Fevipirant in the treatment of asthma. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 199-207.	1.9	23
679	Evaluation of Potential Continuation Rules for Mepolizumab Treatment of Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 874-882.e4.	2.0	19
680	Bronchial Thermoplasty. <i>Clinics in Chest Medicine</i> , 2018, 39, 261-269.	0.8	9
681	A Randomized Trial of Itraconazole vs Prednisolone in Acute-Stage Allergic Bronchopulmonary Aspergillosis Complicating Asthma. <i>Chest</i> , 2018, 153, 656-664.	0.4	116
682	Sputum cell IL-1 receptor expression level is a marker of airway neutrophilia and airflow obstruction in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 415-423.	1.5	31
683	Asthma. <i>Lancet, The</i> , 2018, 391, 783-800.	6.3	1,105
684	Horses With Pasture Asthma Have Airway Remodeling That Is Characteristic of Human Asthma. <i>Veterinary Pathology</i> , 2018, 55, 144-158.	0.8	18
685	Severe asthma: We can fix it? We can try!. <i>Respirology</i> , 2018, 23, 260-261.	1.3	2
686	Sputum Eosinophilia and Magnetic Resonance Imaging Ventilation Heterogeneity in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 876-884.	2.5	76

#	ARTICLE	IF	CITATIONS
687	Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma. <i>European Respiratory Journal</i> , 2018, 51, 1701688.	3.1	52
688	Inhaler adherence in severe asthma: is there an electronic solution?. <i>European Respiratory Journal</i> , 2018, 51, 1702219.	3.1	6
689	New and emerging drug treatments for severe asthma. <i>Clinical and Experimental Allergy</i> , 2018, 48, 241-252.	1.4	32
690	Nerve ablation after bronchial thermoplasty and sustained improvement in severe asthma. <i>BMC Pulmonary Medicine</i> , 2018, 18, 29.	0.8	47
691	Occupational Asthma, Not a Trivial Disorder and a Source of Fatal and Near-Fatal Events. <i>Current Treatment Options in Allergy</i> , 2018, 5, 1-10.	0.9	2
692	Health care resource utilization and characteristics of patients with eosinophilic asthma in secondary health care in Finland. <i>European Clinical Respiratory Journal</i> , 2018, 5, 1458560.	0.7	11
693	Diagnosis and treatment of severe asthma: a phenotype-based approach. <i>Clinical Medicine</i> , 2018, 18, s36-s40.	0.8	45
694	Azithromycin Efficacy in Adults with Severe Persistent Uncontrolled Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1086-1088.	2.0	0
695	Severe Asthma in Primary Care: Identification and Management. <i>American Journal of Medicine</i> , 2018, 131, 484-491.	0.6	26
696	Asthma Phenotypes Defined From Parameters Obtained During Recovery From a Hospital-Treated Exacerbation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1960-1967.	2.0	22
697	Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults. <i>European Clinical Respiratory Journal</i> , 2018, 5, 1440868.	0.7	40
698	Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study. <i>European Respiratory Journal</i> , 2018, 51, 1702523.	3.1	186
699	Risk factors of asthma exacerbation based on asthma severity: a nationwide population-based observational study in South Korea. <i>BMJ Open</i> , 2018, 8, e020825.	0.8	48
700	Nanoparticle-based CpG-oligonucleotide therapy for treating allergic asthma. <i>Immunotherapy</i> , 2018, 10, 595-604.	1.0	20
701	Tralokinumab for the treatment of severe, uncontrolled asthma: the ATMOSPHERE clinical development program. <i>Immunotherapy</i> , 2018, 10, 473-490.	1.0	16
702	Research highlights from the 2017 ERS International Congress: airway diseases in focus. <i>ERJ Open Research</i> , 2018, 4, 00163-2017.	1.1	5
703	Oral corticosteroid exposure and adverse effects in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 110-116.e7.	1.5	211
704	BMAL1 links the circadian clock to viral airway pathology and asthma phenotypes. <i>Mucosal Immunology</i> , 2018, 11, 97-111.	2.7	115

#	ARTICLE	IF	CITATIONS
705	Omaliuzumab versus Mepolizumab as add-on therapy in asthma patients not well controlled on at least an inhaled corticosteroid: A network meta-analysis. <i>Journal of Asthma</i> , 2018, 55, 89-100.	0.9	27
706	The role of oral methotrexate as a steroid sparing agent in refractory eosinophilic asthma. <i>Chronic Respiratory Disease</i> , 2018, 15, 85-87.	1.0	6
707	Biologic treatment eligibility for real-world patients with severe asthma: The IDEAL study. <i>Journal of Asthma</i> , 2018, 55, 152-160.	0.9	87
708	The interplay between neuroendocrine activity and psychological stress-induced exacerbation of allergic asthma. <i>Allergology International</i> , 2018, 67, 32-42.	1.4	40
709	Sputum transcriptomics reveal upregulation of IL-1 receptor family members in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 560-570.	1.5	166
710	Investigation of bronchiectasis in severe uncontrolled asthma. <i>Clinical Respiratory Journal</i> , 2018, 12, 1212-1218.	0.6	43
711	Asthma medication use among adults with current asthma by work-related asthma status, Asthma Call-back Survey, 29 states, 2012-2013. <i>Journal of Asthma</i> , 2018, 55, 364-372.	0.9	9
712	The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 50-63.	2.7	49
713	Comorbidities in Difficult-to-Control Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 108-113.	2.0	57
714	Fungal immunomodulatory protein-fve could modulate airway remodel through by affect IL17 cytokine. <i>Journal of Microbiology, Immunology and Infection</i> , 2018, 51, 598-607.	1.5	23
715	The road to precision medicine in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 1-3.	1.2	10
716	Treatable traits of chronic airways disease. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 24-31.	1.2	24
717	Controversies and opportunities in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 83-93.	1.2	9
720	Internet-Based Monitoring in the Severe Asthma Research Program Identifies a Subgroup of Patients With Labile Asthma Control. <i>Chest</i> , 2018, 153, 378-386.	0.4	6
721	High prevalence of severe asthma in a large random population study. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2256-2264.e2.	1.5	28
722	Discovering Pediatric Asthma Phenotypes on the Basis of Response to Controller Medication Using Machine Learning. <i>Annals of the American Thoracic Society</i> , 2018, 15, 49-58.	1.5	32
723	MyD88-dependent dendritic and epithelial cell crosstalk orchestrates immune responses to allergens. <i>Mucosal Immunology</i> , 2018, 11, 796-810.	2.7	18
724	New approaches for identifying and testing potential new anti-asthma agents. <i>Expert Opinion on Drug Discovery</i> , 2018, 13, 51-63.	2.5	31

#	ARTICLE	IF	CITATIONS
725	TH1 signatures are present in the lower airways of children with severe asthma, regardless of allergic status. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 2048-2060.e13.	1.5	103
726	Airway pathology in severe asthma is related to airflow obstruction but not symptom control. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 635-643.	2.7	30
727	Personalized medicine with biologics for severe type 2 asthma: current status and future prospects. <i>MAbs</i> , 2018, 10, 34-45.	2.6	63
728	Precision medicine in asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 4-10.	1.2	61
729	Targeting the interleukin-4 and interleukin-13 pathways in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2018, 24, 50-55.	1.2	44
731	Asthma severity and heterogeneity: Insights from prevalence trends and associated demographic variables and anthropometric indices among Israeli adolescents. <i>Journal of Asthma</i> , 2018, 55, 826-836.	0.9	9
732	“This illness diminishes me. What it does is like theft” – A qualitative meta-synthesis of people's experiences of living with asthma. <i>Health Expectations</i> , 2018, 21, 23-40.	1.1	21
733	Impact of gastric reflux on asthma in clinical practice. <i>Respirology</i> , 2018, 23, 230-231.	1.3	3
734	Distinct Phenotypes of Smokers with Fixed Airflow Limitation Identified by Cluster Analysis of Severe Asthma. <i>Annals of the American Thoracic Society</i> , 2018, 15, 33-41.	1.5	46
735	Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population. <i>Thorax</i> , 2018, 73, 116-124.	2.7	116
736	Mepolizumab for Treating Severe Eosinophilic Asthma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. <i>Pharmacoeconomics</i> , 2018, 36, 131-144.	1.7	21
737	The impact of long-term systemic glucocorticoid use in severe asthma: A UK retrospective cohort analysis. <i>Journal of Asthma</i> , 2018, 55, 651-658.	0.9	38
738	After asthma: redefining airways diseases. <i>Lancet, The</i> , 2018, 391, 350-400.	6.3	744
739	Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. <i>Lancet Respiratory Medicine</i> , 2018, 6, 51-64.	5.2	220
740	Moving toward consensus on diagnosis and management of severe asthma in adults. <i>Current Medical Research and Opinion</i> , 2018, 34, 387-399.	0.9	9
741	Managing problematic severe asthma: beyond the guidelines. <i>Archives of Disease in Childhood</i> , 2018, 103, 392-397.	1.0	34
742	Moving toward consensus on diagnosis and management of severe asthma in children. <i>Current Medical Research and Opinion</i> , 2018, 34, 447-458.	0.9	7
743	Comorbid “treatable traits” in difficult asthma: Current evidence and clinical evaluation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1369-1382.	2.7	113



#	ARTICLE	IF	CITATIONS
744	Physical Activity and Exercise Capacity in Severe Asthma: Key Clinical Associations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 814-822.	2.0	65
745	A Practical Approach to Severe Asthma in Children. <i>Annals of the American Thoracic Society</i> , 2018, 15, 399-408.	1.5	35
746	A retrospective cohort study in severe asthma describing commonly measured biomarkers: Eosinophil count and IgE levels. <i>Respiratory Medicine</i> , 2018, 134, 117-123.	1.3	24
747	<i>Aspergillus fumigatus</i> -sensitive IgE is associated with bronchial hypersensitivity in a murine model of neutrophilic airway inflammation. <i>Journal De Mycologie Medicale</i> , 2018, 28, 128-136.	0.7	3
748	Exhaled breath temperature in optimally treated asthmatics: severity and underlying mechanisms. <i>Journal of Breath Research</i> , 2018, 12, 026013.	1.5	6
749	Pharmacologic Therapies for Severe Asthma. , 2018, , 99-122.		0
750	Basics of Severe Asthma in Clinical Practice. , 2018, , 3-12.		1
751	Biomarkers in Severe Asthma. , 2018, , 59-88.		0
752	Asthma versus chronic obstructive pulmonary disease, the Dutch versus British hypothesis, and role of interleukin-5. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 26-31.	1.1	9
753	Pathway discovery using transcriptomic profiles in adult-onset severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1280-1290.	1.5	105
754	Emerging understanding of the mechanism of action of Bronchial Thermoplasty in asthma. , 2018, 181, 101-107.		34
755	More than a decade follow-up in patients with severe or difficult-to-treat asthma: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) II. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1590-1597.e9.	1.5	62
756	Bronchial thermoplasty: an update for the interventional pulmonologist. <i>AME Medical Journal</i> , 2018, 3, 82-82.	0.4	2
757	Asthma phenotypes and their impact on treatment. <i>Practice Nursing</i> , 2018, 29, 573-577.	0.1	0
758	Appropriate use of oral corticosteroids for severe asthma. <i>Medical Journal of Australia</i> , 2018, 209, S18-S21.	0.8	44
759	Forced expiratory volume in 1-second and blood gas analysis in children during asthma attacks. <i>Paediatrica Indonesiana</i> , 2018, 58, 221-6.	0.0	0
760	Preview of highlighted presentations from the European Respiratory Societyâ€™ clinical assembly. <i>Journal of Thoracic Disease</i> , 2018, 10, S3034-S3042.	0.6	0
761	Chinese expert consensus on diagnosis and management of severe asthma. <i>Journal of Thoracic Disease</i> , 2018, 10, 7020-7044.	0.6	9

#	ARTICLE	IF	CITATIONS
762	Bronchiectasis after bronchial thermoplasty. <i>Journal of Thoracic Disease</i> , 2018, 10, E721-E726.	0.6	10
763	Diagnosis of severe asthma. <i>Medical Journal of Australia</i> , 2018, 209, S3-S10.	0.8	10
764	Biological treatments for severe asthma: where do we stand?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 509-518.	1.1	23
766	Lung Function Trajectory Types in Never-Smoking Adults With Asthma: Clinical Features and Inflammatory Patterns. <i>Allergy, Asthma and Immunology Research</i> , 2018, 10, 614.	1.1	10
767	Factors associated with daily life physical activity in patients with asthma. <i>Health Science Reports</i> , 2018, 1, e84.	0.6	18
768	Asthme. <i>Revue Des Maladies Respiratoires Actualites</i> , 2018, 10, S24-S31.	0.0	0
769	Managing comorbid conditions in severe asthma. <i>Medical Journal of Australia</i> , 2018, 209, S11-S17.	0.8	34
770	Health-related quality of life burden in severe asthma. <i>Medical Journal of Australia</i> , 2018, 209, S28-S33.	0.8	62
771	Models of care for severe asthma: the role of primary care. <i>Medical Journal of Australia</i> , 2018, 209, S34-S40.	0.8	19
772	Silent Airflow Obstruction and Air Trapping on Discharge in Children Hospitalized with Asthma. <i>Current Respiratory Medicine Reviews</i> , 2018, 14, 83-88.	0.1	0
773	Management of Severe Asthma in Children. <i>Current Treatment Options in Pediatrics</i> , 2018, 4, 438-455.	0.2	0
774	A century of "intrinsic asthma". <i>Allergo Journal</i> , 2018, 27, 19-23.	0.1	2
775	Utility of a thin bronchoscope in facilitating bronchial thermoplasty. <i>Journal of Asthma and Allergy</i> , 2018, Volume 11, 261-266.	1.5	8
776	Eligibility of monoclonal antibody-based therapy for patients with severe asthma: a Canadian cross-sectional perspective. <i>Allergy, Asthma and Clinical Immunology</i> , 2018, 14, 68.	0.9	13
777	Less exacerbations and sustained asthma control 12 months after high altitude climate treatment for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 628-630.	2.7	17
778	Small, Prospective, Observational, Pilot Study in Patients with Severe Asthma after Discontinuation of Omalizumab Treatment. <i>Clinical Therapeutics</i> , 2018, 40, 1942-1953.	1.1	2
779	An evaluation of fevipiprant for the treatment of asthma: a promising new therapy?. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 2087-2093.	0.9	6
780	Rhynchophylline attenuates allergic bronchial asthma by inhibiting transforming growth factor- $\beta$ -mediated Smad and mitogen-activated protein kinase signaling transductions <i>in vivo</i> and <i>in vitro</i> . <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 251-259.	1.1	8

#	ARTICLE	IF	CITATIONS
781	Comorbidities are associated with different features of severe asthma. <i>Clinical and Molecular Allergy</i> , 2018, 16, 25.	0.8	22
782	Personalized Approach to Severe Asthma. <i>BioMed Research International</i> , 2018, 2018, 1-2.	0.9	3
783	Biomarkers in asthma: state of the art. <i>Asthma Research and Practice</i> , 2018, 4, 10.	1.2	78
784	CD9+ Regulatory B Cells Induce T Cell Apoptosis via IL-10 and Are Reduced in Severe Asthmatic Patients. <i>Frontiers in Immunology</i> , 2018, 9, 3034.	2.2	42
785	Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma – a systematic review and meta-analysis. <i>European Clinical Respiratory Journal</i> , 2018, 5, 1536097.	0.7	47
786	Inflammatory and Comorbid Features of Children Admitted to a PICU for Status Asthmaticus*. <i>Pediatric Critical Care Medicine</i> , 2018, 19, e585-e594.	0.2	19
787	Letting the right one in: evaluating the generalisability of clinical trials. <i>European Respiratory Journal</i> , 2018, 52, 1802218.	3.1	8
788	Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis. <i>World Allergy Organization Journal</i> , 2018, 11, 26.	1.6	40
789	The North-Western Italian experience with anti IL-5 therapy and comparison with regulatory trials. <i>World Allergy Organization Journal</i> , 2018, 11, 34.	1.6	36
790	Severe refractory asthma: current treatment options and ongoing research. <i>Drugs in Context</i> , 2018, 7, 1-15.	1.0	22
791	Managing patients with severe asthma in Australia: Current challenges with the existing models of care. <i>Internal Medicine Journal</i> , 2018, 48, 1536-1541.	0.5	15
792	Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma. <i>BioMed Research International</i> , 2018, 2018, 1-8.	0.9	42
793	Eosinophils Target Therapy for Severe Asthma: Critical Points. <i>BioMed Research International</i> , 2018, 2018, 1-6.	0.9	37
794	Clinical and economic burden of severe asthma: A French cohort study. <i>Respiratory Medicine</i> , 2018, 144, 42-49.	1.3	33
795	Pulmonary Function, Biomarkers, and Bronchoprovocation Testing. , 2018, , 1-28.		0
796	Adherence to medication in children and adolescents with asthma: methods for monitoring and intervention. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 1055-1063.	1.3	45
797	Personalisierte Medizin bei Asthma und chronisch-obstruktiver Lungenerkrankung. <i>Karger Kompass Pneumologie</i> , 2018, 6, 149-156.	0.0	0
798	Bronchial thermoplasty reduces gas trapping in severe asthma. <i>BMC Pulmonary Medicine</i> , 2018, 18, 155.	0.8	16

#	ARTICLE	IF	CITATIONS
799	Perceptions of Severe Asthma and Asthma-COPD Overlap Syndrome Among Specialists: A Questionnaire Survey. <i>Allergy, Asthma and Immunology Research</i> , 2018, 10, 225.	1.1	13
801	Airway Eosinophilopoietic and Autoimmune Mechanisms of Eosinophilia in Severe Asthma. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 639-654.	0.7	30
802	Enhanced oxidative stress in smoking and ex-smoking severe asthma in the U-BIOPRED cohort. <i>PLoS ONE</i> , 2018, 13, e0203874.	1.1	18
803	Characteristics of patients with severe, uncontrolled, eosinophilic asthma enrolled in a French cohort. <i>Journal of Asthma and Allergy</i> , 2018, Volume 11, 217-224.	1.5	5
804	Omalizumab dampens type 2 inflammation in a group of long-term treated asthma patients and detaches IgE from Fc $\mu$ RI. <i>European Journal of Immunology</i> , 2018, 48, 2005-2014.	1.6	40
805	Revisiting IL-13 blockade: can we reach the wonderland the inhaled way?. <i>EBioMedicine</i> , 2018, 35, 6-7.	2.7	2
806	Asthma: Differential Diagnosis and Comorbidities. <i>Frontiers in Pediatrics</i> , 2018, 6, 276.	0.9	44
807	Sulforaphane ameliorates steroid insensitivity through an Nrf2-dependent pathway in cigarette smoke-exposed asthmatic mice. <i>Free Radical Biology and Medicine</i> , 2018, 129, 473-485.	1.3	25
808	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. <i>Therapeutic Advances in Respiratory Disease</i> , 2018, 12, 175346661880849.	1.0	53
809	Randomised controlled trials in severe asthma: selection by phenotype or stereotype. <i>European Respiratory Journal</i> , 2018, 52, 1801444.	3.1	70
811	Non-eosinophilic asthma: current perspectives. <i>Journal of Asthma and Allergy</i> , 2018, Volume 11, 267-281.	1.5	81
812	Age and Sex Associations with Systemic Corticosteroid-Induced Morbidity in Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2014-2023.e2.	2.0	25
813	Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use. <i>Therapeutics and Clinical Risk Management</i> , 2018, Volume 14, 2059-2068.	0.9	11
814	Is phrenic nerve conduction affected in patients with difficult-to-treat asthma?. <i>Arquivos De Neuro-Psiquiatria</i> , 2018, 76, 177-182.	0.3	5
815	Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD. <i>Monaldi Archives for Chest Disease</i> , 2018, 88, 886.	0.3	17
816	Airway and esophageal eosinophils in children with severe uncontrolled asthma. <i>Pediatric Pulmonology</i> , 2018, 53, 1598-1603.	1.0	9
817	The Use and Interpretation of Impedance Oscillometry in Pulmonary Disorders. <i>Current Pulmonology Reports</i> , 2018, 7, 196-202.	0.5	1
818	Evidence-Based Assessment of Bronchial Thermoplasty in Asthma: Mechanisms and Outcomes. <i>Current Pulmonology Reports</i> , 2018, 7, 188-195.	0.5	0

#	ARTICLE	IF	CITATIONS
819	The Severe Paediatric Asthma Collaborative in Europe (SPACE) ERS Clinical Research Collaboration: enhancing participation of children with asthma in therapeutic trials of new biologics and receptor blockers. <i>European Respiratory Journal</i> , 2018, 52, 1801665.	3.1	25
820	Exhaled Nitric Oxide. <i>Immunology and Allergy Clinics of North America</i> , 2018, 38, 573-585.	0.7	33
821	Differentiation of adult severe asthma from difficult-to-treat asthma – Outcomes of a systematic assessment protocol. <i>Respiratory Medicine</i> , 2018, 145, 41-47.	1.3	45
822	IL-17A Attenuates IFN- $\gamma$ Expression by Inducing Suppressor of Cytokine Signaling Expression in Airway Epithelium. <i>Journal of Immunology</i> , 2018, 201, 2392-2402.	0.4	25
823	A Charter to Improve Patient Care in Severe Asthma. <i>Advances in Therapy</i> , 2018, 35, 1485-1496.	1.3	59
824	Health care resource utilization and cost for asthma patients regularly treated with oral corticosteroids – a Swedish observational cohort study (PACEHR). <i>Respiratory Research</i> , 2018, 19, 168.	1.4	30
825	Interventions on Adherence to Treatment in Children With Severe Asthma: A Systematic Review. <i>Frontiers in Pediatrics</i> , 2018, 6, 232.	0.9	33
826	Treating Pediatric Asthma According Guidelines. <i>Frontiers in Pediatrics</i> , 2018, 6, 234.	0.9	39
827	Omaliuzumab for Severe Asthma: Beyond Allergic Asthma. <i>BioMed Research International</i> , 2018, 2018, 1-10.	0.9	29
828	Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. <i>European Respiratory Journal</i> , 2018, 52, 1800703.	3.1	202
829	Dietary Intake of Flavonoids and Ventilatory Function in European Adults: A GA2LEN Study. <i>Nutrients</i> , 2018, 10, 95.	1.7	26
830	Is Omaliuzumab a Problem-Solving Remedy in Severe Asthma?. <i>Allergy, Asthma and Immunology Research</i> , 2018, 10, 95.	1.1	1
831	Can Controlling Endoplasmic Reticulum Dysfunction Treat Allergic Inflammation in Severe Asthma With Fungal Sensitization?. <i>Allergy, Asthma and Immunology Research</i> , 2018, 10, 106.	1.1	8
832	Impact of reslizumab on outcomes of severe asthmatic patients: current perspectives. <i>Patient Related Outcome Measures</i> , 2018, Volume 9, 267-273.	0.7	8
833	Severe Asthma: Updated Therapy Approach Based on Phenotype and Biomarker. , 2018, , .		1
834	Subcellular Organelles in Immune Responses of Severe Asthma: The Roles of Mitochondria and Endoplasmic Reticulum. , 2018, , .		0
835	FKBP51 modulates steroid sensitivity and NF- $\kappa$ B signalling: A novel anti-inflammatory drug target. <i>European Journal of Immunology</i> , 2018, 48, 1904-1914.	1.6	42
836	Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis. <i>Lung</i> , 2018, 196, 517-530.	1.4	43

#	ARTICLE	IF	CITATIONS
837	Genome-Wide Posttranscriptional Dysregulation by MicroRNAs in Human Asthma as Revealed by Frac-seq. <i>Journal of Immunology</i> , 2018, 201, 251-263.	0.4	28
838	Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma. <i>Allergology International</i> , 2018, 67, S3-S11.	1.4	36
839	Optimising experimental research in respiratory diseases: an ERS statement. <i>European Respiratory Journal</i> , 2018, 51, 1702133.	3.1	98
840	Prospective predictors of exacerbation status in severe asthma over a 3-year follow-up. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1137-1146.	1.4	48
841	Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. <i>Lancet Respiratory Medicine</i> , 2018, 6, 511-525.	5.2	175
842	Anti-allergy and anti-tussive activity of <i>Clitoria ternatea</i> L. in experimental animals. <i>Journal of Ethnopharmacology</i> , 2018, 224, 15-26.	2.0	16
843	Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 499-510.	5.2	104
844	Dynamic hyperinflation during the 6-min walk test in severely asthmatic subjects. <i>ERJ Open Research</i> , 2018, 4, 00143-2017.	1.1	8
846	Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no!. <i>European Respiratory Journal</i> , 2018, 51, 1800730.	3.1	5
847	Assessment of airway inflammation and remodeling in children with severe asthma: The next challenge. <i>Pediatric Pulmonology</i> , 2018, 53, 1171-1173.	1.0	7
848	Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review. <i>Drugs</i> , 2018, 78, 809-821.	4.9	36
849	The construction and validation of the Severe Asthma Questionnaire. <i>European Respiratory Journal</i> , 2018, 52, 1800618.	3.1	25
850	Current and Emerging Biologic Therapies for Asthma and COPD. <i>Respiratory Care</i> , 2018, 63, 699-707.	0.8	22
851	Maternal asthma is associated with increased risk of perinatal mortality. <i>PLoS ONE</i> , 2018, 13, e0197593.	1.1	39
852	New therapeutic options in asthma. <i>Medicina Clínica (English Edition)</i> , 2018, 151, 16-17.	0.1	0
853	The effect of omalizumab treatment on the low affinity immunoglobulin E receptor (CD23/fc epsilon) Tj ETQq1 1 0.784314 rgBT /Ove	1.0	2
854	Characterizing patients with asthma who received Global Initiative for Asthma steps 4-5 therapy and managed in a specialty care setting. <i>Allergy and Asthma Proceedings</i> , 2018, 39, 27-35.	1.0	13
855	Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab. <i>Advances in Therapy</i> , 2018, 35, 1059-1068.	1.3	14

#	ARTICLE	IF	CITATIONS
856	Asthma Endotyping and Biomarkers in Childhood Asthma. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2018, 31, 44-55.	0.3	123
857	High prevalence of house dust mite sensitization in children with severe asthma living at high altitude in a tropical country. <i>Pediatric Pulmonology</i> , 2018, 53, 1356-1361.	1.0	13
859	Ability of Exhaled Nitric Oxide to Discriminate for Airflow Obstruction Among Frequent Exacerbators of Clinically Diagnosed Asthma. <i>Lung</i> , 2018, 196, 455-462.	1.4	2
860	The Role of the Body Clock in Asthma and COPD: Implication for Treatment. <i>Pulmonary Therapy</i> , 2018, 4, 29-43.	1.1	36
861	An Integrative Transcriptomic and Metabolomic Study of Lung Function in Children With Asthma. <i>Chest</i> , 2018, 154, 335-348.	0.4	52
862	Use of biomarkers to identify phenotypes and endotypes of severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 121, 414-420.	0.5	51
863	Reply to Upham: The Bronchial Epithelial Secretory IgA System in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1236-1238.	2.5	2
864	Update on new biologics for intractable eosinophilic asthma: impact of reslizumab. <i>Drug Design, Development and Therapy</i> , 2018, Volume 12, 1173-1181.	2.0	17
865	Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. <i>Current Medical Research and Opinion</i> , 2018, 34, 2075-2088.	0.9	72
866	The role of miR-29c/B7-H3 axis in children with allergic asthma. <i>Journal of Translational Medicine</i> , 2018, 16, 218.	1.8	32
867	Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma. <i>Journal of Asthma and Allergy</i> , 2018, Volume 11, 63-72.	1.5	22
868	miR-142-3p is associated with aberrant WNT signaling during airway remodeling in asthma. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2018, 315, L328-L333.	1.3	37
869	Measuring Airway Obstruction in Severe Asthma in Children. <i>Frontiers in Pediatrics</i> , 2018, 6, 189.	0.9	7
870	Optimising treatment for severe asthma. <i>Medical Journal of Australia</i> , 2018, 209, S22-S27.	0.8	20
871	Urgent need for pragmatic trial platforms in severe asthma. <i>Lancet Respiratory Medicine</i> , 2018, 6, 581-583.	5.2	15
873	Management of Severe Asthma in Adults. , 2018, , 19-32.		0
874	Management and Prevention of Severe Asthma in Children. , 2018, , 33-47.		0
875	Discovery and Validation of New Biomarkers for Personalizing Asthma Therapy. , 2018, , 87-95.		1

#	ARTICLE	IF	CITATIONS
876	Imaging Procedures and Bronchial Thermoplasty for Asthma Assessment and Intervention. , 2018, , 191-205.		1
877	Anti-IL-5 therapy in patients with severe eosinophilic asthma â€œ clinical efficacy and possible criteria for treatment response. BMC Pulmonary Medicine, 2018, 18, 119.	0.8	96
878	Add-on Therapy for Symptomatic Asthma despite Long-Acting Beta-Agonists/Inhaled Corticosteroid. Tuberculosis and Respiratory Diseases, 2018, 81, 1.	0.7	5
879	Misdiagnosis of asthma and COPD and underuse of spirometry in primary care unselected patients. Respiratory Medicine, 2018, 142, 48-52.	1.3	81
880	High Prevalence of Asthma in Elderly Women: Findings From a Korean National Health Database and Adult Asthma Cohort. Allergy, Asthma and Immunology Research, 2018, 10, 387.	1.1	41
881	Asthma Precision. Translational Bioinformatics, 2018, , 361-385.	0.0	0
882	Selecting the right biologic for your patients with severe asthma. Annals of Allergy, Asthma and Immunology, 2018, 121, 406-413.	0.5	41
883	Neutrophil cytoplasts induce T <sub>H</sub> 17 differentiation and skew inflammation toward neutrophilia in severe asthma. Science Immunology, 2018, 3, .	5.6	157
884	Influenza A virus infection dysregulates the expression of microRNA-22 and its targets; CD147 and HDAC4, in epithelium of asthmatics. Respiratory Research, 2018, 19, 145.	1.4	47
885	Rhinosinutis and Asthma in Children. Sinusitis, 2018, 3, 3.	0.2	2
886	Difficult vs. Severe Asthma: Definition and Limits of Asthma Control in the Pediatric Population. Frontiers in Pediatrics, 2018, 6, 170.	0.9	59
887	Towards precision medicine in severe asthma: Treatment algorithms based on treatable traits. Respiratory Medicine, 2018, 142, 15-22.	1.3	22
888	Blood Eosinophils as Biomarkers to Drive Treatment Choices in Asthma and COPD. Current Drug Targets, 2018, 19, 1882-1896.	1.0	60
889	Rhinology Future Debates 2017 by <scp>EUFOREA</scp>: Novel treatments and surgical solutions in rhinology. Clinical Otolaryngology, 2018, 43, 1429-1438.	0.6	3
890	Update on Diagnosis and Management of Severe Asthma. Journal for Nurse Practitioners, 2018, 14, 520-525.	0.4	1
891	Does allergy explain why some children have severe asthma?. Clinical and Experimental Allergy, 2018, 48, 1594-1605.	1.4	11
892	Therapeutic Effect of Omalizumab in Severe Asthma: A Real-World Study in Korea. Allergy, Asthma and Immunology Research, 2018, 10, 121.	1.1	19
893	Effects of endogenous sex hormones on lung function and symptom control in adolescents with asthma. BMC Pulmonary Medicine, 2018, 18, 58.	0.8	74



#	ARTICLE	IF	CITATIONS
894	Taming Asthma in School-Aged Children: A Comprehensive Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 726-735.	2.0	22
895	Prevalence and management of severe asthma in primary care: an observational cohort study in Sweden (PACEHR). <i>Respiratory Research</i> , 2018, 19, 12.	1.4	71
896	Pediatric severe asthma: a case series report and perspectives on anti-IgE treatment. <i>BMC Pediatrics</i> , 2018, 18, 73.	0.7	12
897	Severe, eosinophilic asthma in primary care in Canada: a longitudinal study of the clinical burden and economic impact based on linked electronic medical record data. <i>Allergy, Asthma and Clinical Immunology</i> , 2018, 14, 15.	0.9	16
899	Severe Asthma: Challenges and Pitfalls in Management. <i>Indian Journal of Pediatrics</i> , 2018, 85, 763-772.	0.3	2
900	The Tempest: Difficult to Control Asthma in Adolescence. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 738-748.	2.0	9
901	Anticalin® Proteins as Therapeutic Agents in Human Diseases. <i>BioDrugs</i> , 2018, 32, 233-243.	2.2	78
902	Biological function of eosinophil extracellular traps in patients with severe eosinophilic asthma. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-8.	3.2	59
903	Bronchial Thermoplasty-Induced Acute Airway Effects Assessed with Optical Coherence Tomography in Severe Asthma. <i>Respiration</i> , 2018, 96, 564-570.	1.2	30
904	The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. <i>Respiratory Research</i> , 2018, 19, 154.	1.4	33
905	Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. <i>Respiratory Medicine</i> , 2018, 143, 31-38.	1.3	41
906	Obesity-associated severe asthma in an adult Japanese population. <i>Respiratory Investigation</i> , 2018, 56, 440-447.	0.9	24
907	Polymeric gels for diagnostics applications. , 2018, , 373-393.		0
908	Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma. <i>European Respiratory Journal</i> , 2018, 52, 1800936.	3.1	173
909	Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. <i>Respiratory Medicine</i> , 2018, 142, 66-72.	1.3	18
910	Efficacy and effectiveness of omalizumab in the treatment of childhood asthma. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 745-754.	1.0	7
911	Severe bronchial asthma in children: a review of novel biomarkers used as predictors of the disease. <i>Journal of Asthma and Allergy</i> , 2018, Volume 11, 11-18.	1.5	16
912	<i>Bifidobacterium breve</i> MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration. <i>Scientific Reports</i> , 2018, 8, 12024.	1.6	42

#	ARTICLE	IF	CITATIONS
913	Quantitative CT detects changes in airway dimensions and air-trapping after bronchial thermoplasty for severe asthma. <i>European Journal of Radiology</i> , 2018, 107, 33-38.	1.2	27
914	Transfer coefficients better reflect emphysematous changes than carbon monoxide diffusing capacity in obstructive lung diseases. <i>Journal of Applied Physiology</i> , 2018, 125, 183-189.	1.2	12
915	Dietary patterns and respiratory health in adults from nine European countries—Evidence from the GALEN study. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1474-1482.	1.4	14
917	Implications of Changes in U.S. Food and Drug Administration Prescribing Information Regarding the Safety and Use of Asthma Biologics during Pregnancy. <i>Annals of the American Thoracic Society</i> , 2018, 15, 1131-1136.	1.5	8
918	Epithelial folliculin enhances airway inflammation in aspirin-exacerbated respiratory disease. <i>Clinical and Experimental Allergy</i> , 2018, 48, 1464-1473.	1.4	18
919	An extracellular matrix fragment drives epithelial remodeling and airway hyperresponsiveness. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	33
920	Can inflammatory markers in induced sputum be used to detect phenotypes and endotypes of pediatric severe therapy-resistant asthma?. <i>Pediatric Pulmonology</i> , 2018, 53, 1208-1217.	1.0	24
921	Synergistic activation of pro-inflammatory type-2 CD8+ T lymphocytes by lipid mediators in severe eosinophilic asthma. <i>Mucosal Immunology</i> , 2018, 11, 1408-1419.	2.7	46
922	Mobile direct observation of therapy (MDOT) - A rapid systematic review and pilot study in children with asthma. <i>PLoS ONE</i> , 2018, 13, e0190031.	1.1	51
923	Substantial variation exists in spirometry interpretation practices for airflow obstruction in accredited lung function laboratories across Australia and New Zealand. <i>Internal Medicine Journal</i> , 2019, 49, 41-47.	0.5	6
924	T cells and ILC2s are major effector cells in influenza-induced exacerbation of allergic airway inflammation in mice. <i>European Journal of Immunology</i> , 2019, 49, 144-156.	1.6	43
925	Wheezing in Older Children. , 2019, , 686-721.e4.		2
926	Severe Asthma. , 2019, , 722-736.e5.		0
928	Are high- and low-molecular-weight sensitizing agents associated with different clinical phenotypes of occupational asthma?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 261-272.	2.7	69
929	Clinical Approach to the Therapy of Asthma-COPD Overlap. <i>Chest</i> , 2019, 155, 168-177.	0.4	44
930	Endotypes of severe allergic asthma patients who clinically benefit from anti-IgE therapy. <i>Clinical and Experimental Allergy</i> , 2019, 49, 44-53.	1.4	32
931	Economic impact of severe asthma in Spain: multicentre observational longitudinal study. <i>Journal of Asthma</i> , 2019, 56, 861-871.	0.9	22
932	Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 165-174.e4.	2.0	30

#	ARTICLE	IF	CITATIONS
933	Case study: A Combination of Mepolizumab and Omalizumab injections for severe asthma. <i>Journal of Asthma</i> , 2019, 56, 473-474.	0.9	17
934	Clinical significance of the bronchodilator response in children with severe asthma. <i>Pediatric Pulmonology</i> , 2019, 54, 1694-1703.	1.0	10
936	Real-life studies of biologics used in asthma patients: key differences and similarities to trials. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 951-958.	1.3	20
937	Impact of Gene Expression Associated with Glucocorticoid-Induced Transcript 1 (GLCCI1) on Severe Asthma and Future Exacerbation. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 1746-1752.	0.6	10
938	Glucocorticoidsâ€™ All-Rounders Tackling the Versatile Players of the Immune System. <i>Frontiers in Immunology</i> , 2019, 10, 1744.	2.2	170
939	Severe exacerbations in moderate-to-severe asthmatics are associated with increased pro-inflammatory and type 1 mediators in sputum and serum. <i>BMC Pulmonary Medicine</i> , 2019, 19, 144.	0.8	28
940	Discovery of the Oral Leukotriene C4 Synthase Inhibitor (1 <i>S</i> )-2-((5-((5-Chloro-2,4-difluorophenyl)(2-fluoro-2-methylpropyl)amino)-3-methoxypyrazin-2-yl)carbonyl)cyclopropanecarboxylic Acid (AZD9898) as a New Treatment for Asthma. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7769-7787.	2.0	14
941	Treatable traits in acute exacerbations of chronic airway diseases. <i>Chronic Respiratory Disease</i> , 2019, 16, 147997311986795.	1.0	48
942	The Safety and Efficacy of Anti-IL-13 Treatment with Tralokinumab (CAT-354) in Moderate to Severe Asthma: A Systematic Review and Meta-Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2661-2671.e3.	2.0	14
943	Asthma from immune pathogenesis to precision medicine. <i>Seminars in Immunology</i> , 2019, 46, 101294.	2.7	35
944	Severe Occupational Asthma: Insights From a Multicenter European Cohort. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2309-2318.e4.	2.0	39
945	Difficult-to-treat and severe asthma in general practice: delivery and evaluation of an educational program. <i>BMC Family Practice</i> , 2019, 20, 99.	2.9	4
946	Activation of Resolution Pathways to Prevent and Fight Chronic Inflammation: Lessons From Asthma and Inflammatory Bowel Disease. <i>Frontiers in Immunology</i> , 2019, 10, 1699.	2.2	54
947	Managing severe asthma: back to the basic elements of care. <i>The Prescriber</i> , 2019, 30, 32-35.	0.1	1
948	Severe asthma: Comparison of different classifications of severity and control. <i>Respiratory Medicine</i> , 2019, 156, 1-7.	1.3	7
949	Application of structured statistical analyses to identify a biomarker predictive of enhanced tralokinumab efficacy in phase III clinical trials for severe, uncontrolled asthma. <i>BMC Pulmonary Medicine</i> , 2019, 19, 129.	0.8	6
950	Immunomodulation in Pediatric Asthma. <i>Frontiers in Pediatrics</i> , 2019, 7, 289.	0.9	35
951	Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. <i>Paediatric Drugs</i> , 2019, 21, 215-237.	1.3	48

#	ARTICLE	IF	CITATIONS
952	Asthma severity in four countries of Latin America. <i>BMC Pulmonary Medicine</i> , 2019, 19, 123.	0.8	15
953	Protocol on a systematic review of qualitative studies on asthma treatment challenges experienced in Sub-Saharan Africa. <i>Systematic Reviews</i> , 2019, 8, 149.	2.5	3
954	Forced oscillation technique may identify severe asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2857-2860.e1.	2.0	5
955	Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2689-2696.e2.	2.0	24
956	Association of depressive symptoms with health status and markers of uncontrolled severe asthma. <i>Allergy and Asthma Proceedings</i> , 2019, 40, 230-239.	1.0	3
957	Anti-Neutrophil Cytoplasmic Antibodies Positivity and Anti-Leukotrienes in Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Monocentric Study on 134 Italian Patients. <i>International Archives of Allergy and Immunology</i> , 2019, 180, 64-71.	0.9	16
958	Airway mycosis in allergic airway disease. <i>Advances in Immunology</i> , 2019, 142, 85-140.	1.1	29
960	A Patient-Centered Description of Severe Asthma: Patient Understanding Leading to Assessment for a Severe Asthma Referral (PULSAR). <i>Patient</i> , 2019, 12, 539-549.	1.1	6
961	Living well with severe asthma. <i>Breathe</i> , 2019, 15, e40-e49.	0.6	21
962	Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101830.	1.1	44
963	Transthoracic ultrasound sign in severe asthmatic patients: a lack of "œgliding sign" mimic pneumothorax. <i>BJR   case Reports</i> , 2019, 5, 20190030.	0.1	8
964	High prevalence of bronchiectasis on chest CT in a selected cohort of children with severe Asthma. <i>BMC Pulmonary Medicine</i> , 2019, 19, 136.	0.8	10
965	Bronchial thermoplasty increases airway volume measured by functional respiratory imaging. <i>Respiratory Research</i> , 2019, 20, 157.	1.4	21
966	Biologics targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitis. <i>European Journal of Immunology</i> , 2019, 49, 1334-1343.	1.6	19
967	Anxiety and Depression in Adolescents with Severe Asthma and in Their Parents: Preliminary Results after 1 Year of Treatment. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2019, 9, 78.	1.0	23
968	Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA. <i>Respiratory Research</i> , 2019, 20, 169.	1.4	34
969	Serum levels of IL-5, IL-6, IL-8, IL-13 and IL-17A in pre-defined groups of adult patients with moderate and severe bronchial asthma. <i>Respiratory Medicine</i> , 2019, 154, 144-154.	1.3	29
970	Evidence-Based Medicine and the American Thoracic Society Guidelines. <i>JAMA Internal Medicine</i> , 2019, 179, 1002.	2.6	0

#	ARTICLE	IF	CITATIONS
971	Severe Asthma in Childhood. <i>Immunology and Allergy Clinics of North America</i> , 2019, 39, 243-257.	0.7	5
972	Exhaled volatile organic compounds in adult asthma: a systematic review. <i>European Respiratory Journal</i> , 2019, 54, 1900056.	3.1	35
973	Severe asthma phenotypes in patients controlled with omalizumab: A real-world study. <i>Respiratory Medicine</i> , 2019, 159, 105804.	1.3	8
974	Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1205-1212.	1.0	25
975	Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis. <i>BMC Pulmonary Medicine</i> , 2019, 19, 176.	0.8	40
976	&lt;p&gt;Approaches to the assessment of severe asthma: barriers and strategies&lt;/p&gt;. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 235-251.	1.5	25
977	Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. <i>Pediatric Pulmonology</i> , 2019, 54, 1957-1967.	1.0	61
978	Living with severe asthma: the role of perceived competence and goal achievement. <i>Chronic Illness</i> , 2019, 17, 174239531988410.	0.6	3
979	Disparate Eosinophilic Phenotypes with Age: Impact on Eligibility for Anti-IL-5 Therapies in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2697-2698.	2.0	0
980	Dehydroepiandrosterone Supplementation May Benefit Women with Asthma Who Have Low Androgen Levels: A Pilot Study. <i>Pulmonary Therapy</i> , 2019, 5, 213-220.	1.1	16
981	House-Dust Mite Immunotherapy in Asthma: Uncertainties and Therapeutic Strategies. <i>Current Treatment Options in Allergy</i> , 2019, 6, 363-376.	0.9	1
982	Symptoms and exacerbations in asthma: an apparent paradox?. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231988438.	1.1	5
983	Asthma and the Biologics Revolution, Part 1: Here and Now. <i>Current Treatment Options in Allergy</i> , 2019, 6, 447-467.	0.9	0
984	Efficacy and safety of bronchial thermoplasty in clinical practice: a prospective, longitudinal, cohort study using evidence from the UK Severe Asthma Registry. <i>BMJ Open</i> , 2019, 9, e026742.	0.8	17
985	Severe Asthma—Perspectives From Adult and Pediatric Pulmonology. <i>Frontiers in Pediatrics</i> , 2019, 7, 389.	0.9	16
986	Long-term Safety and Clinical Benefit of Mepolizumab in Patients With the Most Severe Eosinophilic Asthma: The COSMEX Study. <i>Clinical Therapeutics</i> , 2019, 41, 2041-2056.e5.	1.1	102
987	ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions. <i>European Respiratory Journal</i> , 2019, 54, 1900900.	3.1	56
988	Acute Severe Asthma in Adolescent and Adult Patients: Current Perspectives on Assessment and Management. <i>Journal of Clinical Medicine</i> , 2019, 8, 1283.	1.0	30

#	ARTICLE	IF	CITATIONS
989	Korean childhood asthma study (KAS): a prospective, observational cohort of Korean asthmatic children. <i>BMC Pulmonary Medicine</i> , 2019, 19, 64.	0.8	8
990	Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations. <i>Clinical and Translational Allergy</i> , 2019, 9, 41.	1.4	46
992	Short-term pulmonary infiltrate with eosinophilia caused by asthma: a phenotype of severe, eosinophilic asthma? Five cases and a review of the literature. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 48.	0.9	0
993	Severe Eosinophilic Asthma. <i>Journal of Clinical Medicine</i> , 2019, 8, 1375.	1.0	73
994	Anti-interleukin-5 therapy (mepolizumab) in life-threatening asthma attack: A case-based discussion. <i>Respiratory Medicine Case Reports</i> , 2019, 28, 100927.	0.2	5
995	Comparison of the Association between Circulating Vitamin D<sub>3</sub> Levels and Clinical Outcomes in Patients with Asthma and Chronic Obstructive Pulmonary Disease: A Prospective Observational Study. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 1861-1866.	0.6	2
996	New Treatments for Asthma. <i>Pediatric Clinics of North America</i> , 2019, 66, 925-939.	0.9	14
997	Severe asthma phenotypes and endotypes. <i>Seminars in Immunology</i> , 2019, 46, 101301.	2.7	43
998	Long-term effect of home-based pulmonary rehabilitation in severe asthma. <i>Respiratory Medicine</i> , 2019, 157, 36-41.	1.3	16
999	Defining severe obstructive lung disease in the biologic era: an endotype-based approach. <i>European Respiratory Journal</i> , 2019, 54, 1900108.	3.1	12
1000	Inhaled corticosteroids in asthma and the need for universal health coverage. <i>European Respiratory Journal</i> , 2019, 54, 1900963.	3.1	1
1001	Does maintenance azithromycin reduce asthma exacerbations? An individual participant data meta-analysis. <i>European Respiratory Journal</i> , 2019, 54, 1901381.	3.1	47
1002	Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1336-1342.e7.	1.5	70
1003	One year of mepolizumab. Efficacy and safety in real-life in Italy. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 58, 101836.	1.1	57
1004	Is it safe to SCUBA dive with asthma?. <i>Expert Review of Respiratory Medicine</i> , 2019, 13, 1069-1077.	1.0	2
1005	What have recent advances in therapy taught us about severe asthma disease mechanisms?. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1145-1153.	1.3	7
1006	Allergen-induced asthma, chronic rhinosinusitis and transforming growth factor- $\beta$ superfamily signaling: mechanisms and functional consequences. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 1155-1170.	1.3	6
1007	Evidence for a MAIT-17 $\alpha$ high phenotype in children with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1714-1716.e6.	1.5	25

#	ARTICLE	IF	CITATIONS
1008	Modified Shuttle Test Distance Correlates With Peak Oxygen Uptake in Children and Adolescents With Severe Therapy-Resistant Asthma. <i>Frontiers in Physiology</i> , 2019, 10, 1245.	1.3	2
1009	Time to rethink severe asthma care. <i>British Journal of Health Care Management</i> , 2019, 25, 264-268.	0.1	0
1011	Resistance to apoptosis underpins the corticosteroid insensitivity of group 2 innate lymphoid cells. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, 1722-1726.e10.	1.5	5
1012	Mouse models of severe asthma for evaluation of therapeutic cytokine targeting. <i>Immunology Letters</i> , 2019, 207, 73-83.	1.1	13
1013	Experimental and investigational phosphodiesterase inhibitors in development for asthma. <i>Expert Opinion on Investigational Drugs</i> , 2019, 28, 261-266.	1.9	10
1014	Multiview Cluster Analysis Identifies Variable Corticosteroid Response Phenotypes in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1358-1367.	2.5	91
1015	Impaired immunoregulatory network of the <sc>CD</sc>4 T lymphocytes in refractory asthma. <i>Clinical and Experimental Allergy</i> , 2019, 49, 644-654.	1.4	2
1016	Outpatient pulmonary rehabilitation for severe asthma with fixed airway obstruction: Comparison with COPD. <i>Journal of Asthma</i> , 2019, 56, 1325-1333.	0.9	8
1017	Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. <i>Respiratory Research</i> , 2019, 20, 14.	1.4	51
1018	Passive smoking induces pediatric asthma by affecting the balance of Treg/Th17 cells. <i>Pediatric Research</i> , 2019, 85, 469-476.	1.1	14
1019	Bronchial Thermoplasty. <i>Clinics in Chest Medicine</i> , 2019, 40, 193-207.	0.8	10
1020	Chitinase-like protein YKL-40 correlates with inflammatory phenotypes, anti-asthma responsiveness and future exacerbations. <i>Respiratory Research</i> , 2019, 20, 95.	1.4	35
1021	Extrapulmonary associations of health status in severe asthma and bronchiectasis: Comorbidities and functional outcomes. <i>Respiratory Medicine</i> , 2019, 154, 93-101.	1.3	16
1022	Autoimmune Diseases and Asthma. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 246-248.	0.6	4
1023	&lt;p&gt;A multicenter, open-label, noninterventional study to evaluate the impact on clinical effects, user-friendliness and patientsâ€™ acceptance of AirFluSal Forspiro in the treatment of asthma under real-life conditions (ASSURE)&lt;/p&gt;. <i>Journal of Pragmatic and Observational Research</i> , 2019, Volume 10, 29-39.	1.1	0
1024	Amoxicillin-Induced Aseptic Meningitis: 2 Case Reports and Appraisal of the Literature. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 248-250.	0.6	5
1025	Current and future targeted therapies for severe asthma: Managing treatment with biologics based on phenotypes and biomarkers. <i>Pharmacological Research</i> , 2019, 146, 104296.	3.1	30
1026	Epidemiology of Asthma in Children and Adults. <i>Frontiers in Pediatrics</i> , 2019, 7, 246.	0.9	614

#	ARTICLE	IF	CITATIONS
1027	Efficacy and Safety of Benralizumab for Korean Patients With Severe, Uncontrolled Eosinophilic Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2019, 11, 508.	1.1	19
1028	Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility. <i>Respiratory Medicine</i> , 2019, 154, 69-75.	1.3	28
1029	A Case of Persistent Asthma Resistant to Available Treatment Options: Management Dilemma. <i>Cureus</i> , 2019, 11, e4194.	0.2	2
1030	Protocol for the Wessex AsThma CoHort of difficult asthma (WATCH): a pragmatic real-life longitudinal study of difficult asthma in the clinic. <i>BMC Pulmonary Medicine</i> , 2019, 19, 99.	0.8	22
1031	Anti-inflammatory Property of Galectin-1 in a Murine Model of Allergic Airway Inflammation. <i>Journal of Immunology Research</i> , 2019, 2019, 1-10.	0.9	8
1032	Rosiglitazone Improves Glucocorticoid Resistance in a Sudden Sensorineural Hearing Loss by Promoting MAP Kinase Phosphatase-1 Expression. <i>Mediators of Inflammation</i> , 2019, 2019, 1-10.	1.4	6
1033	Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. <i>Respiratory Research</i> , 2019, 20, 108.	1.4	40
1034	Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Real-life observation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2539-2541.	2.7	36
1035	Pulmonary type-2 innate lymphoid cells in paediatric severe asthma: phenotype and response to steroids. <i>European Respiratory Journal</i> , 2019, 54, 1801809.	3.1	51
1037	Pulmonary Function, Biomarkers, and Bronchoprovocation Testing. , 2019, , 755-781.		0
1038	Prevalence of severe asthma according to the drug regulatory agency perspective: An Italian experience. <i>World Allergy Organization Journal</i> , 2019, 12, 100032.	1.6	21
1039	Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis. <i>Respiratory Research</i> , 2019, 20, 83.	1.4	40
1040	Disease burden in patients with asthma before initiating biologics: A retrospective cohort database study. <i>Allergy and Asthma Proceedings</i> , 2019, 40, 146-153.	1.0	11
1041	Less is more: the impact of maintenance treatment adherence in severe asthma clinical trials. <i>European Respiratory Journal</i> , 2019, 53, 1900599.	3.1	1
1042	Severe asthma in children and adolescents. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2280-2282.	2.7	4
1043	EUFOR EA consensus on biologics for CRSwNP with or without asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2312-2319.	2.7	239
1044	<sc>EAACI</sc> Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 855-873.	2.7	191
1045	Health effects of diesel engine exhaust emissions exposure (DEEE) can mimic allergic asthma and rhinitis. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 31.	0.9	3



#	ARTICLE	IF	CITATIONS
1046	IL-2 modulates Th2 cell responses to glucocorticosteroid: A cause of persistent type 2 inflammation?. <i>Immunity, Inflammation and Disease</i> , 2019, 7, 112-124.	1.3	19
1047	Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 57-63.e2.	0.5	10
1048	Effects of homogeneous and heterogeneous changes in the lung periphery on spirometry results. <i>Computer Methods and Programs in Biomedicine</i> , 2019, 173, 139-145.	2.6	7
1049	An evaluation of mepolizumab for the treatment of severe asthma. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 491-500.	1.4	5
1050	Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 84-93.	0.6	48
1051	Predictors of reversible airway obstruction with omalizumab in severe asthma: a real-life study. <i>Therapeutic Advances in Respiratory Disease</i> , 2019, 13, 175346661984127.	1.0	29
1052	Th2/Th17 cytokine profile in phenotyped Greek asthmatics and relationship to biomarkers of inflammation. <i>Respiratory Medicine</i> , 2019, 151, 102-110.	1.3	9
1053	Sex and intimacy in people with severe asthma: a qualitative study. <i>BMJ Open Respiratory Research</i> , 2019, 6, e000382.	1.2	5
1054	Asthma progression and mortality: the role of inhaled corticosteroids. <i>European Respiratory Journal</i> , 2019, 54, 1900491.	3.1	96
1055	The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1716-1726.	2.7	106
1056	Reduction of oral corticosteroids in patients with severe eosinophilic asthma treated with Benralizumab: could it represent a marker of treatment efficacy?. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 601-606.	1.4	12
1057	Roles of Periostin in Asthma. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1132, 145-159.	0.8	17
1058	Increase in blood eosinophils during follow-up is associated with lung function decline in adult asthma. <i>Respiratory Medicine</i> , 2019, 152, 60-66.	1.3	23
1059	Real-life effectiveness of inhaler device switch from dry powder inhalers to pressurized metered-dose inhalers in patients with asthma treated with ICS/LABA. <i>Respirology</i> , 2019, 24, 972-979.	1.3	13
1060	Pulmonary rehabilitation for obstructive lung disease. <i>Respirology</i> , 2019, 24, 871-878.	1.3	26
1063	Use of Symptoms Scores, Spirometry, and Other Pulmonary Function Testing for Asthma Monitoring. <i>Frontiers in Pediatrics</i> , 2019, 7, 54.	0.9	38
1064	Severe asthma in Japan. <i>Allergology International</i> , 2019, 68, 167-171.	1.4	21
1065	Bronchiectasis in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 71-78.	1.2	16

#	ARTICLE	IF	CITATIONS
1066	Biologics for paediatric severe asthma: trick or TREAT?. <i>Lancet Respiratory Medicine</i> , 2019, 7, 294-296.	5.2	29
1067	Primary care of asthma: new options for severe eosinophilic asthma. <i>Current Medical Research and Opinion</i> , 2019, 35, 1309-1318.	0.9	10
1068	Extracellular DNA, Neutrophil Extracellular Traps, and Inflammasome Activation in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1076-1085.	2.5	165
1069	A pilot study to test the feasibility of histological characterisation of asthmaâ€œCOPD overlap. <i>European Respiratory Journal</i> , 2019, 53, 1801941.	3.1	14
1070	&lt;p&gt;Severe uncontrolled asthma with bronchiectasis: a pilot study of an emerging phenotype that responds to mepolizumab&lt;/p&gt;. <i>Journal of Asthma and Allergy</i> , 2019, Volume 12, 83-90.	1.5	51
1071	Nonatopic severe asthma might still be atopic: Sensitization toward <i>Staphylococcus aureus</i> enterotoxins. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 2279-2280.e2.	1.5	16
1072	Is there an association between asthma and periodontal disease among adults? Systematic review and meta-analysis. <i>Life Sciences</i> , 2019, 223, 74-87.	2.0	25
1073	Medicaid Expansion and Mechanical Ventilation in Asthma, Chronic Obstructive Pulmonary Disease, and Heart Failure. <i>Annals of the American Thoracic Society</i> , 2019, 16, 886-893.	1.5	12
1074	Severe asthmaâ€œA population study perspective. <i>Clinical and Experimental Allergy</i> , 2019, 49, 819-828.	1.4	70
1075	The prevalence and disease burden of severe eosinophilic asthma in Japan. <i>Journal of Asthma</i> , 2019, 56, 1147-1158.	0.9	17
1076	European consensus meeting/statement on Bronchial Thermoplasty Who? Where? How?. <i>Respiratory Medicine</i> , 2019, 150, 161-164.	1.3	10
1077	Evaluation of Neutrophil Activation Status According to the Phenotypes of Adult Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2019, 11, 381.	1.1	21
1079	Precision medicine for the discovery of treatable mechanisms in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1649-1659.	2.7	75
1080	Long-Term Azithromycin Reduces <i>Haemophilus influenzae</i> and Increases Antibiotic Resistance in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 200, 309-317.	2.5	121
1081	Rapid effects of benralizumab on severe asthma during surgery for residual tumor after advanced lung squamous cell carcinoma treatment with pembrolizumab. <i>Respiratory Medicine Case Reports</i> , 2019, 26, 292-295.	0.2	6
1082	Severe asthma in childrenâ€œa review of definitions, epidemiology, and treatment options in 2019. <i>Pediatric Pulmonology</i> , 2019, 54, 778-787.	1.0	50
1083	Toward clinically applicable biomarkers for asthma: An EAACI position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1835-1851.	2.7	135
1084	What we know, do not know, and should know about severe asthma. <i>Allergology International</i> , 2019, 68, 133-134.	1.4	4

#	ARTICLE	IF	CITATIONS
1085	Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study. <i>Respiratory Medicine</i> , 2019, 151, 49-54.	1.3	27
1086	Selection of Biologics in Severe Asthma: A Multifaceted Algorithm. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 325-328.	0.6	5
1087	Exosomes: A new approach to asthma pathology. <i>Clinica Chimica Acta</i> , 2019, 495, 139-147.	0.5	51
1088	Cost-utility analysis of reslizumab for patients with severe eosinophilic asthma inadequately controlled with high-dose inhaled corticosteroids and long-acting $\beta_2$ -agonists in South Korea. <i>Current Medical Research and Opinion</i> , 2019, 35, 1597-1605.	0.9	4
1089	Variability in total serum IgE over 1 year in severe asthmatics. <i>Allergy, Asthma and Clinical Immunology</i> , 2019, 15, 20.	0.9	14
1090	The impact of severe asthma on patients' autonomy: A qualitative study. <i>Health Expectations</i> , 2019, 22, 528-536.	1.1	18
1091	Inflammatory profile in optimally treated patients with adult versus early-onset asthma. <i>Postgraduate Medicine</i> , 2019, 131, 324-329.	0.9	2
1092	Serum Levels of Eosinophil-Derived Neurotoxin: A Biomarker for Asthma Severity in Adult Asthmatics. <i>Allergy, Asthma and Immunology Research</i> , 2019, 11, 394.	1.1	53
1093	Referral Criteria for Asthma: Consensus Document. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2019, 29, 422-430.	0.6	17
1094	Analysis of lncRNA Expression in Patients With Eosinophilic and Neutrophilic Asthma Focusing on LNC_000127. <i>Frontiers in Genetics</i> , 2019, 10, 141.	1.1	36
1095	Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1440-1449.	2.0	12
1096	Asthma in the Primary Care Setting. <i>Medical Clinics of North America</i> , 2019, 103, 435-452.	1.1	55
1097	Immunological methods for diagnosis and monitoring of IgE-mediated allergy caused by industrial sensitizing agents (IMExAllergy). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1885-1897.	2.7	16
1098	Controversies in Allergy: Should Severe Asthma with Eosinophilic Phenotype Always Be Treated with Anti-IL-5 Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1430-1436.	2.0	3
1099	Severe Asthma and Allergy: A Pediatric Perspective. <i>Frontiers in Pediatrics</i> , 2019, 7, 28.	0.9	16
1100	Biological treatments for severe asthma: A major advance in asthma care. <i>Allergology International</i> , 2019, 68, 158-166.	1.4	122
1101	Lung Lavage Granulocyte Patterns and Clinical Phenotypes in Children with Severe, Therapy-Resistant Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1803-1812.e10.	2.0	45
1102	Predicting Response to Triamcinolone in Severe Asthma by Machine Learning. Solving the Enigma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1299-1300.	2.5	2

#	ARTICLE	IF	CITATIONS
1103	Airway smooth muscle reduction after bronchial thermoplasty in severe asthma correlates with <math>FEV_1</math>. Clinical and Experimental Allergy, 2019, 49, 541-544.	1.4	16
1104	Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 823-829.	2.5	31
1105	Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respiratory Medicine, 2019, 150, 51-62.	1.3	31
1106	Pulmonary Physiology. , 2019, , 586-612.		1
1107	Academic achievement of adolescents with asthma or atopic disease. Clinical and Experimental Allergy, 2019, 49, 892-899.	1.4	14
1108	Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Organization Journal, 2019, 12, 100007.	1.6	82
1109	Dysfunctional ErbB2, an EGF receptor family member, hinders repair of airway epithelial cells from asthmatic patients. Journal of Allergy and Clinical Immunology, 2019, 143, 2075-2085.e10.	1.5	21
1110	Randomised controlled trials in severe asthma: selection by phenotype or stereotype. European Respiratory Journal, 2019, 53, 1802187.	3.1	3
1111	Rehabilitation in chronic respiratory diseases: Live your life to the max. Respirology, 2019, 24, 828-829.	1.3	3
1112	<p></p>Real-world characteristics and disease burden of patients with asthma prior to treatment initiation with mepolizumab or omalizumab: a retrospective cohort database study<p></p>. Journal of Asthma and Allergy, 2019, Volume 12, 43-58.	1.5	14
1113	The Burden of Severe Asthma in France: A Case-Control Study Using a Medical Claims Database. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1477-1487.	2.0	51
1114	Efficacy and Safety of Reslizumab in Patients with Severe Asthma with Inadequate Response to Omalizumab: A Multicenter, Open-Label Pilot Study. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2277-2283.e2.	2.0	33
1115	A sputum 6-gene signature predicts future exacerbations of poorly controlled asthma. Journal of Allergy and Clinical Immunology, 2019, 144, 51-60.e11.	1.5	50
1116	DP <math>2</math> antagonism reduces airway smooth muscle mass in asthma by decreasing eosinophilia and myofibroblast recruitment. Science Translational Medicine, 2019, 11, .	5.8	57
1117	Asthma. Annals of Internal Medicine, 2019, 171, ITC49.	2.0	28
1118	Bronchial Thermoplasty: A New Therapeutic Option in Severe Uncontrolled Asthma. , 0, , .		0
1119	Classification of asthma. Allergy and Asthma Proceedings, 2019, 40, 385-388.	1.0	52
1120	Prevalence of oral corticosteroid use in the German severe asthma population. ERJ Open Research, 2019, 5, 00092-2019.	1.1	24

#	ARTICLE	IF	CITATIONS
1121	Real-life effectiveness of omalizumab in difficult-to-treat <i>versus</i> severe asthma: a national cohort study in Belgium. ERJ Open Research, 2019, 5, 00253-2018.	1.1	6
1122	CD8<sup>+</sup>Tc2 cells: underappreciated contributors to severe asthma. European Respiratory Review, 2019, 28, 190092.	3.0	30
1123	Elevated serum IgE, oral corticosteroid dependence and IL-17/22 expression in highly neutrophilic asthma. European Respiratory Journal, 2019, 54, 1900068.	3.1	62
1124	Oral steroids in asthma: a double-edged sword. European Respiratory Journal, 2019, 54, 1902034.	3.1	7
1125	Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study. Thorax, 2019, 74, 1113-1119.	2.7	27
1126	Efficacy of azithromycin in severe asthma from the AMAZES randomised trial. ERJ Open Research, 2019, 5, 00056-2019.	1.1	27
1127	Chinese expert consensus-based guideline on assessment and management of asthma exacerbation. Journal of Thoracic Disease, 2019, 11, 4918-4935.	0.6	7
1128	“Everybody's Got Asthma” When Misunderstanding and Public Opinion Become Obstacles to the Care of Patients with Severe Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2622-2623.	2.0	1
1129	Clinical effect on uncontrolled asthma using a novel digital automated self-management solution: a physician-blinded randomised controlled crossover trial. European Respiratory Journal, 2019, 54, 1900983.	3.1	23
1130	Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respiratory Medicine, 2019, 159, 105806.	1.3	43
1131	Pulmonary rehabilitation for adults with asthma. The Cochrane Library, 0, , .	1.5	1
1132	Asthma and the Biologics Revolution, Part 2: Failures and the Future Potential. Current Treatment Options in Allergy, 2019, 6, 468-492.	0.9	0
1133	Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial. ERJ Open Research, 2019, 5, 00009-2019.	1.1	36
1134	Immunostimulants in respiratory diseases: focus on Pidotimod. Multidisciplinary Respiratory Medicine, 2019, 14, 31.	0.6	20
1135	Immunological biomarkers in severe asthma. Seminars in Immunology, 2019, 46, 101332.	2.7	35
1136	Severe asthma: A focus on diagnosis risk assessment and costs. Journal of Precision Respiratory Medicine, 2019, 2, 1-4.	0.1	0
1137	Comorbidities associated with severe asthma. Journal of Precision Respiratory Medicine, 2019, 2, 5-9.	0.1	4
1140	Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?. Italian Journal of Pediatrics, 2019, 45, 151.	1.0	16

#	ARTICLE	IF	CITATIONS
1141	&lt;p&gt;Recent Developments In Bronchial Thermoplasty For Severe Asthma&lt;/p&gt;. Journal of Asthma and Allergy, 2019, Volume 12, 375-387.	1.5	21
1142	Comparison of Normal and Metaplastic Epithelium in Patients with Stable versus Persistently Symptomatic Severe Asthma Using Laser-Capture Microdissection and Data-Independent Acquisitionâ€“Mass Spectrometry. American Journal of Pathology, 2019, 189, 2358-2365.	1.9	3
1143	Asthma severity, nature or nurture: genetic determinants. Current Opinion in Pediatrics, 2019, 31, 340-348.	1.0	12
1144	Adverse events of benralizumab in moderate to severe eosinophilic asthma. Medicine (United States), 2019, 98, e15868.	0.4	32
1146	The effectiveness of Reslizumab in severe asthma treatment: a real-world experience. Respiratory Research, 2019, 20, 289.	1.4	35
1147	Effectiveness and Safety of Bronchial Thermoplasty in Severe Asthma in Clinical Practice in Spain. Biomedicine Hub, 2019, 3, 1-9.	0.4	1
1148	Increased mortality in patients with corticosteroid-dependent asthma: a nationwide population-based study. European Respiratory Journal, 2019, 54, 1900804.	3.1	55
1149	Blood Eosinophilia May Not Adequately Estimate Lung Fluid Eosinophilia in Childhood Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 2497-2498.	2.0	5
1150	Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients. Nature Communications, 2019, 10, 5711.	5.8	141
1151	Endomorphin-2- and Neurotensin- Based Chimeric Peptide Attenuates Airway Inflammation in Mouse Model of Nonallergic Asthma. International Journal of Molecular Sciences, 2019, 20, 5935.	1.8	8
1152	Probiotics, prebiotics, and synbiotics for the treatment of asthma. Medicine (United States), 2019, 98, e17840.	0.4	12
1153	<p>Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma</p>. Journal of Asthma and Allergy, 2019, Volume 12, 401-413.	1.5	28
1154	Asthme et allergie. Revue Des Maladies Respiratoires Actualites, 2019, 11, S5-S9.	0.0	0
1155	Exhaled breath condensate volatilome allows sensitive diagnosis of persistent asthma. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 527-534.	2.7	33
1156	A Single Institution Retrospective Study of the Clinical Efficacy of Tiotropium Respimat in Never-Smoking Elderly Asthmatics with Irreversible Airflow Limitation. Drug Research, 2019, 69, 211-217.	0.7	2
1157	Treatable traits can be identified in a severe asthma registry and predict future exacerbations. Respiriology, 2019, 24, 37-47.	1.3	136
1158	Examination of the uses, needs, and preferences for health technology use in adolescents with asthma. Journal of Asthma, 2019, 56, 964-972.	0.9	21
1159	CISH is a negative regulator of IL-13-induced CCL26 production in lung fibroblasts. Allergology International, 2019, 68, 101-109.	1.4	16

#	ARTICLE	IF	CITATIONS
1160	Characteristics of Adult Severe Refractory Asthma in Korea Analyzed From the Severe Asthma Registry. <i>Allergy, Asthma and Immunology Research</i> , 2019, 11, 43.	1.1	35
1162	Life Cycle of Childhood Asthma. <i>Clinics in Chest Medicine</i> , 2019, 40, 125-147.	0.8	10
1163	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 54, 87-89.	1.1	15
1164	â€œT2-highâ€•in severe asthma related to blood eosinophil, exhaled nitric oxide andÂserum periostin. <i>European Respiratory Journal</i> , 2019, 53, 1800938.	3.1	104
1165	Does Changing Inhaler Device Impact Real-Life Asthma Outcomes? Clinical and Economic Evaluation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 934-942.	2.0	12
1166	Omalizumab discontinuation in children with severe allergic asthma: An observational real-life study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 999-1003.	2.7	24
1167	The Severe Asthma Network in Italy: Findings and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1462-1468.	2.0	112
1168	Single Maintenance and Reliever Therapy ( SMART ) Regimen for Management of Persistent Asthma. <i>Academic Emergency Medicine</i> , 2019, 26, 567-570.	0.8	0
1169	Variability of blood eosinophils in patients in a clinic for severe asthma. <i>Clinical and Experimental Allergy</i> , 2019, 49, 163-170.	1.4	28
1170	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> ,the, 2019, 7, 46-59.	5.2	216
1171	Measuring the effects of bronchial thermoplasty using oscillometry. <i>Respirology</i> , 2019, 24, 431-436.	1.3	13
1172	Comprehensive analysis of miRNAâ€“mRNAâ€“lncRNA networks in severe asthma. <i>Epigenomics</i> , 2019, 11, 115-131.	1.0	34
1173	Strategies to reduce corticosteroid-related adverse events in asthma. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2019, 19, 61-67.	1.1	28
1174	Severe asthma in children: Evaluation and management. <i>Allergology International</i> , 2019, 68, 150-157.	1.4	61
1175	Identification and prospective stability of electronic nose (eNose)â€“derived inflammatory phenotypes in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1811-1820.e7.	1.5	74
1176	IL-17F, rather than IL-17A, underlies airway inflammation in a steroid-insensitive toluene diisocyanate-induced asthma model. <i>European Respiratory Journal</i> , 2019, 53, 1801510.	3.1	20
1177	Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 113-120.	1.5	14
1178	Mobile health tools for the management of chronic respiratory diseases. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1292-1306.	2.7	66

#	ARTICLE	IF	CITATIONS
1179	New Drugs for Pediatric Asthma. <i>Frontiers in Pediatrics</i> , 2018, 6, 432.	0.9	10
1180	Predicting response to bronchial thermoplasty in patients with severe uncontrolled asthma: An elusive goal. <i>Respirology</i> , 2019, 24, 11-12.	1.3	4
1181	Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 432-448.	2.7	37
1182	What's new in the Global Initiative for Asthma 2018 report and beyond. <i>Allergo Journal International</i> , 2019, 28, 63-72.	0.9	14
1183	Physical activity associates with disease characteristics of severe asthma, bronchiectasis and COPD. <i>Respirology</i> , 2019, 24, 352-360.	1.3	27
1184	A Transcriptomic Method to Determine Airway Immune Dysfunction in T2-High and T2-Low Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 465-477.	2.5	98
1185	Severe asthma and cystic fibrosis: Overlapping phenotypes?. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2019, 3, 76-83.	0.2	1
1186	Efficacy of a Mediterranean diet supplemented with fatty fish in ameliorating inflammation in paediatric asthma: a randomised controlled trial. <i>Journal of Human Nutrition and Dietetics</i> , 2019, 32, 185-197.	1.3	36
1187	Elevated levels of interleukin-33 are associated with allergic and eosinophilic asthma. <i>Scandinavian Journal of Immunology</i> , 2019, 89, e12724.	1.3	15
1188	Higher parental education was associated with better asthma control. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2019, 108, 920-926.	0.7	11
1189	IL-37 alleviates house dust mite-induced chronic allergic asthma by targeting TSLP through the NF- $\kappa$ B and ERK1/2 signaling pathways. <i>Immunology and Cell Biology</i> , 2019, 97, 403-415.	1.0	24
1190	Role of Biologics in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 433-445.	2.5	296
1192	A systematic review of the adverse events and economic impact associated with oral corticosteroids in asthma. <i>Journal of Asthma</i> , 2019, 56, 1334-1346.	0.9	33
1193	Association Between Epithelial Cytokines and Clinical Phenotypes of Elderly Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2019, 11, 79.	1.1	23
1194	Obesity and severe asthma. <i>Allergology International</i> , 2019, 68, 135-142.	1.4	82
1195	Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 1742-1751.e7.	1.5	212
1196	Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 578-588.e2.	2.0	39
1197	Different upper airway microbiome and their functional genes associated with asthma in young adults and elderly individuals. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 709-719.	2.7	53



#	ARTICLE	IF	CITATIONS
1198	Breathing pattern disorder in difficult asthma: Characteristics and improvement in asthma control and quality of life after breathing retraining. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 201-203.	2.7	16
1199	Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 122-130.e1.	2.0	44
1200	Children with Neutrophil-Predominant Severe Asthma Have Proinflammatory Neutrophils With Enhanced Survival and Impaired Clearance. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 516-525.e6.	2.0	59
1201	Uncontrolled severe asthma: starting from the unmet needs. <i>Current Medical Research and Opinion</i> , 2019, 35, 175-177.	0.9	11
1202	Bronchial Thermoplasty: A Decade of Experience: State of the Art. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 71-80.	2.0	31
1203	Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. <i>Journal of Asthma</i> , 2019, 56, 1110-1119.	0.9	50
1204	A successful bronchial thermoplasty procedure in a "every severe" asthma patient with rare complications: a case report. <i>Journal of Asthma</i> , 2019, 56, 1004-1007.	0.9	8
1205	Refractory airway type 2 inflammation in a large subgroup of asthmatic patients treated with inhaled corticosteroids. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 104-113.e14.	1.5	135
1206	Severe asthma in obese patients: Improvement of lung function after treatment with omalizumab. <i>Pulmonology</i> , 2019, 25, 15-20.	1.0	20
1207	Relationship between upper airway diseases, exhaled nitric oxide, and bronchial hyperresponsiveness to methacholine. <i>Journal of Asthma</i> , 2019, 56, 53-60.	0.9	4
1208	Effect of inhaled corticosteroid use on weight (BMI) in pediatric patients with moderate-severe asthma. <i>Journal of Asthma</i> , 2019, 56, 263-269.	0.9	17
1209	Obese- and allergic-related asthma phenotypes among children across the United States. <i>Journal of Asthma</i> , 2019, 56, 512-521.	0.9	12
1210	Clustering analysis in asthmatic outpatients: An experience in clinical practice. <i>Journal of Asthma</i> , 2019, 56, 475-477.	0.9	2
1211	"I've said I wish I was dead, you'd be better off without me": A systematic review of people's experiences of living with severe asthma. <i>Journal of Asthma</i> , 2019, 56, 311-322.	0.9	33
1212	Treatment of severe, uncontrolled eosinophilic asthma: Where we are heading. <i>Journal of Asthma</i> , 2019, 56, 459-472.	0.9	7
1213	Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma. <i>Journal of Asthma</i> , 2020, 57, 71-78.	0.9	7
1214	Severe asthma and bronchiectasis. <i>Journal of Asthma</i> , 2020, 57, 505-509.	0.9	27
1215	Disparate diagnostic accuracy of lung function tests as predictors of poor asthma control in children. <i>Journal of Asthma</i> , 2020, 57, 327-334.	0.9	10

#	ARTICLE	IF	CITATIONS
1216	Four seasons of Czech asthma study: asthma characteristics and management reality in the Czech Republic. <i>Journal of Asthma</i> , 2020, 57, 898-910.	0.9	5
1217	Janus looks both ways: How do the upper and lower airways interact?. <i>Paediatric Respiratory Reviews</i> , 2020, 34, 59-66.	1.2	6
1218	Effectiveness of Omalizumab in Severe Allergic Asthma and Nasal Polyposis: A Real-Life Study. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 49-57.	0.6	41
1219	Asthma phenotypes and associated comorbidities in a large cohort of adolescents in Israel. <i>Journal of Asthma</i> , 2020, 57, 722-735.	0.9	17
1220	Key factors associated with uncontrolled asthma – the Asthma Control in Latin America Study. <i>Journal of Asthma</i> , 2020, 57, 113-122.	0.9	24
1221	Linking endotypes to omics profiles in difficult-to-control asthma using the diagnostic Chinese medicine syndrome differentiation algorithm. <i>Journal of Asthma</i> , 2020, 57, 532-542.	0.9	5
1222	Omaliuzumab Treatment Patterns Among Patients with Asthma in the US Medicare Population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 507-515.e10.	2.0	13
1223	Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 276-293.	2.5	182
1224	Estimated Ventricular Size, Asthma Severity, and Exacerbations. <i>Chest</i> , 2020, 157, 258-267.	0.4	4
1225	Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2020, 55, 1900588.	3.1	380
1226	Structural and clinical impact of anti-allergy agents: An overview. <i>Bioorganic Chemistry</i> , 2020, 94, 103351.	2.0	24
1227	Safety and Effectiveness of Bronchial Thermoplasty When FEV1 Is Less Than 50%. <i>Chest</i> , 2020, 157, 509-515.	0.4	15
1228	Update in Pediatric Asthma: Selected Issues. <i>Disease-a-Month</i> , 2020, 66, 100886.	0.4	22
1229	Severe asthma during childhood and adolescence: A longitudinal study. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 140-146.e9.	1.5	45
1230	Asthma, Comorbidities, and Aggravating Circumstances: The GEMA-FORUM II Task Force. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2020, 30, 140-143.	0.6	3
1231	Prevalence and predictors of adherence to controller therapy in adult patients with severe/difficult-to-treat asthma: a systematic review and meta-analysis. <i>Journal of Asthma</i> , 2020, 57, 1379-1388.	0.9	22
1232	Towards Precision Medicine in Pediatric Severe Asthma: An Update on Current and Emerging Biomarkers. <i>Current Respiratory Medicine Reviews</i> , 2020, 15, 187-194.	0.1	0
1233	Prevalence, disease burden, and treatment reality of patients with severe, uncontrolled asthma in Japan. <i>Allergology International</i> , 2020, 69, 53-60.	1.4	63

#	ARTICLE	IF	CITATIONS
1234	Different endotypes and phenotypes drive the heterogeneity in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 302-310.	2.7	68
1235	Structural lung abnormalities on computed tomography correlate with asthma inflammation in bronchoscopic alveolar lavage fluid. <i>Journal of Asthma</i> , 2020, 57, 968-979.	0.9	7
1236	The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization. <i>Journal of Asthma</i> , 2020, 57, 1092-1102.	0.9	10
1237	Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. <i>Journal of Asthma</i> , 2020, 57, 987-998.	0.9	21
1238	Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study. <i>Journal of Asthma</i> , 2020, 57, 1006-1016.	0.9	4
1239	Eosinophil extracellular traps activate type 2 innate lymphoid cells through stimulating airway epithelium in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 95-103.	2.7	61
1240	Lost in the transition from pediatric to adult healthcare? Experiences of young adults with severe asthma. <i>Journal of Asthma</i> , 2020, 57, 1119-1127.	0.9	30
1242	The effect of <i>Plantago major</i> seed and Almond gum on refractory asthma: A proof-of-concept study. <i>Journal of Herbal Medicine</i> , 2020, 19, 100297.	1.0	8
1243	New biological treatments for asthma and skin allergies. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 546-560.	2.7	70
1244	Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. <i>Current Medical Research and Opinion</i> , 2020, 36, 23-32.	0.9	19
1245	Rational oral corticosteroid use in adult severe asthma: A narrative review. <i>Respirology</i> , 2020, 25, 161-172.	1.3	58
1246	Evaluation in a severe asthma expert center improves asthma outcomes regardless of step-up in asthma therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1439-1442.e2.	2.0	6
1247	Predicting the Response to Bronchial Thermoplasty. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1253-1260.e2.	2.0	21
1248	Recent Advances in Severe Asthma. <i>Chest</i> , 2020, 157, 516-528.	0.4	96
1249	New Therapies for Emerging Endotypes of Asthma. <i>Annual Review of Medicine</i> , 2020, 71, 289-302.	5.0	17
1250	New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant. <i>Pharmacological Research</i> , 2020, 155, 104490.	3.1	20
1252	30 years of sublingual immunotherapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1107-1120.	2.7	41
1253	Blockade of IL-4 inhibits group 2 innate lymphoid cell responses in asthma patients. <i>Clinical and Experimental Allergy</i> , 2020, 50, 267-270.	1.4	15

#	ARTICLE	IF	CITATIONS
1254	Asthma biologics. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 44-56.	0.5	50
1255	Bronchodilator Dose Responsiveness in Children and Adolescents: Clinical Features and Association with Future Asthma Exacerbations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 953-964.	2.0	5
1256	Development and initial validation of the Asthma Severity Scoring System (ASSESS). <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 127-139.	1.5	19
1257	Muscarinic receptor M3 contributes to vascular and neural growth factor up-regulation in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 717-720.	2.7	5
1258	Insomnia symptoms and asthma control – Interrelations and importance of comorbidities. <i>Clinical and Experimental Allergy</i> , 2020, 50, 170-177.	1.4	21
1259	Prevalence and impact of comorbid laryngeal dysfunction in asthma: A systematic review and meta-analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1165-1173.	1.5	45
1260	Evolving phenotypes to endotypes: is precision medicine achievable in asthma?. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 163-172.	1.0	7
1261	Anti-IL-4/IL-13 for the treatment of asthma: the story so far. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 283-294.	1.4	25
1262	Severe Asthma and Biological Therapy: When, Which, and for Whom. <i>Pulmonary Therapy</i> , 2020, 6, 47-66.	1.1	63
1263	Chimeric antigen receptor -T cell therapy: Applications and challenges in treatment of allergy and asthma. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109685.	2.5	34
1264	Safety of live attenuated influenza vaccine (LAIV) in children with moderate to severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1157-1164.e6.	1.5	16
1265	Biologics and Bronchial Thermoplasty for severe refractory asthma treatment: From eligibility criteria to real practice. A cross-sectional study. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 60, 101874.	1.1	5
1266	Severe asthma in the US population and eligibility for mAb therapy. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1295-1297.e6.	1.5	13
1267	Isorhynchophylline exerts anti-asthma effects in mice by inhibiting the proliferation of airway smooth muscle cells: The involvement of miR-200a-mediated FOXC1/NF- $\kappa$ B pathway. <i>Biochemical and Biophysical Research Communications</i> , 2020, 521, 1055-1060.	1.0	17
1268	The Long-Term Effectiveness and Safety of Omalizumab on Patient- and Physician-Reported Asthma Control: A Three-Year, Real-Life Observational Study. <i>Advances in Therapy</i> , 2020, 37, 353-363.	1.3	10
1269	Triptolide inhibits PDGF-induced proliferation of ASMCs through G0/G1 cell cycle arrest and suppression of the AKT/NF- $\kappa$ B/cyclinD1 signaling pathway. <i>European Journal of Pharmacology</i> , 2020, 867, 172811.	1.7	25
1270	Age- and sex-dependent differences in patients with severe asthma included in the German Asthma Net cohort. <i>Respiratory Medicine</i> , 2020, 162, 105858.	1.3	24
1271	Severe asthma is related to high societal costs and decreased health related quality of life. <i>Respiratory Medicine</i> , 2020, 162, 105860.	1.3	19

#	ARTICLE	IF	CITATIONS
1272	Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma. <i>European Respiratory Journal</i> , 2020, 55, 1901147.	3.1	27
1273	Biologics for severe asthma: what we can learn from real-life experiences?. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 64-70.	1.1	8
1274	International Severe Asthma Registry. <i>Chest</i> , 2020, 157, 805-814.	0.4	38
1275	Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma. <i>Advances in Therapy</i> , 2020, 37, 718-729.	1.3	48
1276	A critical role for c-Myb in group 2 innate lymphoid cell activation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 841-852.	2.7	22
1277	Sputum transcriptomics implicates increased p38 signalling activity in severe asthma. <i>Respirology</i> , 2020, 25, 709-718.	1.3	20
1278	Targeting treatable traits in severe asthma: a randomised controlled trial. <i>European Respiratory Journal</i> , 2020, 55, 1901509.	3.1	121
1279	Efficacy of immunoglobulin replacement therapy and azithromycin in severe asthma with antibody deficiency. <i>Allergology International</i> , 2020, 69, 215-222.	1.4	8
1280	Biologics in Children with Allergic Diseases. <i>Current Pediatric Reviews</i> , 2020, 16, 140-147.	0.4	16
1281	The clinical characteristics and prognosis of ABPA are closely related to the mucus plugs in central bronchiectasis. <i>Clinical Respiratory Journal</i> , 2020, 14, 140-147.	0.6	13
1282	Characterization of Severe Asthma Worldwide. <i>Chest</i> , 2020, 157, 790-804.	0.4	165
1283	Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 465-473.	2.0	54
1284	The burden of corticosteroid overload in severe and difficult to treat asthma: how to reduce this?. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 90-96.	1.2	2
1285	The impact of comorbidities on severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2020, 26, 47-55.	1.2	40
1286	Longitudinal trajectories of severe wheeze exacerbations from infancy to school age and their association with early-life risk factors and late asthma outcomes. <i>Clinical and Experimental Allergy</i> , 2020, 50, 315-324.	1.4	26
1287	If it's not "only" asthma, why are children still dying?. <i>Archives of Disease in Childhood</i> , 2020, 105, 494-498.	1.0	10
1288	Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. <i>Clinical Rheumatology</i> , 2020, 39, 1581-1590.	1.0	16
1289	Chemiluminescent Measurement of Hydrogen Peroxide in the Exhaled Breath Condensate of Healthy and Asthmatic Adults. <i>Analytical Chemistry</i> , 2020, 92, 14594-14600.	3.2	25

#	ARTICLE	IF	CITATIONS
1290	Bronchiectasis and increased mortality in patients with corticosteroid-dependent severe asthma: a nationwide population study. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662096303.	1.0	20
1291	Response to mepolizumab treatment is sustained across 4-weekly dosing periods. <i>ERJ Open Research</i> , 2020, 6, 00068-2020.	1.1	4
1292	CASCADE: a phase 2, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the effect of tezepelumab on airway inflammation in patients with uncontrolled asthma. <i>Respiratory Research</i> , 2020, 21, 265.	1.4	21
1293	NAVIGATOR: a phase 3 multicentre, randomized, double-blind, placebo-controlled, parallel-group trial to evaluate the efficacy and safety of tezepelumab in adults and adolescents with severe, uncontrolled asthma. <i>Respiratory Research</i> , 2020, 21, 266.	1.4	45
1294	<p>Action of 1,25(OH) <sub>2</sub> D <sub>3</sub> on Human Asthmatic Bronchial Fibroblasts: Implications for Airway Remodeling in Asthma</p>. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 249-264.	1.5	4
1295	Determinants of exercise capacity in children and adolescents with severe therapy-resistant asthma. <i>Journal of Asthma</i> , 2022, 59, 115-125.	0.9	6
1296	Pediatric Severe Asthma in the Era of Biologic Treatments. <i>Pediatric, Allergy, Immunology, and Pulmonology</i> , 2020, 33, 118-120.	0.3	0
1297	Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study. <i>Respiratory Research</i> , 2020, 21, 278.	1.4	25
1299	Increased expression of serine palmitoyl transferase and ORMDL3 polymorphism are associated with eosinophilic inflammation and airflow limitation in aspirin-exacerbated respiratory disease. <i>PLoS ONE</i> , 2020, 15, e0240334.	1.1	7
1300	Effectiveness of pulmonary rehabilitation at high-altitude compared to sea-level in adults with severe refractory asthma. <i>Respiratory Medicine</i> , 2020, 171, 106123.	1.3	10
1301	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). <i>World Allergy Organization Journal</i> , 2020, 13, 100464.	1.6	30
1302	Correlation between DNA methylation and Thymic Stromal Lymphopoietin expression in asthmatic airway epithelial cells. <i>Genes and Genomics</i> , 2020, 42, 1399-1406.	0.5	1
1303	Severe Asthma Toolkit: an online resource for multidisciplinary health professionalsâ€™ needs assessment, development process and user analytics with survey feedback. <i>BMJ Open</i> , 2020, 10, e032877.	0.8	7
1304	Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 64, 101964.	1.1	8
1305	Availability and reimbursement of biological products for severe asthma in Bulgaria. <i>SAGE Open Medicine</i> , 2020, 8, 205031212095106.	0.7	5
1306	Biologics for the Treatments of Allergic Conditions. <i>Immunology and Allergy Clinics of North America</i> , 2020, 40, 549-564.	0.7	9
1307	IFRD1 regulates the asthmatic responses of airway via NF-ÎB pathway. <i>Molecular Immunology</i> , 2020, 127, 186-192.	1.0	4
1308	Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities. <i>World Allergy Organization Journal</i> , 2020, 13, 100462.	1.6	38

#	ARTICLE	IF	CITATIONS
1309	Eosinophilic Phenotype: The Lesson from Research Models to Severe Asthma. , 2020, , .		3
1310	Development of self-assessed work ability among middle-aged asthma patientsâ€™a 10 year follow-up study. Journal of Asthma, 2020, 58, 1-9.	0.9	3
1311	Serum Eosinophil-Derived Neurotoxin Better Reflect Asthma Control Status Than Blood Eosinophil Counts. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2681-2688.e1.	2.0	33
1312	Statins for asthma. The Cochrane Library, 2020, 2020, CD013268.	1.5	7
1313	Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma. BMJ Case Reports, 2020, 13, e233161.	0.2	7
1314	The Role of Aeroallergen Sensitization Testing in Asthma Management. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2526-2532.	2.0	8
1315	Prevalence and characterization of severe asthma in Hungary. Scientific Reports, 2020, 10, 9274.	1.6	8
1316	Current practice patterns, challenges, and educational needs of asthma care providers in the United States. Journal of Asthma, 2020, 58, 1-10.	0.9	4
1317	Finding the true prevalence of obstructive lung disease: two steps forward and one step back. European Respiratory Journal, 2020, 55, 2001514.	3.1	1
1318	Monoclonal antibodies for the treatment of severe asthma. The Prescriber, 2020, 31, 23-28.	0.1	3
1319	<p>Self-Administered Mepolizumab in the Management of Severe Asthma: Usability and Patient Acceptance</p>. Patient Preference and Adherence, 2020, Volume 14, 1669-1682.	0.8	5
1320	Clinical and biological factors associated with irreversible airway obstruction in adult asthma. Respiratory Medicine, 2020, 175, 106202.	1.3	17
1321	<p>Frequency of Tiotropium Bromide Use and Clinical Features of Patients with Severe Asthma in a Real-Life Setting: Data from the Severe Asthma Network in Italy (SANI) Registry</p>. Journal of Asthma and Allergy, 2020, Volume 13, 599-604.	1.5	8
1322	Management of severe asthma: summary of the European Respiratory Society/American Thoracic Society task force report. Breathe, 2020, 16, 200058.	0.6	5
1323	&lt;p&gt;Switch from IL-5 to IL-5-Receptor Î± Antibody Treatment in Severe Eosinophilic Asthma&lt;/p&gt;. Journal of Asthma and Allergy, 2020, Volume 13, 605-614.	1.5	30
1324	The Fungal Microbiome and Asthma. Frontiers in Cellular and Infection Microbiology, 2020, 10, 583418.	1.8	35
1325	Biologics to Treat Severe Asthma in Children and Adolescents: A Practical Update. Pediatric, Allergy, Immunology, and Pulmonology, 2020, 33, 168-176.	0.3	3
1326	Fibrocyte localisation to the ASM bundle in asthma: bidirectional effects on cell phenotype and behaviour. Clinical and Translational Immunology, 2020, 9, e1205.	1.7	7

#	ARTICLE	IF	CITATIONS
1327	Molecular Targets for Biological Therapies of Severe Asthma. <i>Frontiers in Immunology</i> , 2020, 11, 603312.	2.2	65
1328	Defining pediatric asthma: phenotypes to endotypes and beyond. <i>Pediatric Research</i> , 2021, 90, 45-51.	1.1	41
1329	Biologic treatment options for severe asthma. <i>Current Opinion in Immunology</i> , 2020, 66, 151-160.	2.4	23
1330	Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662096515.	1.0	4
1331	The role of antifungals in the management of patients with severe asthma. <i>Clinical and Translational Allergy</i> , 2020, 10, 46.	1.4	22
1332	Combined Extracts of <i>Epimedii Folium</i> and <i>Ligustri Lucidi Fructus</i> with Budesonide Attenuate Airway Remodeling in the Asthmatic Rats by Regulating Apoptosis and Autophagy. <i>Evidence-based Complementary and Alternative Medicine</i> , 2020, 2020, 1-18.	0.5	8
1333	Clinical Characterization of the Frequent Exacerbator Phenotype in Asthma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2226.	1.0	8
1334	Evolution of our view on the IgE molecule role in bronchial asthma and the clinical effect of its modulation by omalizumab: Where do we stand today?. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842094238.	1.0	8
1335	Causes and Phenotypes of Work-Related Asthma. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 4713.	1.2	27
1336	Global Quality Standard for Identification and Management of Severe Asthma. <i>Advances in Therapy</i> , 2020, 37, 3645-3659.	1.3	11
1337	Personalized Approach of Severe Eosinophilic Asthma Patients Treated with Mepolizumab and Benralizumab. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 746-753.	0.9	16
1338	The Hidden Burden of Severe Asthma: From Patient Perspective to New Opportunities for Clinicians. <i>Journal of Clinical Medicine</i> , 2020, 9, 2397.	1.0	6
1339	Increased Serum Periostin Levels and Eosinophils in Nasal Polyps Are Associated with the Preventive Effect of Endoscopic Sinus Surgery for Asthma Exacerbations in Chronic Rhinosinusitis Patients. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 862-870.	0.9	11
1340	Association of low-dosage systemic corticosteroid use with disease burden in asthma. <i>Npj Primary Care Respiratory Medicine</i> , 2020, 30, 35.	1.1	12
1341	The reality of LAMAs for adult asthmatic patients. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 1087-1094.	1.0	2
1342	7 Immunologic Diseases of the Lung. , 2020, , .		0
1343	Chronic oral corticosteroids use and persistent eosinophilia in severe asthmatics from the Belgian severe asthma registry. <i>Respiratory Research</i> , 2020, 21, 214.	1.4	10
1344	Biologics in severe asthma: the overlap endotype - opportunities and challenges. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 1427-1434.	1.4	16



#	ARTICLE	IF	CITATIONS
1345	4 Indications. , 2020, , .		0
1346	Phenotypic characteristics and asthma severity in an East African cohort of adults and adolescents with asthma: findings from the African severe asthma project. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000484.	1.2	10
1347	Comparative efficacy of glucocorticoid receptor agonists on Th2 cell function and attenuation by progesterone. <i>BMC Immunology</i> , 2020, 21, 54.	0.9	9
1348	Combined in Vitro-in Silico Approach to Predict Deposition and Pharmacokinetics of Budesonide Dry Powder Inhalers. <i>Pharmaceutical Research</i> , 2020, 37, 209.	1.7	9
1349	Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore. <i>Journal of Asthma</i> , 2022, 59, 189-199.	0.9	10
1350	COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry. <i>European Respiratory Journal</i> , 2020, 56, 2002857.	3.1	52
1351	Novel Therapies for Pneumonia-Associated Severe Asthma Phenotypes. <i>Trends in Molecular Medicine</i> , 2020, 26, 1047-1058.	3.5	6
1352	Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?. <i>Respiratory Research</i> , 2020, 21, 268.	1.4	30
1353	Insights Into Type I and III Interferons in Asthma and Exacerbations. <i>Frontiers in Immunology</i> , 2020, 11, 574027.	2.2	32
1354	Serum prednisolone levels as a marker of oral corticosteroid adherence in severe asthma. <i>BMC Pulmonary Medicine</i> , 2020, 20, 228.	0.8	2
1355	Impact of mepolizumab on exacerbations in severe asthma: Results from a U.S. insurance claims data base. <i>Allergy and Asthma Proceedings</i> , 2020, 41, 341-347.	1.0	15
1356	An update on the role of chronic rhinosinusitis with nasal polyps as a co-morbidity in severe asthma. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 1197-1205.	1.0	15
1357	&lt;p&gt;The CHRONICLE Study of US Adults with Subspecialist-Treated Severe Asthma: Objectives, Design, and Initial Results&lt;/p&gt;. <i>Journal of Pragmatic and Observational Research</i> , 2020, Volume 11, 77-90.	1.1	16
1358	Challenges faced in managing adult asthma: A perspective from Asian countries. <i>Respirology</i> , 2020, 25, 1235-1242.	1.3	14
1359	A Multi-Omics Approach Reveals New Signatures in Obese Allergic Asthmatic Children. <i>Biomedicines</i> , 2020, 8, 359.	1.4	12
1360	The precision interventions for severe and/or exacerbation-prone asthma (PrecISE) adaptive platform trial: statistical considerations. <i>Journal of Biopharmaceutical Statistics</i> , 2020, 30, 1026-1037.	0.4	11
1361	Effect of individual allergen sensitization on omalizumab treatment outcomes in patients with severe allergic asthma determined using data from the Czech Anti-IgE Registry. <i>Allergy, Asthma and Clinical Immunology</i> , 2020, 16, 81.	0.9	5
1362	Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma. <i>International Journal of Immunopathology and Pharmacology</i> , 2020, 34, 205873842095085.	1.0	43

#	ARTICLE	IF	CITATIONS
1363	Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. <i>European Respiratory Journal</i> , 2020, 56, 2000151.	3.1	84
1364	International severe asthma registry (ISAR): protocol for a global registry. <i>BMC Medical Research Methodology</i> , 2020, 20, 212.	1.4	29
1365	Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?. <i>Lung</i> , 2020, 198, 767-770.	1.4	12
1366	Blood and Salivary Amphiregulin Levels as Biomarkers for Asthma. <i>Frontiers in Medicine</i> , 2020, 7, 561866.	1.2	9
1367	Therapeutic efficacy of IL-17A neutralization with corticosteroid treatment in a model of antigen-driven mixed-granulocytic asthma. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L693-L709.	1.3	17
1368	Der p 2.1 Peptide Abrogates House Dust Mites-Induced Asthma Features in Mice and Humanized Mice by Inhibiting DC-Mediated T Cell Polarization. <i>Frontiers in Immunology</i> , 2020, 11, 565431.	2.2	4
1369	Monoclonal Antibodies and Airway Diseases. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9477.	1.8	10
1370	Bronchiectasis in Severe Asthma: Does It Make a Difference?. <i>Respiration</i> , 2020, 99, 1136-1144.	1.2	10
1371	Bronchial thermoplasty reduces ventilation heterogeneity measured by multiple breath nitrogen washout. <i>Respiratory Research</i> , 2020, 21, 308.	1.4	4
1372	Difficult and Severe Asthma in Children. <i>Children</i> , 2020, 7, 286.	0.6	12
1373	How Frequently Is Asthma Objectively Demonstrated before Starting a Biologic? Quality Assessment of a Group Practice of Allergists and Immunologists. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 9482.	1.2	2
1374	PC945, a Novel Inhaled Antifungal Agent, for the Treatment of Respiratory Fungal Infections. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 373.	1.5	20
1375	Long-term effects of asthma medication on asthma symptoms: an application of the targeted maximum likelihood estimation. <i>BMC Medical Research Methodology</i> , 2020, 20, 307.	1.4	1
1376	Correlation of matrix-related airway remodeling and bradykinin B1 receptor expression with fixed airflow obstruction in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1886-1890.	2.7	6
1377	First analysis of the Severe Paediatric Asthma Collaborative in Europe registry. <i>ERJ Open Research</i> , 2020, 6, 00566-2020.	1.1	5
1378	A golden age of asthma research. <i>European Respiratory Journal</i> , 2020, 56, 2003820.	3.1	2
1379	Reducing oral corticosteroids in severe asthma (ROSA Project): a nationwide Portuguese consensus. <i>Pulmonology</i> , 2020, 27, 313-327.	1.0	7
1380	Risk factors associated with frequent exacerbations in asthma. <i>Respiratory Medicine: X</i> , 2020, 2, 100022.	1.4	2

#	ARTICLE	IF	CITATIONS
1383	The effect of bronchial thermoplasty on airway volume measured 12 months post-procedure. <i>ERJ Open Research</i> , 2020, 6, 00300-2020.	1.1	4
1384	Summary of ERS / ATS guideline on managing severe asthma. <i>The Prescriber</i> , 2020, 31, 27-31.	0.1	1
1385	The Climate-Ready Home: Teaching Climate Change in the Context of Asthma Management. <i>Environmental Justice</i> , 2020, 13, 101-108.	0.8	3
1386	Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype. <i>Clinical and Experimental Allergy</i> , 2020, 50, 780-788.	1.4	52
1387	Bronchial thermoplasty versus mepolizumab: Comparison of outcomes in a severe asthma clinic. <i>Respirology</i> , 2020, 25, 1243-1249.	1.3	17
1388	Novel Biologics for the Treatment of Pediatric Severe Asthma. <i>Current Respiratory Medicine Reviews</i> , 2020, 15, 195-204.	0.1	1
1389	Promises and challenges of biologics for severe asthma. <i>Biochemical Pharmacology</i> , 2020, 179, 114012.	2.0	26
1390	Should we consider paranasal and chest computed tomography in severe asthma patients?. <i>Respiratory Medicine</i> , 2020, 169, 106013.	1.3	4
1392	Looking back to go forward: adherence to inhaled therapy before biologic therapy in severe asthma. <i>European Respiratory Journal</i> , 2020, 55, 2000954.	3.1	8
1393	Documento de consenso de asma grave en adultos. Actualización 2020. <i>Open Respiratory Archives</i> , 2020, 2, 158-174.	0.0	24
1394	G Protein-Coupled Receptors in Asthma Therapy: Pharmacology and Drug Action. <i>Pharmacological Reviews</i> , 2020, 72, 1-49.	7.1	69
1395	Treatable traits: a step closer to the holy grail of asthma control?. <i>European Respiratory Journal</i> , 2020, 55, 2000002.	3.1	6
1396	The effect of tezepelumab on hospitalizations and emergency department visits in patients with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 211-214.	0.5	12
1397	Evidence for Exacerbation-Prone Asthma and Predictive Biomarkers of Exacerbation Frequency. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 973-982.	2.5	105
1398	Effectiveness and safety of benralizumab for severe asthma in clinical practice (J-BEST): a prospective study. <i>Annals of Translational Medicine</i> , 2020, 8, 438-438.	0.7	14
1399	Modulation of fear behavior and neuroimmune alterations in house dust mite exposed A/J mice, a model of severe asthma. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 688-698.	2.0	16
1400	Treatment Eligibility of Real-Life Mepolizumab-Treated Severe Asthma Patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2999-3008.e1.	2.0	17
1401	A comparison of biologics in the treatment of adults with severe asthma – real-life experiences. <i>Asthma Research and Practice</i> , 2020, 6, 2.	1.2	16

#	ARTICLE	IF	CITATIONS
1402	Disease Burden and Long-Term Risk of Persistent Very Poorly Controlled Asthma: TENOR II. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2243-2253.	2.0	16
1403	Effectiveness and safety of dupilumab for the treatment of severe asthma in a real-life French multi-centre adult cohort. <i>Clinical and Experimental Allergy</i> , 2020, 50, 789-798.	1.4	79
1404	The Link between Asthma and Bronchiectasis: State of the Art. <i>Respiration</i> , 2020, 99, 463-476.	1.2	32
1405	A Feasibility Study of a Randomized Controlled Trial of Asthma-Tailored Pulmonary Rehabilitation Compared with Usual Care in Adults with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3418-3427.	2.0	16
1406	<i>HSD3B1</i> genotype identifies glucocorticoid responsiveness in severe asthma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 2187-2193.	3.3	27
1407	Lysophosphatidylserine induces eosinophil extracellular trap formation and degranulation: Implications in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3159-3170.	2.7	29
1408	A Gap Between Asthma Guidelines and Management for Adolescents and Young Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3056-3065.e2.	2.0	22
1409	Clinical and Economic Outcomes in Patients with Persistent Asthma Who Attain Healthcare Effectiveness and Data Information Set Measures. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3443-3454.e2.	2.0	1
1410	Thymic stromal lymphopoietin: its role and potential as a therapeutic target in asthma. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 777-792.	1.5	108
1411	Emerging therapeutic targets and preclinical models for severe asthma. <i>Expert Opinion on Therapeutic Targets</i> , 2020, 24, 845-857.	1.5	5
1412	Efficacy of omalizumab in children, adolescents, and adults with severe allergic asthma: a systematic review, meta-analysis, and call for new trials using current guidelines for assessment of severe asthma. <i>Allergy, Asthma and Clinical Immunology</i> , 2020, 16, 49.	0.9	25
1413	Bringing asthma care into the twenty-first century. <i>Npj Primary Care Respiratory Medicine</i> , 2020, 30, 25.	1.1	28
1414	Management of Severe Asthma Beyond the Guidelines. <i>Current Allergy and Asthma Reports</i> , 2020, 20, 47.	2.4	4
1415	Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3428-3433.e1.	2.0	21
1416	Anaphylaxis to three humanized antibodies for severe asthma: a case study. <i>Allergy, Asthma and Clinical Immunology</i> , 2020, 16, 46.	0.9	7
1417	How to compare the efficacy of biologic agents in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 137-149.	0.5	12
1418	Measuring inflammation in paediatric severe asthma: biomarkers in clinical practice. <i>Breathe</i> , 2020, 16, 190301.	0.6	23
1419	Burden of Asthma in Elderly Japanese Patients: Using Hospital-Based Administrative Claims Data. <i>Pulmonary Therapy</i> , 2020, 6, 247-260.	1.1	6

#	ARTICLE	IF	CITATIONS
1420	Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 315-324.e7.	1.5	90
1421	Single-Session Bronchial Thermoplasty Guided by <sup>129</sup> Xe Magnetic Resonance Imaging. A Pilot Randomized Controlled Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 524-534.	2.5	52
1422	A Comprehensive Evaluation of Mepolizumab Effectiveness in a Real-Life Setting. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 606-612.	0.9	17
1423	The influence of smoking on asthma in the real-life. <i>Respiratory Medicine</i> , 2020, 170, 106066.	1.3	13
1424	Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma. <i>European Respiratory Journal</i> , 2020, 55, 1902259.	3.1	55
1425	Connectivity patterns between multiple allergen specific IgE antibodies and their association with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 821-830.	1.5	33
1426	Exploring the relationship between generalised anxiety/depression scales and asthma-specific quality of life/control questionnaires in a specialist asthma clinic. <i>Journal of Asthma</i> , 2021, 58, 912-920.	0.9	9
1427	Clinical and lung function outcomes in a cohort of children with severe asthma. <i>BMC Pulmonary Medicine</i> , 2020, 20, 66.	0.8	11
1428	Physical Activity: A Missing Link in Asthma Care. <i>Journal of Clinical Medicine</i> , 2020, 9, 706.	1.0	43
1429	The evolving algorithm of biological selection in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1555-1563.	2.7	30
1430	Bronchial Thermoplasty. <i>Chest</i> , 2020, 157, 479-480.	0.4	0
1431	Effectiveness of myAirCoach: A mHealth Self-Management System in Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1972-1979.e8.	2.0	42
1432	High levels of plasma fibrinogen could predict frequent asthma exacerbations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2392-2395.e7.	2.0	11
1433	The asthma evidence base: a call for core outcomes in interventional trials. <i>Journal of Asthma</i> , 2021, 58, 855-864.	0.9	4
1434	The burden of allergic diseases in the Indian subcontinent: barriers and challenges. <i>The Lancet Global Health</i> , 2020, 8, e478-e479.	2.9	36
1435	Real-world experience with mepolizumab: Does it deliver what it has promised?. <i>Clinical and Experimental Allergy</i> , 2020, 50, 687-695.	1.4	54
1436	Planned primary health care asthma contacts during 12-year follow-up after Finnish National Asthma Programme: focus on spirometry. <i>Npj Primary Care Respiratory Medicine</i> , 2020, 30, 8.	1.1	11
1437	RGS4 promotes allergen- and aspirin-associated airway hyperresponsiveness by inhibiting PGE2 biosynthesis. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 146, 1152-1164.e13.	1.5	12

#	ARTICLE	IF	CITATIONS
1438	Systematic Assessment of Difficult-to-Treat Asthma: Principles and Perspectives. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2222-2233.	2.0	31
1439	Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab. <i>Drug Safety</i> , 2020, 43, 409-425.	1.4	47
1440	Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma. <i>SAGE Open Medical Case Reports</i> , 2020, 8, 2050313X2090696.	0.2	17
1441	Incidence, risk factors and re-exacerbation rate of severe asthma exacerbations in a multinational, multidatabase pediatric cohort study. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 496-505.	1.1	25
1442	Benralizumab: an updated treatment of eosinophilic asthma. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 435-444.	1.0	11
1443	Multinational cohort study of mortality in patients with asthma and severe asthma. <i>Respiratory Medicine</i> , 2020, 165, 105919.	1.3	31
1444	Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma. <i>Biomedicine and Pharmacotherapy</i> , 2020, 129, 110444.	2.5	29
1445	Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with nasal polyps: a PROXIMA study post hoc analysis. <i>Clinical and Translational Allergy</i> , 2020, 10, 25.	1.4	20
1446	Advances toward precision medicine for asthma. <i>Biochemical Pharmacology</i> , 2020, 179, 114081.	2.0	4
1447	Severe asthma during the COVID-19 pandemic: Clinical observations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2787-2789.	2.0	13
1448	Current Role of Biomarkers in Severe Uncontrolled Asthma. <i>Archivos De Bronconeumologia</i> , 2020, 56, 347-348.	0.4	3
1449	Efficacy and safety of omalizumab in children with moderate-to-severe asthma: a meta-analysis. <i>Journal of Asthma</i> , 2021, 58, 1350-1358.	0.9	23
1450	Early experiences of SARS-CoV-2 infection in severe asthmatics receiving biologic therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2784-2786.	2.0	14
1451	Reslizumab as add-on therapy in patients with refractory asthma. <i>BMJ Open Respiratory Research</i> , 2020, 7, e000494.	1.2	8
1452	Real-life experience with benralizumab during 6 months. <i>BMC Pulmonary Medicine</i> , 2020, 20, 184.	0.8	41
1453	Efficacy of Reslizumab Treatment in Exacerbation-Prone Patients with Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 3434-3442.e4.	2.0	8
1454	Biologics for oral corticosteroid-dependent asthma. <i>Allergy and Asthma Proceedings</i> , 2020, 41, 151-157.	1.0	5
1455	Efficacy of Pidotimod use in treating allergic rhinitis in a pediatric population. <i>Italian Journal of Pediatrics</i> , 2020, 46, 93.	1.0	3

#	ARTICLE	IF	CITATIONS
1456	Effect of clinically significant thresholds of eosinophil elevation on health care resource use in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 182-189.	0.5	3
1457	How real patients with severe asthma experience their disease: An ethnographic study. <i>Atencion Primaria Practica</i> , 2020, 2, 100057.	0.0	2
1458	Predicting the Response to Bronchial Thermoplasty: The Needier, the Better. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1261-1262.	2.0	4
1459	Factors that affect blood eosinophil counts in a non-asthmatic population: Post hoc analysis of data from Brazil. <i>World Allergy Organization Journal</i> , 2020, 13, 100119.	1.6	11
1460	How do biologicals and other novel therapies effect clinically used biomarkers in severe asthma?. <i>Clinical and Experimental Allergy</i> , 2020, 50, 994-1006.	1.4	11
1461	Relationship between sputum periostin level and inflammatory asthma phenotypes in Egyptian patients. <i>Journal of Asthma</i> , 2020, 58, 1-7.	0.9	8
1462	Impaired airway epithelial cell wound healing capacity is associated with airway remodelling following RSV infection in severe preschool wheeze. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 3195-3207.	2.7	18
1463	Switching from omalizumab to mepolizumab: real-life experience from Southern Italy. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346662092923.	1.0	38
1464	ERS International Congress, Madrid, 2019: highlights from the Airway Diseases, Asthma and COPD Assembly. <i>ERJ Open Research</i> , 2020, 6, 00341-2019.	1.1	3
1465	Protective effects of N-acetylcysteine on a chemical-induced murine model of asthma. <i>Journal of Asthma</i> , 2021, 58, 1208-1215.	0.9	9
1466	Fractional Exhaled Nitric Oxide as an Inflammatory Biomarker in Chronic Obstructive Pulmonary Disease (COPD) with or without Concurrent Diagnosis of Asthma: The Canadian Cohort Obstructive Lung Disease (CanCOLD). <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2020, 17, 355-365.	0.7	2
1467	Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics. <i>European Respiratory Journal</i> , 2020, 56, 2000260.	3.1	92
1468	Newer Biological Agents in the Treatment of Severe Asthma: Real-World Results from a Tertiary Referral Center. <i>Lung</i> , 2020, 198, 653-659.	1.4	4
1469	MicroRNAs in chronic airway diseases: Clinical correlation and translational applications. <i>Pharmacological Research</i> , 2020, 160, 105045.	3.1	20
1470	Long non-coding RNA growth arrest specific-5: a potential biomarker for early diagnosis of severe asthma. <i>Journal of Thoracic Disease</i> , 2020, 12, 1960-1971.	0.6	10
1471	Updates for the treatment of EGPA. <i>Presse Medicale</i> , 2020, 49, 104036.	0.8	22
1472	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. <i>Respiratory Medicine</i> , 2020, 171, 106080.	1.3	28
1473	Osteopontin contributes to late-onset asthma phenotypes in adult asthma patients. <i>Experimental and Molecular Medicine</i> , 2020, 52, 253-265.	3.2	16

#	ARTICLE	IF	CITATIONS
1474	Airway wall thickness and airflow limitations in asthma assessed in quantitative computed tomography. <i>Therapeutic Advances in Respiratory Disease</i> , 2020, 14, 175346661989859.	1.0	11
1475	Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab) Tj ETQq1 1 0.784314 rgBT /O... recommendations on the use of biologicals in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1023-1042.	2.7	232
1476	Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study. <i>Frontiers in Pharmacology</i> , 2019, 10, 1630.	1.6	5
1477	&lt;p&gt;&lt;p&gt;Patient-Reported Outcome in Two Chronic Diseases: A Comparison of Quality of Life and Response Profiles in Severe Migraine and Severe Asthma&lt;/p&gt;. <i>Patient Related Outcome Measures</i> , 2020, Volume 11, 27-37.	0.7	12
1478	Severe asthma: what is new in the new millennium. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2020, 20, 202-207.	1.1	8
1479	Comparison of the effects of pulmonary and extra-pulmonary symptoms on health-related quality of life in patients with severe asthma. <i>Respiratory Medicine</i> , 2020, 162, 105870.	1.3	3
1480	How can we minimise the use of regular oral corticosteroids in asthma?. <i>European Respiratory Review</i> , 2020, 29, 190085.	3.0	34
1481	The Role of Lung and Gut Microbiota in the Pathology of Asthma. <i>Immunity</i> , 2020, 52, 241-255.	6.6	329
1482	The impact of dysfunctional breathing on the level of asthma control in difficult asthma. <i>Respiratory Medicine</i> , 2020, 163, 105894.	1.3	15
1483	Sirtuin 1: Endocan and Sestrin 2 in Different Biological Samples in Patients with Asthma. Does Severity Make the Difference?. <i>Journal of Clinical Medicine</i> , 2020, 9, 473.	1.0	12
1484	An update on pulmonary rehabilitation techniques for patients with chronic obstructive pulmonary disease. <i>Expert Review of Respiratory Medicine</i> , 2020, 14, 149-161.	1.0	41
1485	Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life. <i>Pulmonary Pharmacology and Therapeutics</i> , 2020, 61, 101899.	1.1	46
1486	Home Self-Administration of Biologics â€“ A German Survey among Omalizumab-Treated Patients with Severe Asthma and their Treating Physicians. <i>Pneumologie</i> , 2020, 74, 103-111.	0.1	15
1487	Clinical utility of fractional exhaled nitric oxide in severe asthma management. <i>European Respiratory Journal</i> , 2020, 55, 1901633.	3.1	83
1488	Persistent Asthma from Childhood to Adulthood Presents a Distinct Phenotype of Adult Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1921-1927.e2.	2.0	22
1489	Systematic Assessment for Difficult and Severe Asthma Improves Outcomes and Halves Oral Corticosteroid Burden Independent of Monoclonal Biologic Use. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 1616-1624.	2.0	25
1490	Eosinophilic Granulomatosis With Polyangiitis. <i>Chest</i> , 2020, 157, 1086-1099.	0.4	26
1491	The Current State of Biologic Therapies for Treatment of Refractory Asthma. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 195-207.	2.9	28



#	ARTICLE	IF	CITATIONS
1492	Real-life retrospective observational study to determine the prevalence and economic burden of severe asthma in Spain. <i>Journal of Medical Economics</i> , 2020, 23, 492-500.	1.0	12
1493	Intersection of biology and therapeutics: type 2 targeted therapeutics for adult asthma. <i>Lancet</i> , The, 2020, 395, 371-383.	6.3	102
1494	Managing Chronic Cough Due to Asthma and NAEB in Adults and Adolescents. <i>Chest</i> , 2020, 158, 68-96.	0.4	36
1495	Vaping effects on asthma: results from a web survey and clinical investigation. <i>Internal and Emergency Medicine</i> , 2020, 15, 663-671.	1.0	9
1496	PAGE Study: Summary of a Study Protocol to Estimate the Prevalence of Severe Asthma in Spain Using Big Data Methods. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2021, 31, 308-315.	0.6	8
1497	&lt;p&gt;Sputum IL-26 Is Overexpressed in Severe Asthma and Induces Proinflammatory Cytokine Production and Th17 Cell Generation: A Case&acirc;Control Study of Women&lt;p&gt;. <i>Journal of Asthma and Allergy</i> , 2020, Volume 13, 95-107.	1.5	18
1498	T2&acirc;Low&acirc;Asthma: Overview and Management Strategies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 452-463.	2.0	82
1499	Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2678-2680.	2.7	10
1500	COVID-19&acirc;related Genes in Sputum Cells in Asthma. Relationship to Demographic Features and Corticosteroids. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 83-90.	2.5	370
1501	Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. <i>Respiratory Medicine</i> , 2022, 191, 105991.	1.3	13
1502	The six-gene expression signature in whole sampled sputum provides clinically feasible inflammatory phenotyping of asthma. <i>ERJ Open Research</i> , 2020, 6, 00280-2019.	1.1	6
1503	Which Child with Asthma is a Candidate for Biological Therapies?. <i>Journal of Clinical Medicine</i> , 2020, 9, 1237.	1.0	13
1504	Kids, Difficult Asthma and Fungus. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020, 6, 55.	1.5	21
1505	Patterns of oral corticosteroids use in primary care patients with severe asthma. <i>Respiratory Medicine</i> , 2020, 166, 105946.	1.3	7
1506	Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. <i>Journal of Asthma</i> , 2021, 58, 849-854.	0.9	8
1508	Effectiveness of omalizumab on patient reported outcomes, lung function, and inflammatory markers in severe allergic asthma. <i>Biochemical Pharmacology</i> , 2020, 179, 113944.	2.0	14
1509	Real-World Effectiveness and the Characteristics of a &acirc;Super-Responder&acirc;to Mepolizumab in Severe Eosinophilic Asthma. <i>Chest</i> , 2020, 158, 491-500.	0.4	135
1510	Severe asthma and eligibility for biologics in a Brazilian cohort. <i>Journal of Asthma</i> , 2021, 58, 958-966.	0.9	13

#	ARTICLE	IF	CITATIONS
1511	Diagnostic markers of allergic bronchopulmonary aspergillosis in patients with severe asthma. <i>Mycoses</i> , 2020, 63, 596-603.	1.8	5
1512	Needs for Systems Approaches to Better Treat Individuals With Severe Asthma: Predicting Phenotypes and Responses to Treatments. <i>Frontiers in Medicine</i> , 2020, 7, 98.	1.2	16
1513	Relationship between quality of life and behavioural disorders in children with persistent asthma: a Multiple Indicators Multiple Causes (MIMIC) model. <i>Scientific Reports</i> , 2020, 10, 6957.	1.6	31
1514	Prediction of response to biological treatment with monoclonal antibodies in severe asthma. <i>Biochemical Pharmacology</i> , 2020, 179, 113978.	2.0	34
1515	Severe-controlled asthma 4 years later: is it still controlled?. <i>Journal of Asthma</i> , 2020, 58, 1-9.	0.9	1
1516	Aberrant anti-viral response of natural killer cells in severe asthma. <i>European Respiratory Journal</i> , 2020, 55, 1802422.	3.1	9
1517	NORDSTAR: paving the way for a new era in asthma research. <i>European Respiratory Journal</i> , 2020, 55, 1902476.	3.1	7
1518	Clinical characteristics of the BREATHE cohort – a real-life study on patients with asthma and COPD. <i>European Clinical Respiratory Journal</i> , 2020, 7, 1736934.	0.7	16
1519	Medicina personalizada para el asma y la enfermedad pulmonar obstructiva crónica. <i>Karger Kompass Neumologie</i> , 2020, 2, 10-17.	0.0	0
1520	Metagenomics Reveals a Core Macrolide Resistance Related to Microbiota in Chronic Respiratory Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 433-447.	2.5	58
1521	Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 294-303.e1.	0.5	11
1522	Chronic Stress and Glucocorticoid Receptor Resistance in Asthma. <i>Clinical Therapeutics</i> , 2020, 42, 993-1006.	1.1	27
1523	Drugs for airway disease. <i>Medicine</i> , 2020, 48, 314-322.	0.2	1
1524	Pediatric use of omalizumab for allergic asthma. <i>Expert Opinion on Biological Therapy</i> , 2020, 20, 695-703.	1.4	11
1525	Relationship of sputum mast cells with clinical and inflammatory characteristics of asthma. <i>Clinical and Experimental Allergy</i> , 2020, 50, 696-707.	1.4	16
1526	Bronchial thermoplasty reduces airway resistance. <i>Respiratory Research</i> , 2020, 21, 76.	1.4	16
1527	Mepolizumab in a population with severe eosinophilic asthma and corticosteroid dependence: results from a French early access programme. <i>European Respiratory Journal</i> , 2020, 55, 1902345.	3.1	57
1528	Chronic rhinosinusitis with nasal polyps impact in severe asthma patients: Evidences from the Severe Asthma Network Italy (SANI) registry. <i>Respiratory Medicine</i> , 2020, 166, 105947.	1.3	55

#	ARTICLE	IF	CITATIONS
1529	Impact of asthma severity on long-term asthma control. <i>Journal of Asthma</i> , 2021, 58, 725-734.	0.9	4
1530	Disease burden of eosinophilic airway disease: Comparing severe asthma, <scp>COPD</scp> and <scp>asthma</scp>â€œCOPD</scp> overlap. <i>Respirology</i> , 2021, 26, 52-61.	1.3	16
1531	EAACI Biologicals Guidelinesâ€”Recommendations for severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 14-44.	2.7	156
1532	Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety. <i>Journal of Asthma</i> , 2021, 58, 651-658.	0.9	26
1533	Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. <i>Journal of Asthma</i> , 2021, 58, 448-458.	0.9	30
1534	Spontaneous sputum discriminates inflammatory phenotypes in patients with asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 54-60.e1.	0.5	10
1535	RNAâ€”seqâ€”based profiling of extracellular vesicles in plasma reveals a potential role of miRâ€”122â€”5p in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 366-371.	2.7	18
1536	Treatment options in type-2 low asthma. <i>European Respiratory Journal</i> , 2021, 57, 2000528.	3.1	80
1537	High-resolution CT pulmonary findings in children with severe asthma. <i>Jornal De Pediatria</i> , 2021, 97, 37-43.	0.9	5
1538	Severe asthma assessment, management and the organisation of care in Australia and New Zealand: expert forum roundtable meetings. <i>Internal Medicine Journal</i> , 2021, 51, 169-180.	0.5	5
1539	Pregnancy complicated by allergic bronchopulmonary aspergillosis: A caseâ€”control study. <i>Mycoses</i> , 2021, 64, 35-41.	1.8	4
1540	The Role of Neutrophils in the Pathophysiology of Asthma in Humans and Horses. <i>Inflammation</i> , 2021, 44, 450-465.	1.7	13
1541	Tezepelumab improves patient-reported outcomes in patients with severe, uncontrolled asthma in PATHWAY. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 187-193.	0.5	32
1542	Insights into glucocorticoid responses derived from omics studies. , 2021, 218, 107674.		11
1543	COVIDâ€”19 in Severe Asthma Network in Italy (SANI) patients: Clinical features, impact of comorbidities and treatments. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 887-892.	2.7	69
1544	Sputum macrophage diversity and activation in asthma: Role of severity and inflammatory phenotype. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 775-788.	2.7	25
1545	Bronchial Thermoplasty Induced Airway Smooth Muscle Reduction and Clinical Response in Severe Asthma. The TASMA Randomized Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 175-184.	2.5	58
1546	Urinary Leukotriene E<sub>4</sub> and Prostaglandin D<sub>2</sub> Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type 2 Inflammation. A Clinical Observational Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 37-53.	2.5	49

#	ARTICLE	IF	CITATIONS
1547	Characteristics of Specialistâ€Diagnosed Asthmaâ€COPD Overlap in Severe Asthma: Observations from the Korean Severe Asthma Registry (KoSAR). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 223-232.	2.7	16
1548	Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort. <i>European Respiratory Journal</i> , 2021, 57, 2002127.	3.1	8
1549	Long-term prognosis of new adult-onset asthma in obese patients. <i>European Respiratory Journal</i> , 2021, 57, 2001209.	3.1	15
1550	Determination of the cutoff values of Th2 markers for the prediction of future exacerbation in severe asthma: An analysis from the Hokkaido Severe Asthma Cohort Study. <i>Allergology International</i> , 2021, 70, 68-73.	1.4	7
1551	Multidimensional Assessment of Asthma Identifies Clinically Relevant Phenotype Overlap: A Cross-Sectional Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 349-362.e18.	2.0	18
1552	Mepolizumab 100 mg in severe asthmatic patients with EGPA in remission phase. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1386-1388.	2.0	21
1553	Long-Term Therapy Response to Antiâ€IL-5 Biologics in Severe Asthmaâ€A Real-Life Evaluation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1194-1200.	2.0	102
1554	The Prevalence of Subtypes of Type 2 Inflammation in an Unselected Population of Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1267-1275.	2.0	49
1555	Asthma control and psychological health in pediatric severe asthma. <i>Pediatric Pulmonology</i> , 2021, 56, 42-48.	1.0	8
1556	Treatable Traits That Predict Health Status and Treatment Response in Airway Disease. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1255-1264.e2.	2.0	34
1557	Basophil activation test for <i>Staphylococcus aureus</i> enterotoxins in severe asthmatic patients. <i>Clinical and Experimental Allergy</i> , 2021, 51, 536-545.	1.4	6
1558	Specialized <i>proresolving</i> mediators in infection and lung injury. <i>BioFactors</i> , 2021, 47, 6-18.	2.6	21
1559	Evaluation of olfactory dysfunction to estimate the presence of eosinophilic chronic rhinosinusitis in patients with asthma. <i>Respiratory Investigation</i> , 2021, 59, 126-134.	0.9	5
1560	Severe asthma: adding new evidence â€ Latin American Thoracic Society. <i>ERJ Open Research</i> , 2021, 7, 00318-2020.	1.1	7
1561	Ceramide in apoptosis and oxidative stress in allergic inflammation and asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1936-1948.e9.	1.5	37
1562	The Danish severe asthma register: an electronic platform for severe asthma management and research. <i>European Clinical Respiratory Journal</i> , 2021, 8, 1842117.	0.7	7
1563	Hormonal contraception and the risk of severe asthma exacerbation: 17-year population-based cohort study. <i>Thorax</i> , 2021, 76, 109-115.	2.7	18
1564	<sup>129</sup> Xe MRI as a measure of clinical disease severity for pediatric asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 2146-2153.e1.	1.5	18

#	ARTICLE	IF	CITATIONS
1565	What matters to people with severe asthma? Exploring add-on asthma medication and outcomes of importance. <i>ERJ Open Research</i> , 2021, 7, 00497-2020.	1.1	28
1566	Ceruloplasmin and oxidative stress in severe eosinophilic asthma patients treated with Mepolizumab and Benralizumab. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2021, 1869, 140563.	1.1	11
1567	Prospects for severe asthma treatment. <i>Current Opinion in Pharmacology</i> , 2021, 56, 52-60.	1.7	17
1568	Recent progress in the development of Î²2 adrenergic receptor agonists: a patent review (2015-2020). <i>Expert Opinion on Therapeutic Patents</i> , 2021, 31, 239-246.	2.4	4
1569	Severe Adult Asthmas: Integrating Clinical Features, Biology, and Therapeutics to Improve Outcomes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 809-821.	2.5	72
1570	Neutrophilic asthma features increased airway classical monocytes. <i>Clinical and Experimental Allergy</i> , 2021, 51, 305-317.	1.4	19
1571	“Can Do” Versus “Do Do” in Patients with Asthma at First Referral to a Pulmonologist. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1278-1284.	2.0	9
1572	Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma. A Delphi Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 871-881.	2.5	65
1573	Daily, Once-Weekly, or No Asthma Controller Therapy At All: The Annoying Issue with Disease Remission in Clinical Asthma Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 273-275.	2.5	0
1574	Clinical features associated with a doctor-diagnosis of bronchiectasis in the Severe Asthma Network in Italy (SANI) registry. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 419-424.	1.0	9
1575	Laryngeal Dysfunction in Severe Asthma: A Cross-Sectional Observational Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 897-905.	2.0	16
1576	The Gut Microbiome and Ozone-induced Airway Hyperresponsiveness. Mechanisms and Therapeutic Prospects. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 64, 283-291.	1.4	14
1577	Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma. <i>Chest</i> , 2021, 159, 496-506.	0.4	159
1578	Type 2 “high asthma is associated with a specific indoor mycobiome and microbiome. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1296-1305.e6.	1.5	41
1579	Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma. <i>Journal of Asthma</i> , 2021, 58, 79-84.	0.9	31
1580	Attack, flare-up, or exacerbation? The terminology preferences of patients with severe asthma. <i>Journal of Asthma</i> , 2021, 58, 141-150.	0.9	8
1581	Barriers to belonging: the need for relatedness amongst people living with severe asthma. <i>Journal of Asthma</i> , 2021, 58, 1-9.	0.9	9
1582	Economic impact of severe asthma exacerbations in Spain: multicentre observational study. <i>Journal of Asthma</i> , 2021, 58, 207-212.	0.9	10

#	ARTICLE	IF	CITATIONS
1583	Efficacy of bronchial thermoplasty in patients with severe asthma. <i>Journal of Asthma</i> , 2021, 58, 216-222.	0.9	6
1584	Using community priorities and misconceptions about asthma as a vessel for community-led education among Hispanics. <i>Journal of Asthma</i> , 2021, 58, 405-412.	0.9	2
1585	Clinical characteristics and burden of illness among adolescent and adult patients with severe asthma by asthma control: the IDEAL study. <i>Journal of Asthma</i> , 2021, 58, 459-470.	0.9	21
1586	Demographic and clinical patterns of severe asthma in the Middle East. <i>Annals of Thoracic Medicine</i> , 2021, 16, 172.	0.7	1
1587	Severe asthma in South Africa: A literature review and management approach for primary care. <i>South African Family Practice: Official Journal of the South African Academy of Family Practice/Primary Care</i> , 2021, 63, e1-e10.	0.2	2
1590	Biologics in asthma management – Are we out of breath yet?. <i>Allergologie Select</i> , 2021, 5, 96-102.	1.6	4
1591	Obstructive sleep apnea is a determinant of asthma control independent of smoking, reflux, and rhinitis. <i>Allergy and Asthma Proceedings</i> , 2021, 42, e25-e29.	1.0	6
1592	Nuclear Receptors in Asthma: Empowering Classical Molecules Against a Contemporary Ailment. <i>Frontiers in Immunology</i> , 2020, 11, 594433.	2.2	4
1593	Prior authorization delays biologic initiation and is associated with a risk of asthma exacerbations. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 65-71.	1.0	10
1594	Biologics for atopic diseases: Indication, side effect management, and new developments. <i>Allergologie Select</i> , 2021, 5, 1-25.	1.6	13
1595	Clinical form of asthma and vaccine immunity in preschoolers. <i>Postepy Dermatologii i Alergologii</i> , 2021, 38, 123-130.	0.4	2
1596	Clinical Importance of Work-Exacerbated Asthma: Findings From a Prospective Asthma Cohort in a Highly Industrialized City in Korea. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 256.	1.1	1
1597	Perspectives on decisions for treatment and care in severe asthma. <i>World Allergy Organization Journal</i> , 2021, 14, 100500.	1.6	0
1598	Applying personalized medicine to adult severe asthma. <i>Allergy and Asthma Proceedings</i> , 2021, 42, e8-e16.	1.0	4
1599	Drugs Resistance in Lungs Diseases. , 2021, , 235-254.		0
1600	A-to-I editing of miR-200b-3p in airway cells is associated with moderate-to-severe asthma. <i>European Respiratory Journal</i> , 2021, 58, 2003862.	3.1	10
1601	Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1-11.	1.5	21
1602	Triple therapy in uncontrolled asthma: a network meta-analysis of phase III studies. <i>European Respiratory Journal</i> , 2021, 58, 2004233.	3.1	31

#	ARTICLE	IF	CITATIONS
1603	Recent updates on the role of extracellular vesicles in the pathogenesis of allergic asthma. , 2021, 2, 127-147.		6
1604	Biomarkers for Severe Asthma: Lessons From Longitudinal Cohort Studies. Allergy, Asthma and Immunology Research, 2021, 13, 375.	1.1	40
1605	Asthma and Asthma Education: The Background. , 2021, , 3-38.		0
1606	Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report. Respiratory Medicine Case Reports, 2021, 32, 101336.	0.2	2
1607	An expert review on breaking barriers in severe asthma in Brazil: Time to act. Chronic Respiratory Disease, 2021, 18, 147997312110282.	1.0	3
1608	Pharmacological Management of Asthma and COPD. , 2021, , .		0
1609	Bronchoscopic management of asthma, COPD and emphysema. European Respiratory Review, 2021, 30, 200029.	3.0	3
1610	Expression of cPLA <sub>2</sub> <sup>γ</sup> mRNA and protein differs the response of PBMC from severe and non-severe asthmatics to bacterial lipopolysaccharide and house dust mite allergen. International Journal of Immunopathology and Pharmacology, 2021, 35, 205873842199095.	1.0	2
1611	Clinical and histopathologic predictors of therapeutic response to bronchial thermoplasty in severe refractory asthma. Journal of Allergy and Clinical Immunology, 2021, 148, 1227-1235.e6.	1.5	17
1612	May mepolizumab used in asthma correct subfertility?. Annals of Medicine, 2021, 53, 456-458.	1.5	7
1613	Utility of immunology, microbiology, and helminth investigations in clinical assessment of severe asthma. Journal of Asthma, 2022, 59, 541-551.	0.9	2
1614	Are Volatile Organic Compounds Able to Identify Airflow Decline in Asthma?. Journal of Asthma and Allergy, 2021, Volume 14, 67-70.	1.5	0
1615	“Like a fish on dry land”: an explorative qualitative study into severe asthma and the impact of biologics on patients’ everyday life. Journal of Asthma, 2022, 59, 980-988.	0.9	5
1616	Ozone-Induced Oxidative Stress, Neutrophilic Airway Inflammation, and Glucocorticoid Resistance in Asthma. Frontiers in Immunology, 2021, 12, 631092.	2.2	25
1617	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	1.6	14
1618	Lower Use of Biologics for the Treatment of Asthma in Publicly Insured Individuals. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3969-3976.	2.0	28
1619	The Nose as a Route for Therapy: Part 1. Pharmacotherapy. Frontiers in Allergy, 2021, 2, 638136.	1.2	12
1620	A feasibility randomised controlled trial of Novel Activity Management in severe Asthma-Tailored Exercise (NAMASTE): yoga and mindfulness. BMC Pulmonary Medicine, 2021, 21, 71.	0.8	9

#	ARTICLE	IF	CITATIONS
1621	Molecular Analysis of IL-5 Receptor Subunit Alpha as a Possible Pharmacogenetic Biomarker in Asthma. <i>Frontiers in Medicine</i> , 2020, 7, 624576.	1.2	9
1622	Patterns of azithromycin use in obstructive airway diseases: a real-world observational study. <i>Internal Medicine Journal</i> , 2022, 52, 1016-1023.	0.5	3
1623	Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2715-2724.e5.	2.0	15
1624	Effectiveness of Benralizumab in Improving the Quality of Life of Severe Eosinophilic Asthmatic Patients: Our Real-Life Experience. <i>Frontiers in Pharmacology</i> , 2021, 12, 631660.	1.6	17
1625	Therapeutic Effects of Benralizumab Assessed in Patients with Severe Eosinophilic Asthma: Real-Life Evaluation Correlated with Allergic and Non-Allergic Phenotype Expression. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 163-173.	1.5	39
1626	An inherent dysfunction in soluble guanylyl cyclase is present in the airway of severe asthmatics and is associated with aberrant redox enzyme expression and compromised NO-cGMP signaling. <i>Redox Biology</i> , 2021, 39, 101832.	3.9	14
1627	Association between Physical Activity and Respiratory Diseases in Adolescents: An Age- and Gender-Matched Study. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1397.	1.2	3
1628	Essential role of smooth muscle Rac1 in severe asthma-associated airway remodelling. <i>Thorax</i> , 2021, 76, 326-334.	2.7	13
1629	Identification of biomarkers and pathogenesis in severe asthma by coexpression network analysis. <i>BMC Medical Genomics</i> , 2021, 14, 51.	0.7	11
1630	Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2725-2731.	2.0	24
1631	Measures of ventilation heterogeneity mapped with hyperpolarized helium-3 MRI demonstrate a T2-high phenotype in asthma. <i>Pediatric Pulmonology</i> , 2021, 56, 1440-1448.	1.0	4
1632	The effect of statins for asthma. A systematic review and meta-analysis. <i>Journal of Asthma</i> , 2022, 59, 801-810.	0.9	8
1633	Regulatory T cell monitoring in severe eosinophilic asthma patients treated with mepolizumab. <i>Scandinavian Journal of Immunology</i> , 2021, 94, e13031.	1.3	12
1634	Anti-asthmatic effect of nitric oxide metallo-donor FOR811A [cis-[Ru(bpy)2(2-MIM)(NO)](PF6)3] in the respiratory mechanics of Swiss mice. <i>PLoS ONE</i> , 2021, 16, e0248394.	1.1	6
1635	Characterization of severe asthma in the pediatric population. <i>Allergologia Et Immunopathologia</i> , 2021, 49, 60-65.	1.0	1
1636	Sex differences in the relationship of sleep-disordered breathing and asthma control among children with severe asthma. <i>Journal of Asthma</i> , 2021, , 1-9.	0.9	2
1637	Sputum TNF markers are increased in neutrophilic and severe asthma and are reduced by azithromycin treatment. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2090-2101.	2.7	27
1638	Effect of $\alpha$ 1 antitrypsin deficiency on lung volume decline in severe asthmatic patients undergoing biologic therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1414-1416.	2.0	5



#	ARTICLE	IF	CITATIONS
1639	The Patientsâ€™ Experience of Severe Asthma Add-On Pharmacotherapies: A Qualitative Descriptive Study. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 245-258.	1.5	14
1640	Câ€CSFR antagonism reduces mucosal injury and airways fibrosis in a virusâ€dependent model of severe asthma. <i>British Journal of Pharmacology</i> , 2021, 178, 1869-1885.	2.7	13
1641	Digital Imaging Analysis Reveals Reduced Alveolar Î±-Smooth Muscle Actin Expression in Severe Asthma. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 506-512.	0.6	4
1642	Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 260-274.	5.2	102
1643	Hormone Replacement Therapy and Risk of Severe Asthma Exacerbation in Perimenopausal and Postmenopausal Women: 17-Year National Cohort Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2751-2760.e1.	2.0	12
1644	Cluster Analysis of Inflammatory Biomarker Expression in the International Severe Asthma Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2680-2688.e7.	2.0	50
1645	Dupilumab Improves Asthma Control and Lung Function in Patients with Insufficient Outcome During Previous Antibody Therapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1177-1185.e4.	2.0	43
1646	Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 362-370.	0.7	7
1647	Persistent Uncontrolled Asthma: Long-Term Impact on Physical Activity and Body Composition. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 229-240.	1.5	14
1648	Åžocuklarda AÄŸ±r AstÄ±m, Biyolojik Tedaviler ve Covid-19 Pandemisinde GÄ¼ncel YaklaÅ±mlar. <i>Turkish Journal of Pediatric Disease</i> , 0, , 1-6.	0.0	2
1649	Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3969.	1.8	12
1650	Y a-t-il une place pour lâ€™imagerie dans la prise en charge de lâ€™asthme? <i>Journal D'imagerie Diagnostique Et Interventionnelle</i> , 2021, 4, 85-88.	0.0	0
1651	Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 882-892.	2.5	39
1652	Single-cell characterization of a model of poly I:C-stimulated peripheral blood mononuclear cells in severe asthma. <i>Respiratory Research</i> , 2021, 22, 122.	1.4	8
1653	Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany. <i>Respiratory Research</i> , 2021, 22, 108.	1.4	22
1654	Perioperative Assessment and Management of Patients with Obstructive Sleep Apnea. <i>Benha Journal of Applied Sciences</i> , 2021, 6, 179-184.	0.0	0
1655	Evaluating post-bronchodilator response in well-controlled paediatric severe asthma using hyperpolarised <sup>129</sup> Xe-MRI: A pilot study. <i>Respiratory Medicine</i> , 2021, 180, 106368.	1.3	8
1656	Long-term corticosteroid use, adrenal insufficiency and the need for steroid-sparing treatment in adult severe asthma. <i>Journal of Internal Medicine</i> , 2021, 290, 240-256.	2.7	18

#	ARTICLE	IF	CITATIONS
1657	Both living and dead <i>Faecalibacterium prausnitzii</i> alleviate house dust mite-induced allergic asthma through the modulation of gut microbiota and short-chain fatty acid production. <i>Journal of the Science of Food and Agriculture</i> , 2021, 101, 5563-5573.	1.7	26
1658	High-dimensional profiling clusters asthma severity by lymphoid and non-lymphoid status. <i>Cell Reports</i> , 2021, 35, 108974.	2.9	32
1659	Tezepelumab: A Potential New Biological Therapy for Severe Refractory Asthma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4369.	1.8	33
1660	Characteristics of patients with frequent systemic corticosteroid bursts for asthma in real clinical practice: are there frequent "short bursts"? <i>Journal of Asthma</i> , 2021, , 1-8.	0.9	1
1661	Response of individual airways in vivo to bronchial thermoplasty. <i>Journal of Applied Physiology</i> , 2021, 130, 1205-1213.	1.2	5
1662	Aspergillus-related diseases in a cohort of patients with severe asthma: A SANI single-center report. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2920-2922.e2.	2.0	7
1663	The Predictive Role of Biomarkers and Genetics in Childhood Asthma Exacerbations. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4651.	1.8	18
1664	Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium. <i>Genome Medicine</i> , 2021, 13, 66.	3.6	21
1667	Detection and characterisation of extracellular vesicles in exhaled breath condensate and sputum of COPD and severe asthma patients. <i>European Respiratory Journal</i> , 2021, 58, 2003024.	3.1	8
1668	Trends in oral corticosteroids use in severe asthma: a 14-year population-based study. <i>Respiratory Research</i> , 2021, 22, 103.	1.4	8
1670	The significance of eosinophil and eosinophil lymphocyte ratio (ELR) in predicting response to omalizumab treatment in patients with severe allergic asthma. <i>Tuberkuloz Ve Toraks</i> , 2021, 69, 39-48.	0.2	7
1671	Blood tryptase and thymic stromal lymphopoietin levels predict the risk of exacerbation in severe asthma. <i>Scientific Reports</i> , 2021, 11, 8425.	1.6	8
1672	Eosinophilic asthma and the role of monoclonal antibodies. <i>Nurse Practitioner</i> , 2021, 46, 21-27.	0.2	1
1673	Defining type 2 asthma and patients eligible for dupilumab in Italy: a biomarker-based analysis. <i>Clinical and Molecular Allergy</i> , 2021, 19, 5.	0.8	14
1674	Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study. <i>Allergy and Asthma Proceedings</i> , 2021, 42, 235-242.	1.0	15
1675	Managing Corticosteroid-Related Comorbidities in Severe Asthma. <i>Chest</i> , 2021, 160, 1614-1623.	0.4	8
1676	Expression levels of plasma exosomal miR-124, miR-125b, miR-133b, miR-130a and miR-125b-1-3p in severe asthma patients and normal individuals with emphasis on inflammatory factors. <i>Allergy, Asthma and Clinical Immunology</i> , 2021, 17, 51.	0.9	14
1677	Asthma severity as a contributing factor to cancer incidence: A cohort study. <i>PLoS ONE</i> , 2021, 16, e0250430.	1.1	10

#	ARTICLE	IF	CITATIONS
1678	Novel Anti-Cytokine Strategies for Prevention and Treatment of Respiratory Allergic Diseases. <i>Frontiers in Immunology</i> , 2021, 12, 601842.	2.2	18
1679	Uncontrolled Asthma: Unmet Needs in the Management of Patients. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 457-466.	1.5	24
1680	Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics. <i>Respiratory Research</i> , 2021, 22, 144.	1.4	18
1681	The Roles of Type 2 Cytotoxic T Cells in Inflammation, Tissue Remodeling, and Prostaglandin (PG) D2 Production Are Attenuated by PGD2 Receptor 2 Antagonism. <i>Journal of Immunology</i> , 2021, 206, 2714-2724.	0.4	8
1682	Treating severe asthma: Targeting the IL-5 pathway. <i>Clinical and Experimental Allergy</i> , 2021, 51, 992-1005.	1.4	30
1683	Asthma treatment response to inhaled corticosteroids is associated with variants in VEGFA gene. <i>Gene</i> , 2021, 783, 145573.	1.0	2
1684	Searching for Inflammatory and Oxidative Stress Markers Capable of Clustering Severe Asthma. <i>Archivos De Bronconeumologia</i> , 2021, 57, 338-344.	0.4	2
1685	Treatment for Severe Asthma in Children: What About Biologics?. <i>Pediatric Annals</i> , 2021, 50, e206-e213.	0.3	1
1686	The effect of obstructive sleep apnea on peripheral blood amino acid and biogenic amine metabolome at multiple time points overnight. <i>Scientific Reports</i> , 2021, 11, 10811.	1.6	8
1687	Novel Machine Learning Can Predict Acute Asthma Exacerbation. <i>Chest</i> , 2021, 159, 1747-1757.	0.4	35
1688	Factors Associated with Asthma Severity in Children: Data from the French COBRAPed Cohort. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1969-1979.	2.0	9
1689	Real-life cost-effectiveness of benralizumab in patients with severe asthma. <i>Respiratory Research</i> , 2021, 22, 163.	1.4	16
1690	Safety and effectiveness of bronchial thermoplasty after 10 years in patients with persistent asthma (BT10+): a follow-up of three randomised controlled trials. <i>Lancet Respiratory Medicine</i> , 2021, 9, 457-466.	5.2	63
1691	Targeting eosinophils: another strategy for asthma treatment. <i>Clinical and Experimental Pediatrics</i> , 2021, 64, 223-224.	0.9	1
1692	Dual biologic therapy in a patient with severe asthma and other allergic disorders. <i>BMJ Case Reports</i> , 2021, 14, e242211.	0.2	6
1693	Active ingredients from Chinese medicine plants as therapeutic strategies for asthma: Overview and challenges. <i>Biomedicine and Pharmacotherapy</i> , 2021, 137, 111383.	2.5	26
1694	Evaluation of bronchial wall thickness in asthma using magnetic resonance imaging. <i>European Respiratory Journal</i> , 2022, 59, 2100329.	3.1	4
1695	Overcoming Barriers to the Effective Management of Severe Asthma in Italy. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 481-491.	1.5	2

#	ARTICLE	IF	CITATIONS
1696	2020 Updated Asthma Guidelines: Bronchial thermoplasty in the management of asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1638-1639.	1.5	2
1697	Biological Therapies in Children and Adolescents with Severe Uncontrolled Asthma: A Practical Review. <i>Biologics: Targets and Therapy</i> , 2021, Volume 15, 133-142.	3.0	12
1698	Searching for Inflammatory and Oxidative Stress Markers Capable of Clustering Severe Asthma. <i>Archivos De Bronconeumologia</i> , 2021, 57, 338-344.	0.4	8
1699	The impact of socioeconomic risk factors and mental health on asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 453-457.	0.5	1
1700	Immediate complications and flow volume changes during treatment phases of bronchial thermoplasty: a single-center descriptive study. <i>Journal of Asthma</i> , 2021, , 1-5.	0.9	2
1701	Factors Associated with Persistence of Severe Asthma from Late Adolescence to Early Adulthood. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 776-787.	2.5	16
1702	Precision Medicine for Paediatric Severe Asthma: Current Status and Future Direction. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 525-538.	1.5	6
1703	Pediatric flexible bronchoscopy: A single-center report. <i>Pediatric Pulmonology</i> , 2021, 56, 2634-2641.	1.0	4
1704	Sedentary time in people with obstructive airway diseases. <i>Respiratory Medicine</i> , 2021, 181, 106367.	1.3	5
1705	PreClSE: Precision Medicine in Severe Asthma: An adaptive platform trial with biomarker ascertainment. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 1594-1601.	1.5	27
1706	High serum cytokine levels may predict the responsiveness of patients with severe asthma to benralizumab. <i>Journal of Asthma</i> , 2021, , 1-11.	0.9	6
1707	Corticosteroid resistance in asthma: Cellular and molecular mechanisms. <i>Molecular Aspects of Medicine</i> , 2022, 85, 100969.	2.7	17
1708	In vivo assessment of changes to canine airway smooth muscle following bronchial thermoplasty with OR-OCT. <i>Journal of Applied Physiology</i> , 2021, 130, 1814-1821.	1.2	6
1709	Mepolizumab improves clinical outcomes in patients with severe asthma and comorbid conditions. <i>Respiratory Research</i> , 2021, 22, 171.	1.4	22
1710	Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. <i>Pulmonologiya</i> , 2021, 31, 272-295.	0.2	0
1711	Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials. <i>Respiratory Research</i> , 2021, 22, 184.	1.4	13
1712	Evaluation of Sensitivity and Specificity of Interleukins 25 and 33 in Diagnosis of Pediatric Asthma. <i>Journal of Pure and Applied Microbiology</i> , 2021, 15, 845-850.	0.3	1
1713	Oscillometry of the respiratory system: a translational opportunity not to be missed. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2021, 320, L1038-L1056.	1.3	9

#	ARTICLE	IF	CITATIONS
1714	Noninvasive ventilation use in pediatric status asthmaticus. <i>Journal of Asthma</i> , 2021, , 1-5.	0.9	1
1715	Interrelationship Between Obstructive Sleep Apnea Syndrome and Severe Asthma: From Endo-Phenotype to Clinical Aspects. <i>Frontiers in Medicine</i> , 2021, 8, 640636.	1.2	12
1716	Attitudes of Croatian pulmonologists concerning obstacles to earlier, more appropriate use of biologics in severe asthma: Survey results. <i>PLoS ONE</i> , 2021, 16, e0253468.	1.1	0
1717	Biologic Therapy and Severe Asthma in Children. <i>Biomedicines</i> , 2021, 9, 760.	1.4	14
1719	Bronchial Thermoplasty in Patients with Severe Persistent Asthma: A Literature Review. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 518-522.	0.4	2
1720	Novel therapeutic approaches targeting endotypes of severe airway disease. <i>Expert Review of Respiratory Medicine</i> , 2021, 15, 1303-1316.	1.0	9
1721	Real-World Effectiveness of Anti-IL-5/5R Therapy in Severe Atopic Eosinophilic Asthma with Fungal Sensitization. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2315-2320.e1.	2.0	21
1722	Overview of Severe Asthma, with Emphasis on Pediatric Patients: A Review for Practitioners. <i>Journal of Investigative Medicine</i> , 2021, 69, 1297-1309.	0.7	1
1723	Blood eosinophil counts in the general population and airways disease: a comprehensive review and meta-analysis. <i>European Respiratory Journal</i> , 2022, 59, 2004590.	3.1	37
1724	Raised sputum extracellular DNA confers lung function impairment and poor symptom control in an exacerbation-susceptible phenotype of neutrophilic asthma. <i>Respiratory Research</i> , 2021, 22, 167.	1.4	10
1725	Characterization of Asthma Trajectories from Infancy to Young Adulthood. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2368-2376.e3.	2.0	22
1726	Health-Related Quality of Life and Productivity Among US Patients with Severe Asthma. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 713-725.	1.5	10
1727	Response to Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma and Atopic Phenotypes. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 675-683.	1.5	7
1728	Real-world Effectiveness of Mepolizumab in Severe Eosinophilic Asthma: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2021, 43, e192-e208.	1.1	12
1729	Airway gene expression identifies subtypes of type 2 inflammation in severe asthma. <i>Clinical and Experimental Allergy</i> , 2022, 52, 59-69.	1.4	11
1730	Pro: Access to advanced therapies for severe asthma should be restricted to patients with satisfactory adherence to maintenance treatment. <i>Breathe</i> , 2021, 17, 210024.	0.6	2
1731	Real-World Assessment of Asthma Specialist Visits Among U.S. Patients with Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3662-3671.e1.	2.0	11
1732	Serum macrophage migration inhibitory factor as a potential biomarker to evaluate therapeutic response in patients with allergic asthma: an exploratory study. <i>Journal of Zhejiang University: Science B</i> , 2021, 22, 512-520.	1.3	3

#	ARTICLE	IF	CITATIONS
1733	Retrospective comparison of high-resolution computed tomography of eosinophilic granulomatosis with polyangiitis with severe asthma. <i>Annals of Translational Medicine</i> , 2021, 9, 983-983.	0.7	8
1734	Management Strategies to Reduce Exacerbations in non-T2 Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2588-2597.	2.0	10
1735	Total IgE Variability Is Associated with Future Asthma Exacerbations: A 1-Year Prospective Cohort Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2812-2824.	2.0	4
1736	Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study. <i>Respiratory Investigation</i> , 2021, 59, 478-486.	0.9	11
1737	Real-life effectiveness of biological therapies on symptoms in severe asthma with comorbid CRSwNP. <i>Clinical and Translational Allergy</i> , 2021, 11, e12049.	1.4	16
1738	Bronchial thermoplasty guided by hyperpolarised gas magnetic resonance imaging in adults with severe asthma: a 1-year pilot randomised trial. <i>ERJ Open Research</i> , 2021, 7, 00268-2021.	1.1	10
1739	Transcriptomics of biopsies identifies novel genes and pathways linked to neutrophilic inflammation in severe asthma. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1279-1294.	1.4	15
1740	The impact of using a mobile application to improve asthma patients' adherence to medication in Jordan. <i>Health Informatics Journal</i> , 2021, 27, 146045822110429.	1.1	4
1741	Altered gut microbiome compositions are associated with the severity of asthma. <i>Journal of Thoracic Disease</i> , 2021, 13, 4322-4338.	0.6	21
1742	Unravelling the effects of omalizumab on fibrocytes. <i>Respirology</i> , 2021, 26, 825-827.	1.3	1
1743	Biomarkers of asthma. <i>Minerva Medica</i> , 2022, 113, .	0.3	9
1744	Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 266-271.e2.	1.5	22
1745	Risk factors for severe adult-onset asthma: a multi-factor approach. <i>BMC Pulmonary Medicine</i> , 2021, 21, 214.	0.8	12
1746	Defining a Severe Asthma Super-Responder: Findings from a Delphi Process. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3997-4004.	2.0	74
1747	Risk factors for fatal and nonfatal reactions to immunotherapy (2008-2018): postinjection monitoring and severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 64-69.e1.	0.5	28
1748	Positive change in asthma control using therapeutic patient education in severe uncontrolled asthma: a one-year prospective study. <i>Asthma Research and Practice</i> , 2021, 7, 10.	1.2	3
1749	Effect of omalizumab as add-on therapy to Quality of Life Questionnaire for Korean Asthmatics (KAQLQ) in Korean patients with severe persistent allergic asthma. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 1001-1013.	0.7	3
1750	Hospital-Initiated Care Bundle, Posthospitalization Care, and Outcomes in Adults with Asthma Exacerbation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4007-4013.e8.	2.0	3

#	ARTICLE	IF	CITATIONS
1751	Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab. <i>Life</i> , 2021, 11, 744.	1.1	5
1752	Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. <i>European Respiratory Journal</i> , 2021, 58, 2004605.	3.1	10
1753	Transcriptome genetic differences between responders and non-responders before bronchial thermoplasty. <i>Journal of Asthma</i> , 2022, 59, 1641-1651.	0.9	5
1754	A multistakeholder Delphi consensus core outcome set for clinical trials in moderate-to-severe asthma (coreASTHMA). <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 116-122.e7.	0.5	9
1755	Pathological Roles and Clinical Usefulness of Periostin in Type 2 Inflammation and Pulmonary Fibrosis. <i>Biomolecules</i> , 2021, 11, 1084.	1.8	9
1756	Operational definitions of paediatric asthma used in epidemiological studies: A systematic review. <i>Journal of Global Health</i> , 2021, 11, 04032.	1.2	4
1757	Factors Associated with Frequent Exacerbations in the UK Severe Asthma Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2691-2701.e1.	2.0	13
1758	Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort. <i>Chest</i> , 2021, 160, 53-64.	0.4	10
1759	Severe asthma exacerbations in the United States. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 579-587.e1.	0.5	17
1760	Workup of Severe Asthma. <i>Chest</i> , 2021, 160, 2019-2029.	0.4	18
1761	Multiple lung nodules, eosinophilia and severe asthma. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 0, , 1-4.	0.2	0
1762	Pharmacological Rationale for Targeting IL-17 in Asthma. <i>Frontiers in Allergy</i> , 2021, 2, 694514.	1.2	14
1763	Interleukin-5 receptor alpha (CD125) expression on human blood and lung neutrophils. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 128, 53-60.e3.	0.5	2
1764	Predictors of impaired pulmonary function in people living with HIV in an urban African setting. <i>Southern African Journal of HIV Medicine</i> , 2021, 22, 1252.	0.3	2
1765	Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 407-419.	1.5	16
1766	Neutrophil extracellular traps and neutrophil-derived mediators as possible biomarkers in bronchial asthma. <i>Clinical and Experimental Medicine</i> , 2022, 22, 285-300.	1.9	28
1767	Effectiveness and Safety Studies of Omalizumab in Children and Adolescents With Moderate-To-Severe Asthma. <i>Journal of Pharmacy Practice</i> , 2023, 36, 370-382.	0.5	2
1768	COVID-19 Vaccination in Patients with Severe Asthma on Biologic Treatment: Safety, Tolerability, and Impact on Disease Control. <i>Vaccines</i> , 2021, 9, 853.	2.1	21

#	ARTICLE	IF	CITATIONS
1769	Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4371-4380.e4.	2.0	37
1770	Benefits of Airway Androgen Receptor Expression in Human Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 285-293.	2.5	26
1771	IL-1 $\beta$ augments TGF- $\beta$ 2 inducing epithelial-mesenchymal transition of epithelial cells and associates with poor pulmonary function improvement in neutrophilic asthmatics. <i>Respiratory Research</i> , 2021, 22, 216.	1.4	14
1772	Growing, Growing, Gone: The Double Whammy of Early Deprivation and Impaired Evolution of Lung Function. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 745-746.	2.5	2
1773	Treatment approaches for the patient with T2 low asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 530-535.	0.5	8
1774	Organization, Clinical and Management Indicators on the First Year of Activity of an Outpatient Clinic Dedicated to the Diagnosis and Treatment of Severe Asthma in Italy. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1011-1018.	1.5	1
1775	Sputum mast cell/basophil gene expression relates to inflammatory and clinical features of severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 428-438.	1.5	33
1776	Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 377-384.	1.4	3
1777	Differing perceptions of asthma control and treatment effectiveness by patients with severe asthma and treating subspecialists in the United States. <i>Journal of Asthma</i> , 2022, 59, 1859-1868.	0.9	5
1778	The Role of Dupilumab in Severe Asthma. <i>Biomedicines</i> , 2021, 9, 1096.	1.4	16
1779	The Pathogenesis of Eosinophilic Asthma: A Positive Feedback Mechanism That Promotes Th2 Immune Response via Filaggrin Deficiency. <i>Frontiers in Immunology</i> , 2021, 12, 672312.	2.2	10
1780	Immunobiology of Steroid-Unresponsive Severe Asthma. <i>Frontiers in Allergy</i> , 2021, 2, 718267.	1.2	14
1781	Oxidative Stress Promotes Corticosteroid Insensitivity in Asthma and COPD. <i>Antioxidants</i> , 2021, 10, 1335.	2.2	26
1782	Biological therapy for severe asthma. <i>Asthma Research and Practice</i> , 2021, 7, 12.	1.2	19
1783	Cellular and molecular mechanisms of allergic asthma. <i>Molecular Aspects of Medicine</i> , 2022, 85, 100995.	2.7	71
1784	Asthma Disease Status, COPD, and COVID-19 Severity in a Large Multiethnic Population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3621-3628.e2.	2.0	33
1785	How to use the fractional exhaled nitric oxide test. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2021, , edpract-2019-318326.	0.3	1
1786	Adverse Childhood Experiences and Association With Pediatric Asthma Severity in the 2016-2017 National Survey of Children's Health. <i>Academic Pediatrics</i> , 2021, 21, 1025-1030.	1.0	14



#	ARTICLE	IF	CITATIONS
1787	The dual function of ILC2: From host protection to pathogenic players in type 2 asthma. <i>Molecular Aspects of Medicine</i> , 2021, 80, 100981.	2.7	17
1788	Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial. <i>Respiratory Medicine</i> , 2021, 185, 106494.	1.3	10
1789	Small Airway Dysfunction Links Asthma Severity with Physical Activity and Symptom Control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3359-3368.e1.	2.0	39
1790	A low FEV1 confounds interpretation of FeNO as an eligibility criterion for dupilumab. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 615-616.e1.	2.0	1
1791	Asthma biologics. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 655-660.e1.	0.5	9
1792	Severe Asthma in a General Population Study: Prevalence and Clinical Characteristics. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1105-1115.	1.5	26
1793	ERS/EAACI statement on adherence to international adult asthma guidelines. <i>European Respiratory Review</i> , 2021, 30, 210132.	3.0	14
1794	Eosinophilic and Noneosinophilic Asthma. <i>Chest</i> , 2021, 160, 814-830.	0.4	109
1795	Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 790-798.	1.5	147
1796	Special considerations for pulmonary rehabilitation in conditions other than COPD. , 2021, , 145-164.		3
1797	Association Between a Type 2 Inflammatory Disease Burden Score and Outcomes Among Patients with Asthma. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1173-1183.	1.5	12
1798	Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China. <i>Respiratory Medicine</i> , 2021, 186, 106522.	1.3	8
1799	Quantitative CT metrics are associated with longitudinal lung function decline and future asthma exacerbations: Results from SARP-3. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 752-762.	1.5	30
1800	Anti-IL5 Therapy Is Associated with Attenuated Lung Function Decline in Severe Eosinophilic Asthma Patients From the Belgian Severe Asthma Registry. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 467-477.	2.0	13
1801	Monoclonal antibody treatment for severe uncontrolled asthma in Spain: analytical map. <i>Journal of Asthma</i> , 2022, 59, 1997-2007.	0.9	9
1802	Real-world effectiveness of mepolizumab in patients with severe asthma and associated comorbidities. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 354-362.e2.	0.5	19
1803	Regional differences in the incidence of asthma exacerbations in Japan: A heat map analysis of healthcare insurance claims data. <i>Allergology International</i> , 2022, 71, 47-54.	1.4	7
1804	Omalizumab Effectiveness in Severe Allergic Asthma with Multiple Allergic Comorbidities: A Post-Hoc Analysis of the STELLAIR Study. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1129-1138.	1.5	5

#	ARTICLE	IF	CITATIONS
1805	Latest Progresses in Allergic Diseases Biomarkers: Asthma and Atopic Dermatitis. <i>Frontiers in Pharmacology</i> , 2021, 12, 747364.	1.6	6
1806	Factors leading to discontinuation of biologic therapy in patients with severe asthma. <i>Journal of Asthma</i> , 2022, 59, 1839-1849.	0.9	7
1807	Airway inflammation in severe asthmatics with acid gastro-oesophageal reflux. <i>Thorax</i> , 2022, 77, 398-399.	2.7	2
1808	Eosinophils as Drivers of Severe Eosinophilic Asthma: Endotypes or Plasticity?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10150.	1.8	17
1809	Symptom-based questionnaires predict frequent exacerbations in severe asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4480-4482.e1.	2.0	0
1810	Intrabreath oscillometry is a sensitive test for assessing disease control in adults with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 127, 372-377.	0.5	12
1811	Impact of asthma severity as risk factor to future exacerbations in patients admitted for asthma exacerbation. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 780.	0.6	4
1812	REal world Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study. <i>Drugs</i> , 2021, 81, 1763-1774.	4.9	30
1813	Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1263.	0.8	11
1814	Endoplasmic reticulum-unfolded protein response signalling is altered in severe eosinophilic and neutrophilic asthma. <i>Thorax</i> , 2022, 77, 443-451.	2.7	18
1815	Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 4381-4392.e4.	2.0	52
1816	The Management of Extrapulmonary Comorbidities and Treatable Traits; Obesity, Physical Inactivity, Anxiety, and Depression, in Adults With Asthma. <i>Frontiers in Allergy</i> , 2021, 2, 735030.	1.2	14
1817	An altered sputum macrophage transcriptome contributes to the neutrophilic asthma endotype. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1204-1215.	2.7	14
1818	Neuroimaging and biomarker evidence of neurodegeneration in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 589-598.e6.	1.5	24
1819	Toward a More Precise Solution to Asthma Therapy. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2021, 65, 241-242.	1.4	1
1820	Real-life Cretan asthma registry focused on severe asthma: On behalf of the Cretan registry of the use of Biologics in Severe Asthma™. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1239.	0.8	1
1821	FeNO testing in severe asthma: A clinical argument or an access constraint?. <i>Pulmonology</i> , 2021, 27, 383-385.	1.0	1
1822	Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1165-1172.	1.5	31

#	ARTICLE	IF	CITATIONS
1823	Therapeutic Effects of an Anti-sialyl Lewis X Antibody in a Murine Model of Allergic Asthma. International Journal of Molecular Sciences, 2021, 22, 9961.	1.8	1
1824	Potential role of folate status on pulmonary function in pediatric asthma. Nutrition, 2021, 90, 111267.	1.1	5
1825	Transcriptomic Profiling of Adult-Onset Asthma Related to Damp and Moldy Buildings and Idiopathic Environmental Intolerance. International Journal of Molecular Sciences, 2021, 22, 10679.	1.8	3
1826	Increasing utility of FeNO as a biomarker of type-2 inflammation in severe asthma. Lancet Respiratory Medicine, the, 2021, 9, 1083-1084.	5.2	10
1827	Efficacy of mepolizumab in usual clinical practice and characteristics of responders. Respiratory Medicine, 2021, 187, 106595.	1.3	5
1828	The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia. Biochemical Pharmacology, 2021, 192, 114690.	2.0	12
1830	Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respiratory Medicine, 2021, 187, 106572.	1.3	29
1831	Eosinophils in Health and Disease: A State-of-the-Art Review. Mayo Clinic Proceedings, 2021, 96, 2694-2707.	1.4	103
1832	New Treatments for Asthma. Immunology and Allergy Clinics of North America, 2021, 41, 555-569.	0.7	3
1833	Anti-Interleukin-5 in the Management of Eosinophilic Asthma: A Review of Effectiveness, Safety, and Budgetary Impact From the Perspective of the Brazilian Health System. Value in Health Regional Issues, 2021, 26, 169-181.	0.5	0
1834	Adult Severe Asthma. , 2022, , 383-399.		0
1835	Severe Asthma in Children and Young People. , 2022, , 288-307.		0
1836	Cardiopulmonary Function Abnormalities in Cohort of Adults following Bronchopulmonary Dysplasia as Preterm Infants. American Journal of Perinatology, 2022, 39, 1410-1417.	0.6	2
1837	Serum microRNAs as Tool to Predict Early Response to Benralizumab in Severe Eosinophilic Asthma. Journal of Personalized Medicine, 2021, 11, 76.	1.1	11
1838	The effect of 16 Arg/Gly $\beta_2$ -adrenergic receptors gene polymorphism on pulmonary function in asthmatic children treated with nebulized salbutamol. Biomedical and Biotechnology Research Journal, 2021, 5, 161.	0.3	0
1839	Pharmacogenetics of inhaled corticosteroids and exacerbation risk in adults with asthma. Clinical and Experimental Allergy, 2022, 52, 33-45.	1.4	11
1840	Clinical relevance of sputum bronchial epithelial cells: A retrospective cross-sectional study. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2022, 6, 35-40.	0.2	0
1841	METHODS OF THE ESTIMATED TWO-PARAMETER LINEAR REGRESSION MODELS FOR DIAGNOSIS OF BRONCHIAL ASTHMA SEVERITY IN CHILDREN. Innovare Journal of Medical Sciences, 0, , 23-30.	0.2	0

#	ARTICLE	IF	CITATIONS
1842	Nasal saline irrigation: prescribing habits and attitudes of physicians and pharmacists. <i>Scandinavian Journal of Primary Health Care</i> , 2021, 39, 35-43.	0.6	5
1843	Mepolizumab para el tratamiento de asma grave eosinofílica. <i>Revista Alergia Mexico</i> , 0, 67, .	0.9	3
1845	Cost-effectiveness analysis of anti-IL-5 therapies of severe eosinophilic asthma in Spain. <i>Journal of Medical Economics</i> , 2021, 24, 874-882.	1.0	7
1846	Teaching the Person with Asthma. , 2021, , 515-568.		0
1847	The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children. <i>Annals of Thoracic Medicine</i> , 2021, 16, 4.	0.7	34
1848	Sex Differences in Severe Asthma: Results From Severe Asthma Network in Italy-SANI. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 219.	1.1	31
1849	Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2070-2078.	2.7	18
1850	Statins for asthma. <i>The Cochrane Library</i> , 0, , .	1.5	1
1851	Dupilumab: Basic aspects and applications to allergic diseases. <i>Allergology International</i> , 2020, 69, 187-196.	1.4	60
1852	Childhood asthma heterogeneity at the era of precision medicine: Modulating the immune response or the microbiota for the management of asthma attack. <i>Biochemical Pharmacology</i> , 2020, 179, 114046.	2.0	16
1853	Short-term ozone exposure and asthma severity: Weight-of-evidence analysis. <i>Environmental Research</i> , 2018, 160, 391-397.	3.7	35
1854	A Non-canonical Pathway with Potential for Safer Modulation of Transforming Growth Factor- $\beta$ 21 in Steroid-Resistant Airway Diseases. <i>IScience</i> , 2019, 12, 232-246.	1.9	7
1855	Baseline Features of the Severe Asthma Research Program (SARP III) Cohort: Differences with Age. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 545-554.e4.	2.0	210
1856	Age does not affect the efficacy of anti-IL-5/IL-5R in severe asthmatics. <i>World Allergy Organization Journal</i> , 2019, 12, 100081.	1.6	11
1857	Beliefs and preferences regarding biological treatments for severe asthma. <i>World Allergy Organization Journal</i> , 2020, 13, 100441.	1.6	6
1858	Advances in understanding and reducing the burden of severe asthma in children. <i>Lancet Respiratory Medicine</i> , 2020, 8, 1032-1044.	5.2	73
1859	Choice of biologics in asthma endotypes. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, 21, 79-85.	1.1	16
1860	The impact of fungal allergic sensitization on asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2021, 27, 3-8.	1.2	16

#	ARTICLE	IF	CITATIONS
1861	Severe asthma in children: Current goals and unmet needs. <i>Pediatric Allergy and Immunology</i> , 2020, 31, 40-42.	1.1	5
1862	Protocol for a multicentre randomised controlled trial to investigate the effect on asthma-related quality of life from breathing retraining in patients with incomplete asthma control attending specialist care in Denmark. <i>BMJ Open</i> , 2019, 9, e032984.	0.8	3
1863	Increased Capsaicin Sensitivity in Patients with Severe Asthma Is Associated with Worse Clinical Outcome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 201, 1068-1077.	2.5	35
1864	IL-27 targets Foxp3+ Tregs to mediate antiinflammatory functions during experimental allergic airway inflammation. <i>JCI Insight</i> , 2019, 4, .	2.3	31
1865	The effect of BPIFA1/SPLUNC1 genetic variation on its expression and function in asthmatic airway epithelium. <i>JCI Insight</i> , 2019, 4, .	2.3	23
1866	Integrative study of the upper and lower airway microbiome and transcriptome in asthma. <i>JCI Insight</i> , 2020, 5, .	2.3	44
1867	IRF5 distinguishes severe asthma in humans and drives Th1 phenotype and airway hyperreactivity in mice. <i>JCI Insight</i> , 2017, 2, .	2.3	64
1868	Severe asthma in humans and mouse model suggests a CXCL10 signature underlies corticosteroid-resistant Th1 bias. <i>JCI Insight</i> , 2017, 2, .	2.3	86
1869	High IFN- $\gamma$ and low SLPI mark severe asthma in mice and humans. <i>Journal of Clinical Investigation</i> , 2015, 125, 3037-3050.	3.9	300
1870	Mucus plugs in patients with asthma linked to eosinophilia and airflow obstruction. <i>Journal of Clinical Investigation</i> , 2018, 128, 997-1009.	3.9	337
1871	Characteristics and treatment regimens across ERS SHARP severe asthma registries. <i>European Respiratory Journal</i> , 2020, 55, 1901163.	3.1	56
1872	FASE-CPHG study: a panoramic snapshot of difficult-to-treat, severe asthma in French nonacademic hospitals. <i>ERJ Open Research</i> , 2019, 5, 00069-2019.	1.1	11
1873	Personalised exhaled nitric oxygen fraction ( $F_{\text{ENO}}$ )-driven asthma management in primary care: a $F_{\text{ENO}}$ subgroup analysis of the ACCURATE trial. <i>ERJ Open Research</i> , 2020, 6, 00351-2019.	1.1	5
1874	Patients' experiences of asthma exacerbation and management: a qualitative study of severe asthma. <i>ERJ Open Research</i> , 2021, 7, 00528-2020.	1.1	15
1875	Understanding the experience of people living with severe asthma. , 2019, , 16-29.		12
1876	Mechanisms underlying fixed airflow obstruction and exacerbations. , 2019, , 82-92.		1
1877	Clinical biomarkers and noninvasive assessment of severe asthma. , 2019, , 93-112.		2
1878	SARP: dissecting subphenotypes and endotypes of asthma. , 2019, , 167-183.		2

#	ARTICLE	IF	CITATIONS
1879	Severe asthma: mechanisms in children. , 2019, , 231-245.		2
1880	Evaluation and management of severe asthma in children. , 2019, , 246-264.		1
1881	Outdoor air pollution from industrial chemicals causing new onset of asthma or COPD: a systematic review protocol. Journal of Occupational Medicine and Toxicology, 2020, 15, 38.	0.9	7
1882	Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use. F1000Research, 2020, 9, 637.	0.8	12
1883	Biological treatments for severe asthma. Yeungnam University Journal of Medicine, 2020, 37, 262-268.	0.7	9
1884	Asthma Is More Severe in Older Adults. PLoS ONE, 2015, 10, e0133490.	1.1	80
1885	Synergistic Proinflammatory Responses by IL-17A and Toll-Like Receptor 3 in Human Airway Epithelial Cells. PLoS ONE, 2015, 10, e0139491.	1.1	12
1886	Airway Microbiota in Severe Asthma and Relationship to Asthma Severity and Phenotypes. PLoS ONE, 2016, 11, e0152724.	1.1	159
1887	Eosinophil Count Is a Common Factor for Complex Metabolic and Pulmonary Traits and Diseases: The LifeLines Cohort Study. PLoS ONE, 2016, 11, e0168480.	1.1	28
1888	Severe Asthma: Have We Made Progress?. Annals of the American Thoracic Society, 2016, 13, S68-S77.	1.5	16
1889	Potential Role of the Lung Microbiome in Shaping Asthma Phenotypes. Annals of the American Thoracic Society, 2017, 14, S326-S331.	1.5	31
1890	Mobile applications in surgical patient health education: an integrative review. Revista Da Escola De Enfermagem Da U S P, 2020, 54, e03555.	0.3	9
1892	Smoking asthmatics, a neglected large phenotype of asthmatic patients. Open Journal of Asthma, 2019, 3, 001-008.	2.0	5
1893	Prevalence, morbidity, phenotypes and other characteristics of severe bronchial asthma in Russian Federation. Pulmonologiya, 2018, 28, 341-358.	0.2	32
1894	Biomarkers of airways inflammation in patients with severe asthma in a real clinical practice. Pulmonologiya, 2020, 30, 437-445.	0.2	2
1895	Airway inflammation patterns and clinical and functional features in patients with severe uncontrolled asthma and cold-induced airway hyperresponsiveness. Pulmonologiya, 2017, 26, 701-707.	0.2	13
1896	Long-term effect of antifungal therapy for the treatment of severe resistant asthma: an active comparator clinical trial. Current Medical Mycology, 2019, 5, 1-7.	0.8	5
1897	Exposure to ozone impacted Th1/Th2 imbalance of CD4+ T cells and apoptosis of ASMCS underlying asthmatic progression by activating lncRNA PVT1-miR-15a-5p/miR-29c-3p signaling. Aging, 2020, 12, 25229-25255.	1.4	19

#	ARTICLE	IF	CITATIONS
1898	<p>&lt;p&gt;Real-World Effectiveness of Mepolizumab in Patients with Severe Asthma: An Examination of Exacerbations and Costs&lt;/p&gt;. Journal of Asthma and Allergy, 2020, Volume 13, 77-87.	1.5	41
1899	<p><p>FENOMA Study: Achieving Full Control in Patients with Severe Allergic Asthma</p>. Journal of Asthma and Allergy, 2020, Volume 13, 159-166.	1.5	11
1900	&lt;p&gt;Real-World Reductions in Oral Corticosteroid Use in the USA Following Mepolizumab Therapy for Severe Asthma&lt;/p&gt;. Journal of Asthma and Allergy, 2020, Volume 13, 689-699.	1.5	15
1901	Annual Fractional Exhaled Nitric Oxide Measurements and Exacerbations in Severe Asthma. Journal of Asthma and Allergy, 2020, Volume 13, 731-741.	1.5	8
1902	Severe eosinophilic bronchial asthma: new therapeutic options. Meditsinskiy Sovet, 2018, , 44-52.	0.1	7
1903	A Low Serum CCL4/MIP-1 $\beta$ Level May Predict a Severe Asthmatic Responsiveness to Mepolizumab. Internal Medicine, 2020, 59, 2849-2855.	0.3	8
1904	An Emerging Role for Exhaled Nitric Oxide in Guiding Biological Treatment in Severe Asthma. Current Medicinal Chemistry, 2020, 27, 7159-7167.	1.2	8
1905	Using the Inflammacheck Device to Measure the Level of Exhaled Breath Condensate Hydrogen Peroxide in Patients With Asthma and Chronic Obstructive Pulmonary Disease (The EXHALE Pilot) Tj ETQq1 1 0.784&#147;rgBT7Overload		
1906	Biologics in severe asthma. Minerva Medica, 2022, 113, .	0.3	15
1907	Management of asthma in children. Minerva Pediatrica, 2018, 70, 444-457.	2.6	12
1908	Severe uncontrolled asthma in children: practical approach on diagnosis and management. Minerva Pediatrica, 2020, 72, 196-205.	2.6	6
1909	Competence in bronchial thermoplasty. Panminerva Medica, 2019, 61, 422-428.	0.2	3
1910	Destruction of the bronchial epithelium in patients with severe asthma according to different patterns of inflammation and cold airway hyperresponsiveness. Terapevticheskii Arkhiv, 2019, 91, 31-35.	0.2	5
1911	Nocturnal temperature-controlled laminar airflow device for adults with severe allergic asthma: the LASER RCT. Health Technology Assessment, 2019, 23, 1-140.	1.3	7
1912	Methotrexate as an oral corticosteroid-sparing agent in severe asthma: the emergence of a responder asthma endotype. European Clinical Respiratory Journal, 2014, 1, 25037.	0.7	6
1913	The AKT inhibitor MK2206 suppresses airway inflammation and the pro&#x201c;remodeling pathway in a TDI&#x201c;-induced asthma mouse model. Molecular Medicine Reports, 2020, 22, 3723-3734.	1.1	7
1914	Association of autophagy related gene polymorphisms with neutrophilic airway inflammation in adult asthma. Korean Journal of Internal Medicine, 2016, 31, 375-385.	0.7	49
1915	Association between primary immunodeficiency and asthma exacerbation in adult asthmatics. Korean Journal of Internal Medicine, 2020, 35, 449-456.	0.7	12

#	ARTICLE	IF	CITATIONS
1916	Serum potential biomarkers according to sputum inflammatory cell profiles in adult asthmatics. Korean Journal of Internal Medicine, 2020, 35, 988-997.	0.7	17
1917	Distinct functions of eosinophils in severe asthma with type 2 phenotype: clinical implications. Korean Journal of Internal Medicine, 2020, 35, 823-833.	0.7	23
1918	Diagnosis of Severe Asthma: Definition and Identification. Korean Journal of Medicine, 2018, 93, 153-158.	0.1	3
1919	Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC). Multidisciplinary Respiratory Medicine, 2020, 15, 36.	0.6	40
1920	The Saudi Initiative for Asthma - 2016 update: Guidelines for the diagnosis and management of asthma in adults and children. Annals of Thoracic Medicine, 2016, 11, 3.	0.7	53
1921	Factors leading to refractory asthma in patients from Saudi Arabia. Annals of Thoracic Medicine, 2017, 12, 42.	0.7	2
1922	The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children. Annals of Thoracic Medicine, 2019, 14, 3.	0.7	45
1923	Bronchial thermoplasty-an update. Annals of Thoracic Medicine, 2018, 13, 205.	0.7	4
1924	To evaluate total serum immunoglobulin E level and factors that effect on this level in Iraqi asthmatic children. Biomedical and Biotechnology Research Journal, 2019, 3, 240.	0.3	5
1925	Asthma: What's new, and what should be old but is not!. Pediatric Respirology and Critical Care Medicine, 2017, 1, 2.	0.4	7
1926	Trabecular Bone Score Is More Sensitive to Asthma Severity and Glucocorticoid Treatment Than Bone Mineral Density in Asthmatics. Allergy, Asthma and Immunology Research, 2019, 11, 343.	1.1	7
1927	Future Risks in Patients With Severe Asthma. Allergy, Asthma and Immunology Research, 2019, 11, 763.	1.1	43
1928	Increasing Prevalence and Mortality of Asthma With Age in Korea, 2002â€“2015: A Nationwide, Population-Based Study. Allergy, Asthma and Immunology Research, 2020, 12, 467.	1.1	41
1929	Coexisting COPD Increases Mortality in Patients With Corticosteroid-Dependent Asthma: A Nationwide Population-Based Study. Allergy, Asthma and Immunology Research, 2020, 12, 821.	1.1	10
1930	Evaluation and Management of Difficult-to-Treat and Severe Asthma: An Expert Opinion From the Korean Academy of Asthma, Allergy and Clinical Immunology, the Working Group on Severe Asthma. Allergy, Asthma and Immunology Research, 2020, 12, 910.	1.1	19
1931	New Pharmacological Targets for Asthma Drug Development. Journal of Allergy & Therapy, 2014, 05, .	0.1	4
1932	Omalizumab Treatment for Atopic Severe Persistent Asthma: A Single-Center, Long-Term, Real-Life Experience with 38 Patients. Turkish Thoracic Journal, 2018, 19, 187-192.	0.2	3
1933	Confusing Terminology: Difficult Asthma, Difficult-to-Treat Asthma, Difficult-to-Control Asthma, Therapy-Resistant Asthma, Severe Asthma, and Refractory Asthma. Which One is Truly Severe Asthma?. Turkish Thoracic Journal, 2018, 19, 235-236.	0.2	2



#	ARTICLE	IF	CITATIONS
1934	Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. Turkish Thoracic Journal, 2020, 21, 61-68.	0.2	6
1935	Economic Burden of Pediatric Asthma in Turkey: A Cost of Illness Study from Payer Perspective. Turkish Thoracic Journal, 2020, 21, 248-254.	0.2	4
1936	Schweres Asthma: Definition, Diagnostik und Therapie. Allergologie, 2016, 39, 206-207.	0.1	4
1937	The statement of the Polish Society of Allergology experts on the treatment of difficult-to-treat asthma. Pneumonologia I Alergologia Polska, 2015, 83, 324-334.	0.6	5
1938	Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?. Drugs in Context, 2019, 8, 1-11.	1.0	20
1939	Novel therapeutic targets for allergic airway disease in children. Drugs in Context, 2019, 8, 1-15.	1.0	11
1940	Type 2 immunity-driven diseases: Towards a multidisciplinary approach. Clinical and Experimental Allergy, 2021, 51, 1538-1552.	1.4	11
1941	Effectiveness of benralizumab in severe eosinophilic asthma: Distinct subphenotypes of response identified by cluster analysis. Clinical and Experimental Allergy, 2022, 52, 312-323.	1.4	19
1942	Effectiveness of inhaled corticosteroids and long-acting $\beta_2$ -agonists combinations in real clinical practice: results of a multicenter cross-sectional study in Russian patients with asthma. Pulmonologiya, 2021, 31, 613-626.	0.2	5
1943	Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respiratory Medicine, 2022, 10, 47-58.	5.2	74
1944	Treatment Patterns and Disease Burden Associated with Multiple-Inhaler Triple-Therapy Use in Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 485-494.e5.	2.0	7
1945	Persistent Eosinophilic Inflammation in Adult Asthmatics with High Serum and Urine Levels of Leukotriene E4. Journal of Asthma and Allergy, 2021, Volume 14, 1219-1230.	1.5	12
1946	Severe and Difficult Asthma: Diagnosis and Management—Challenges for a Low-Resource Environment. Indian Journal of Pediatrics, 2022, 89, 156-162.	0.3	5
1948	Mapping geographic variability of severe uncontrolled asthma in the United States. Annals of Allergy, Asthma and Immunology, 2022, 128, 78-88.	0.5	9
1949	MBD2 as a Potential Novel Biomarker for Identifying Severe Asthma With Different Endotypes. Frontiers in Medicine, 2021, 8, 693605.	1.2	4
1950	Forthcoming UK asthma guidelines: an opportunity to improve asthma outcomes. Lancet, 2021, 398, 1856-1858.	6.3	7
1951	Patient and Physician Perspectives on Asthma and Its Therapy in Romania: Results of a Multicenter Survey. Medicina (Lithuania), 2021, 57, 1089.	0.8	3
1953	Global Initiative for Asthma Strategy 2021. Respirology, 2022, 27, 14-35.	1.3	31

#	ARTICLE	IF	CITATIONS
1954	Effectiveness of mepolizumab in severe asthma in Japan: A real-world study using claims data. <i>Clinical and Translational Allergy</i> , 2021, 11, e12063.	1.4	4
1955	Bronchial thermoplasty for severe asthmatics: a real-world clinical study from Malaysia. <i>Singapore Medical Journal</i> , 2024, 65, 119-122.	0.3	0
1956	The needs and well-being of severe asthma and <scp>COPD</scp> carers: A cross-sectional study. <i>Respirology</i> , 2022, 27, 134-143.	1.3	6
1957	Obese, non-eosinophilic asthma: frequent exacerbators in a real-world setting. <i>Journal of Asthma</i> , 2021, , 1-9.	0.9	1
1958	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. <i>European Respiratory Journal</i> , 2022, 59, 2102730.	3.1	218
1959	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 17-35.	2.5	196
1960	Marine-Derived Compounds for the Potential Treatment of Glucocorticoid Resistance in Severe Asthma. <i>Marine Drugs</i> , 2021, 19, 586.	2.2	2
1962	The nitroxide/antioxidant 3-carbamoyl proxyl attenuates disease severity in murine models of severe asthma. <i>Free Radical Biology and Medicine</i> , 2021, 177, 181-188.	1.3	3
1963	Multiple Choice Questions with explanations. , 2012, , 1-196.		0
1964	Questions and guide to answers. <i>The Egyptian Journal of Internal Medicine</i> , 2014, 26, 30-34.	0.3	0
1965	Algorithm of biophenotyping and choice of medication for targeted therapy of severe uncontrolled asthma with eosinophilic type of airways inflammation. <i>Russian Journal of Allergy</i> , 2017, 14, 5-18.	0.1	5
1968	Asthma according to the GINA report 2014. <i>Pediatria I Medycyna Rodzinna</i> , 2015, 11, 10-29.	2.3	2
1969	Asma infantil severa. <i>Revista Colombiana De NeumologÃa</i> , 2016, 27, .	0.1	0
1970	VentilaciÃn mecÃnica no invasiva en crisis asmÃtica. <i>Revista Colombiana De NeumologÃa</i> , 2016, 27, .	0.1	0
1971	FisiopatologÃa del asma: una mirada actual. <i>Revista Colombiana De NeumologÃa</i> , 2016, 27, .	0.1	0
1972	The â€˜problematicâ€™ asthma patient. <i>Singapore Medical Journal</i> , 2015, 56, 368-372.	0.3	1
1973	Asthma control uncontrolled. <i>Polish Archives of Internal Medicine</i> , 2015, 125, 711-712.	0.3	0
1974	New opportunities for treatment of severe bronchial asthma: from clinical studies to portraits of patients. <i>Russian Journal of Allergy</i> , 2015, 12, 51-61.	0.1	0

#	ARTICLE	IF	CITATIONS
1975	Seltene Asthmaformen. , 2016, , 337-347.		0
1979	Modern view on immunopathogenesis of asthma. Russian Journal of Allergy, 2016, 13, 10-14.	0.1	6
1980	Pneumologie. , 2017, , 371-425.		0
1981	Inducible Laryngeal Obstruction/Vocal Cord Dysfunction and the Role It Plays in Refractory Asthma. , 2017, 1, 036-039.		0
1982	National Clinical Guidelines. , 2017, , .		2
1983	8. State of the Art of Bronchial Asthma Treatment and Future Perspectives. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 129b-130a.	0.0	0
1984	Updates on the Management of Severe Asthma. Methodist DeBakey Cardiovascular Journal, 2021, 13, 82.	0.5	0
1985	World Trade Center Asthma. , 2018, , 95-106.		0
1986		0.0	0
1987	8. State of the Art of Bronchial Asthma Treatment and Future Perspectives. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1961-1967.	0.0	0
1988	Exhaled Nitric Oxide Measurement for Asthma Management. Korean Journal of Medicine, 2017, 92, 453-457.	0.1	2
1989	Asthma bronchiale in the context of internal medicine. Vnitřni Lekarství, 2017, 63, 757-769.	0.1	0
1990	Chronic Lower Respiratory Tract Diseases. , 2017, , 263-285.		1
1992	DIAGNOSTIC VALUE OF INFLAMMATORY BLOOD PATTERNS IN VERIFICATION OF UNCONTROLLED COURSE OF BRONCHIAL ASTHMA IN CHILDREN. World of Medicine and Biology, 2018, 14, 023.	0.1	0
1994	Role of Eosinophils in Asthma, and the Relationship with Eosinophilic Sinusitis, Esophagitis and Asthma. Nihon Kikan Shokudoka Gakkai Kaiho, 2018, 69, 134-135.	0.0	0
1996	Bronchospasmolytika und Antiasthmatika. , 2018, , 453-466.		0
1997	Recent Advances in Asthma Management. European Respiratory & Pulmonary Diseases, 2018, 4, 15.	0.2	0
1998	Bronchial asthma diagnostics and therapy highlights. Interni Medicina Pro Praxi, 2018, 20, 14-18.	0.0	1

#	ARTICLE	IF	CITATIONS
1999	Treatment of Severe Asthma. Korean Journal of Medicine, 2018, 93, 159-171.	0.1	0
2000	Biologic Treatment of Severe Asthma. Korean Journal of Medicine, 2018, 93, 172-180.	0.1	1
2001	A 12-week, Randomized, Parallel-group, Phase III Study Comparing the Efficacy of Once-daily Budesonide/formoterol Turbuhaler (160/4.5 $\mu$ g/d) with Twice-daily Budesonide (400 $\mu$ g/d) During the Step-down Period in Well-controlled Asthma. Turkish Thoracic Journal, 2018, 19, 66-72.	0.2	1
2004	A Review of Three New Anti-interleukin-5 Monoclonal Antibody Therapies for Severe Asthma. Cureus, 2018, 10, e3216.	0.2	2
2006	ZOR ASTIM. Kocatepe Tıp Dergisi, 0, , 157-163.	0.0	0
2007	Severe eosinophilic asthma: therapeutic potential of Reslizumab. Meditsinskiy Sovet, 2018, , 70-75.	0.1	0
2008	Uncontrolled asthma: what is behind it?. Klinicheskaia Meditsina, 2018, 96, 485-490.	0.2	0
2009	Bronchial Thermoplasty: Japanese Experiences. Respiratory Disease Series, 2019, , 157-165.	0.1	0
2010	Corticosteroid Resistance in Asthma. Respiratory Disease Series, 2019, , 53-61.	0.1	0
2011	Trabecular Bone Score Is More Sensitive to Asthma Severity and Glucocorticoid Treatment Than Bone Mineral Density in Asthmatics. Allergy, Asthma and Immunology Research, 0, 11, .	1.1	2
2012	Bronchospasmolytika und Antiasthmatica. , 2019, , 595-611.		0
2014	Cognitive Functioning in Asthma: Central Nervous System and Other Influences. , 2019, , 187-200.		0
2016	SEVERE COURSE OF BRONCHIAL ASTHMA PROGNOSING. Asthma and Allergy, 2019, 2019, 9-14.	0.0	0
2017	Long term management for severe asthma in children. Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology, 2019, 33, 88-94.	0.0	0
2018	1. Diagnosis and Phenotypes of Severe Asthma. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 504-508.	0.0	1
2021	Treatment with Paracetamol is not Associated with Increased Airway Sensitivity and Risk of Asthma in Rats. Current Drug Safety, 2019, 14, 109-115.	0.3	1
2022	Imaging severe asthma. , 2019, , 113-131.		0
2023	Clinical phenotypes of severe asthma: adults. , 2019, , 48-63.		1

#	ARTICLE	IF	CITATIONS
2024	Clinical phenotypes of severe asthma: children. , 2019, , 64-81.		0
2025	Evaluation of difficult-to-treat and severe asthma in adults. , 2019, , 265-284.		2
2026	Definition and impact of severe asthma. , 2019, , 1-15.		2
2027	Corticosteroid responsiveness and resistance in severe asthma. , 2019, , 211-230.		1
2028	Pathophysiology of severe asthma. , 2019, , 132-151.		1
2029	Severe asthma: the next decade of continuing progress. , 2019, , 327-333.		0
2031	Severe asthma management in adults. , 2019, , 315-326.		0
2032	VI. Pathophysiology related to refractory asthma. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1149-1155.	0.0	0
2033	ƉC2-high and T2-low bronchial asthma, endotype characteristics and biomarkers. Pulmonologiya, 2019, 29, 216-228.	0.2	10
2034	High-Risk Asthma Clinic: Putting It All Together. Respiratory Medicine, 2020, , 297-311.	0.1	0
2035	Heterogeneity in Severe Asthma. Respiratory Medicine, 2020, , 107-122.	0.1	0
2036	Advances in Inhaled Medications. Respiratory Medicine, 2020, , 91-106.	0.1	0
2037	Addressing Comorbidities in Difficult Asthma. Respiratory Medicine, 2020, , 55-74.	0.1	0
2038	Practical Considerations in the Management of Eosinophilic Asthma. Respiratory Medicine, 2020, , 181-206.	0.1	0
2039	Biomarkers, Targeted Therapies, Biologics, and Bronchial Thermoplasty. Respiratory Medicine, 2020, , 123-153.	0.1	0
2041	Difficult Asthma: Unmet Needs and Future Directions. Respiratory Medicine, 2020, , 313-324.	0.1	0
2042	Severe Asthma in Childhood: Special Considerations. Respiratory Medicine, 2020, , 265-295.	0.1	0
2043	1. Diagnosis and Management of Severe Asthma. The Journal of the Japanese Society of Internal Medicine, 2019, 108, 1860-1865.	0.0	0

#	ARTICLE	IF	CITATIONS
2044	Evaluation of the ventilometric parameters of two football teams in different leagues. Timisoara Physical Education and Rehabilitation Journal, 2019, 12, 39-43.	0.3	0
2047	Treating "Asthma" With A Scalpel: Achalasia Mimicking Asthma. Journal of Investigational Allergology and Clinical Immunology, 2019, 29, 394-396.	0.6	0
2048	Treatment Strategies for Refractory Pulmonary Sarcoidosis. The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders, 2019, 39, 45-47.	0.1	0
2049	The Epidemiology of Severe Childhood Asthma. , 2020, , 3-18.		0
2050	Special Considerations in Preschool Age. , 2020, , 19-46.		1
2051	Future Directions in Severe Childhood Asthma. , 2020, , 343-355.		0
2052	Severe Asthma: Clinical Studies and Clinical Trials in Children. , 2020, , 271-285.		0
2053	A Structured Multidisciplinary Approach to Managing Difficult-to-Treat Asthma in Children. , 2020, , 97-112.		2
2054	Confirming the Diagnosis of Severe Asthma in Children. , 2020, , 49-71.		2
2055	Stepwise Pharmacological Approach to Severe Childhood Asthma. , 2020, , 113-131.		0
2056	Anamnestic characteristics of acute obstructive bronchitis in children infected by chlamidia. Problems of Uninterrupted Medical Training and Science, 2019, 2019, 67-71.	0.1	0
2057	Successful management of severe bronchial asthma: the right choice of biologic therapy in properly selected patients. Meditsinskiy Sovet, 2019, , 22-28.	0.1	0
2058	Precision medicine applications for severe asthma. LymphoSign Journal, 2019, 6, 117-135.	0.1	0
2059	Biological treatment of severe asthma: new objectives and new treatment options. Meditsinskiy Sovet, 2019, , 50-61.	0.1	2
2060	Use of home visits in pediatric severe asthma: randomized controlled trial*. Revista Da Escola De Enfermagem Da U S P, 2020, 54, e003538.	0.3	1
2061	Relationship between airway inflammation and airflow limitation in elderly asthmatics. Asia Pacific Allergy, 2020, 10, e17.	0.6	7
2062	Mechanisms, diagnosis and management of eosinophilic asthma. Journal of Lung, Pulmonary & Respiratory Research, 2020, 7, 28-37.	0.3	1
2064	Yes, there really are individuals with severe asthma: the importance and limitations of data obtained from specialized centers. Jornal Brasileiro De Pneumologia, 2020, 46, e20200191-e20200191.	0.4	1

#	ARTICLE	IF	CITATIONS
2065	Exhaled nitric oxide as a clinical biomarker for choosing biologics for severe asthma treatment. <i>Biomarkers in Medicine</i> , 2020, 14, 499-502.	0.6	2
2066	Clinical features and associated factors with severe asthma in Salvador, Brazil. <i>Jornal Brasileiro De Pneumologia</i> , 2020, 46, e20180341-e20180341.	0.4	3
2067	SANOFI GENZYME - Contrôle de l'asthme sévère : allons plus loin en 2020. <i>Revue Des Maladies Respiratoires Actualites</i> , 2020, 12, S18-S20.	0.0	0
2068	Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use. <i>F1000Research</i> , 2020, 9, 637.	0.8	5
2069	Papel de los biomarcadores en el asma grave no controlada en la actualidad. <i>Archivos De Bronconeumologia</i> , 2020, 56, 347-348.	0.4	4
2071	Evaluation and treatment of severe bronchial asthma. <i>Nihon Shoni Arerugi Gakkaishi the Japanese Journal of Pediatric Allergy and Clinical Immunology</i> , 2020, 34, 179-185.	0.0	0
2072	Therapy and control of bronchial asthma in children and adolescents. <i>Meditinskiy Sovet</i> , 2020, , 101-107.	0.1	1
2073	Characterization and burden of severe eosinophilic asthma in New Zealand: Results from the HealthStat Database. <i>Multidisciplinary Respiratory Medicine</i> , 2020, 15, 662.	0.6	4
2074	Severe acute asthma at the pediatric intensive care unit: can we link the clinical phenotypes to immunological endotypes?. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 25-34.	1.0	3
2075	Benefits and risks of bronchoalveolar lavage in severe asthma in children. <i>ERJ Open Research</i> , 2021, 7, 00332-2021.	1.1	2
2076	Expert meeting report: towards a joint European roadmap to address the unmet needs and priorities of paediatric asthma patients on biologic therapy. <i>ERJ Open Research</i> , 2021, 7, 00381-2021.	1.1	5
2077	Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. <i>Archivos De Bronconeumologia</i> , 2022, 58, 35-51.	0.4	31
2078	A systematic literature review of burden of illness in adults with uncontrolled moderate/severe asthma. <i>Respiratory Medicine</i> , 2022, 191, 106670.	1.3	23
2079	Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma. <i>Biomedicines</i> , 2021, 9, 1550.	1.4	11
2080	Risankizumab in Severe Asthma – A Phase 2a, Placebo-Controlled Trial. <i>New England Journal of Medicine</i> , 2021, 385, 1669-1679.	13.9	54
2081	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, S1-S18.	2.0	66
2082	Changes in oral corticosteroid use in asthma treatment – a 20-year Danish nationwide drug utilization study. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2021, , .	1.2	4
2083	Endobronchial treatment of severe asthma and severe emphysema with hyperinflation. <i>Current Opinion in Pulmonary Medicine</i> , 2021, Publish Ahead of Print, 52-61.	1.2	0

#	ARTICLE	IF	CITATIONS
2084	Use of Omalizumab in Management of Severe Uncontrolled Bronchial Asthma in Children. Doctor Ru, 2020, 19, 53-56.	0.1	2
2085	Structure-Function Imaging of Asthma: Airway and Ventilation Biomarkers. Medical Radiology, 2021, , 153-174.	0.0	0
2086	Efficacy predictors of omalizumab in Chinese patients with moderate-to-severe allergic asthma: Findings from a post-hoc analysis of a randomised phase III study. World Allergy Organization Journal, 2020, 13, 100469.	1.6	1
2087	Prediction of clinical response to omalizumab in moderate-to-severe asthma patients using the change in total serum IgE level. Journal of Thoracic Disease, 2020, 12, 7097-7105.	0.6	9
2088	Identification of clusters of asthma control: A preliminary analysis of the Inspirers studies. Revista Portuguesa De Imunoalergologia, 2020, 28, .	0.1	0
2089	Effects of body weight and posture on pulmonary functions in asthmatic children. African Health Sciences, 2020, 20, 1777-84.	0.3	3
2090	Patient perspectives on living with severe asthma in Denmark and Sweden. European Clinical Respiratory Journal, 2021, 8, 1856024.	0.7	2
2091	Fractional Exhaled Nitric Oxide (FeNO) Integrating Airway Hyperresponsiveness (AHR) Examination Promotes Etiologic Diagnosis and Treatment for Children with Chronic Cough. Medical Science Monitor, 2021, 27, e928502.	0.5	1
2092	Gastroesophageal reflux and asthma: when, how, and why. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 52-58.	1.1	14
2093	Biothérapies dans l'asthme sévère de l'adulte. Revue Des Maladies Respiratoires Actualites, 2020, 12, 2S409-2S414.	0.0	0
2094	Biomarkers in Obstructive Airway Diseases. Respiratory Medicine, 2020, , 131-153.	0.1	0
2095	The treatment of severe uncontrolled asthma using biologics. AIMS Allergy and Immunology, 2020, 4, 1-13.	0.3	0
2097	Efficacy of Mepolizumab for Long-term Treatment in Patients with Severe Asthma. The Showa University Journal of Medical Sciences, 2020, 32, 247-256.	0.1	0
2098	Bronchial thermoplasty for severe asthma: A position statement of the Indian chest society. Lung India, 2020, 37, 86.	0.3	2
2101	A randomized controlled trial study protocol for Xiao-Qing-Long decoction in the treatment of refractory asthma. Medicine (United States), 2020, 99, e18911.	0.4	2
2102	ERKRANKUNGEN DER ATMUNGSORGANE. , 2020, , C-1-C22-4.		0
2103	Bronchospasmolytika und Antiasthmatica. , 2020, , 455-471.		0
2105	Small respiratory passages dysfunction in bronchial asthma. Pulmonologiya, 2020, 29, 725-733.	0.2	0



#	ARTICLE	IF	CITATIONS
2107	A rational approach to the treatment of bronchial asthma in children: what can we do to control the disease?. Meditsinskiy Sovet, 2020, , 140-144.	0.1	1
2108	Biomarkers of Bronchial Asthma. Physiological Research, 2020, 69, S29-S34.	0.4	11
2109	Front-line Developments Concerning Severe Asthma. Nihon Kikan Shokudoka Gakkai Kaiho, 2020, 71, 156-158.	0.0	0
2110	Real-world benefits of biologics for asthma: Exacerbation events and systemic corticosteroid use. World Allergy Organization Journal, 2021, 14, 100600.	1.6	13
2111	Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 422-432.	2.0	28
2112	A RAS inhibitor reduces allergic airway remodeling via regulating IL-33-derived type 2 innate lymphoid cells. Experimental Lung Research, 2021, 47, 1-13.	0.5	1
2113	Keeping Pace with Adolescent Asthma: A Practical Approach to Optimizing Care. Pulmonary Therapy, 2022, 8, 123-137.	1.1	6
2114	Characteristics of new adult users of mepolizumab with asthma in the USA. BMJ Open Respiratory Research, 2021, 8, e001003.	1.2	5
2116	United airways paradigm in guidelines and clinical practice. , 0, , 193-208.		1
2117	Bronchial thermoplasty. , 0, , 294-306.		0
2118	Asthma: definition, severity and impact of pulmonary exacerbations. , 0, , 1-12.		2
2120	Multiple Choice Questions with explanations. , 0, , 1-544.		0
2121	Question 134. , 0, , 277-279.		0
2122	Question 196. , 0, , 405-407.		0
2124	ADRB2 gene polymorphism in children with asthma and obesity. Bulletin Physiology and Pathology of Respiration, 2020, 1, 87-98.	0.0	2
2125	Screening Social Determinants of Health in a Multidisciplinary Severe Asthma Clinical Program. Pediatric Quality & Safety, 2020, 5, e360.	0.4	12
2126	Novel approaches in occupational asthma diagnosis and management. Current Opinion in Pulmonary Medicine, 2021, 27, 9-14.	1.2	2
2127	Managing chronic rhinosinusitis in severe asthma. Current Opinion in Pulmonary Medicine, 2021, 27, 23-28.	1.2	6

#	ARTICLE	IF	CITATIONS
2129	Sensitiser-induced occupational asthma. , 2020, , 34-51.		2
2130	Flexible Bronchoscopy and Pediatric Asthma. Respiratory Medicine, 2021, , 295-316.	0.1	0
2131	Bronchial Thermoplasty. Respiratory Medicine, 2021, , 477-485.	0.1	0
2132	EriÅŸkinlerde aort koarktasyonunun endovaskÃ¼ler tedavisi: Ä°ki olgu sunumu eÅŸliÄŸinde detayli literatÃ¼r derlemesi. Turkish Journal of Clinics and Laboratory, 0, , .	0.2	0
2133	Clinical efficacy of mepolizumab in the treatment of severe eosinophilic asthma in children. Meditsinskiy Sovet, 2020, , 115-121.	0.1	1
2134	Approach to Patients with Severe Asthma: a Consensus Statement from the Respiratory Care Experts' Input Forum (RC-EIF), Iran. Tanaffos, 2015, 14, 73-94.	0.5	0
2135	The Clinical and Health Economic Value of Clinical Laboratory Diagnostics. Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine, 2015, 26, 47-62.	0.7	7
2136	Mepolizumab (Nucala) For Severe Eosinophilic Asthma. P and T, 2016, 41, 619-622.	1.0	3
2137	Targeting Interleukin-5 in Patients With Severe Eosinophilic Asthma: A Clinical Review. P and T, 2017, 42, 196-201.	1.0	0
2139	Innovative Therapies for Severe Asthma. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2017, 34, 25-31.	0.6	2
2140	Inflammatory phenotypes of severe asthma in India. Lung India, 2019, 36, 267-268.	0.3	2
2141	Protective Effects of Thymoquinon on Pulmonary Disorders in Experimental Studies. Tanaffos, 2018, 17, 211-222.	0.5	4
2142	Early radiologic and bronchoscopic changes after bronchial thermoplasty in patients with severe asthma. Experimental and Therapeutic Medicine, 2020, 20, 278.	0.8	0
2143	An approach to the management of children with problematic severe asthma. Acta Biomedica, 2020, 91, e2020055.	0.2	2
2144	Anxiety in adolescents with severe asthma and response to treatment. Acta Biomedica, 2020, 91, e2020186.	0.2	0
2145	Chronic rhinosinusitis with nasal polyposis: the role of personalized and integrated medicine. Acta Biomedica, 2020, 91, 11-18.	0.2	12
2146	Evaluation of the Effect of Caffeic Acid Phenethyl Ester (CAPE) on Pharmacological Responses of Isolated Rat Trachea in vitro. Tanaffos, 2020, 19, 256-261.	0.5	2
2147	Role of Common Variables: Age, Gender, BMI, Rhinosinusitis, and Smoking among Asthmatic and Severe Asthmatic Patients. Tanaffos, 2020, 19, 195-200.	0.5	0

#	ARTICLE	IF	CITATIONS
2148	15LO1 dictates glutathione redox changes in asthmatic airway epithelium to worsen type 2 inflammation. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	45
2149	Association between Glucose-6-Phosphate Dehydrogenase Deficiency and Asthma. <i>Journal of Clinical Medicine</i> , 2021, 10, 5639.	1.0	6
2150	Indacaterol/glycopyrronium/mometasone fixed dose combination for uncontrolled asthma. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 183-195.	1.0	5
2151	Patient perspectives of the influence of severe and non-severe asthma on their quality of life: A national survey of asthma patients in Spain. <i>Clinical Respiratory Journal</i> , 2022, 16, 130-141.	0.6	5
2152	Asthma phenotypes and endotypes. <i>Minerva Medica</i> , 2021, 112, 547-563.	0.3	14
2153	Difficult-to-Treat Asthma Management in School-Age Children. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 359-375.	2.0	15
2154	A real-world study of ICS use in patients with severe eosinophilic asthma treated with mepolizumab. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, , .	0.5	2
2155	Severe asthma: One disease and multiple definitions. <i>World Allergy Organization Journal</i> , 2021, 14, 100606.	1.6	18
2158	Preliminary development of a questionnaire to measure the extra-pulmonary symptoms of severe asthma. <i>BMC Pulmonary Medicine</i> , 2021, 21, 369.	0.8	0
2159	Association of Differential Mast Cell Activation with Granulocytic Inflammation in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 397-411.	2.5	30
2160	Combined approach to define the clinical impact and decision making in asthmatics. <i>Minerva Medica</i> , 2021, 112, 539-541.	0.3	3
2161	Epidemiology of severe asthma and international register. <i>Minerva Medica</i> , 2021, 112, 542-546.	0.3	4
2162	Type 2-High Severe Asthma with and without Bronchiectasis: A Prospective Observational Multicentre Study. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1441-1452.	1.5	21
2163	Mold, Mycotoxins and a Dysregulated Immune System: A Combination of Concern?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12269.	1.8	19
2164	Nebulised liposomal amphotericin-B as maintenance therapy in allergic bronchopulmonary aspergillosis: a randomised, multicentre trial. <i>European Respiratory Journal</i> , 2022, 59, 2102218.	3.1	18
2165	The use of biologics in personalized asthma care. <i>Expert Review of Clinical Immunology</i> , 2021, , 1-9.	1.3	0
2166	The Impact of Adherence and Health Literacy on Difficult-to-Control Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 386-394.	2.0	11
2167	Long-Term Natural History of Severe Asthma Exacerbations and Their Impact on the Disease Course. <i>Annals of the American Thoracic Society</i> , 2022, 19, 907-915.	1.5	2

#	ARTICLE	IF	CITATIONS
2168	Bronchial Thermoplasty in Patients With Severe Asthma at 5 Years. <i>Chest</i> , 2022, 161, 614-628.	0.4	17
2169	The Precision Interventions for Severe and/or Exacerbation-Prone (PreciSE) Asthma Network: An overview of Network organization, procedures, and interventions. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 488-516.e9.	1.5	24
2170	Safety of delivering bronchial thermoplasty in two treatment sessions. <i>Respiratory Research</i> , 2021, 22, 307.	1.4	2
2171	Metabo-Endotypes of Asthma Reveal Differences in Lung Function: Discovery and Validation in Two TOPMed Cohorts. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 288-299.	2.5	17
2173	A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment. <i>Respiratory Medicine Case Reports</i> , 2021, 34, 101557.	0.2	2
2174	A multicenter study on the safety and efficacy of bronchial thermoplasty in adults with severe asthma. <i>Lung India</i> , 2021, 38, 524.	0.3	3
2175	Bronchospasmolytika und Antiasthmatica. , 2021, , 361-377.		0
2176	Impact of 27glnglu polymorphisms of Î²2-adrenergic receptor gene on pulmonary function in asthmatic children treated with nebulized salbutamol. <i>Biomedical and Biotechnology Research Journal</i> , 2021, 5, 435.	0.3	1
2178	Stratified approaches for using biomarkers in phenotyping for the management of severe asthma in India. <i>Lung India</i> , 2022, 39, 65.	0.3	2
2179	The Need for Testingâ€”The Exercise Challenge Test to Disentangle Causes of Childhood Exertional Dyspnea. <i>Frontiers in Pediatrics</i> , 2021, 9, 773794.	0.9	0
2180	PHENOTYPES AND STATES OF UNCONTROLLED BRONCHIAL ASTHMA. <i>Problemy ZdorovĚ1Ã¢ I Ã¢kologii</i> , 2016, , 34-38.	0.0	0
2181	Early radiologic and bronchoscopic changes after bronchial thermoplasty in patients with severe asthma. <i>Experimental and Therapeutic Medicine</i> , 2020, 20, 1-1.	0.8	0
2182	Clinical evolution of a severe asthmatics group in the use of immunobiological therapy in a Brazilian Public Hospital. <i>Revista Da AssociaÃ§o MÃ©dica Brasileira</i> , 2021, 67, 931-936.	0.3	0
2183	Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society â€” 2021 update. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2021, 24, .	0.3	5
2184	Mode of onset and triggers of severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 128, 466-467.	0.5	1
2185	TFEB signaling attenuates NLRP3â€driven inflammatory responses in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2131-2146.	2.7	19
2186	Refractory neutrophilic asthma and ciliary genes. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1970-1980.	1.5	9
2187	Effectiveness of mepolizumab in patients with severe eosinophilic asthma: results from real-world clinical practice in Finland. <i>Journal of Asthma</i> , 2022, 59, 2375-2385.	0.9	3

#	ARTICLE	IF	CITATIONS
2188	Otitis media in severe asthma associated with chronic rhinosinusitis with nasal polyps: a new therapeutic target for biologics. <i>Journal of Asthma</i> , 2023, 60, 139-144.	0.9	2
2189	Severe asthma exacerbation rates are increased among female, Black, Hispanic, and younger adult patients: results from the US CHRONICLE study. <i>Journal of Asthma</i> , 2022, 59, 2495-2508.	0.9	10
2190	Current unmet needs and potential solutions to uncontrolled asthma. <i>European Respiratory Review</i> , 2022, 31, 210176.	3.0	24
2191	Newly diagnosed asthma in China: initial severity and changes over a 1-year management period. <i>Annals of Translational Medicine</i> , 2022, 10, 75-75.	0.7	1
2192	Respiratory-related death in individuals with incident asthma and COPD: a competing risk analysis. <i>BMC Pulmonary Medicine</i> , 2022, 22, 28.	0.8	7
2193	Differential diagnosis of pulmonary eosinophilia. , 2022, , 19-36.		3
2194	Omalizumab: An Optimal Choice for Patients with Severe Allergic Asthma. <i>Journal of Personalized Medicine</i> , 2022, 12, 165.	1.1	5
2196	Biologic Therapies for Severe Asthma. <i>New England Journal of Medicine</i> , 2022, 386, 157-171.	13.9	268
2197	Heterogeneous Response of Airway Eosinophilia to Anti-IL-5 Biologics in Severe Asthma Patients. <i>Journal of Personalized Medicine</i> , 2022, 12, 70.	1.1	2
2198	Asthma in the Americas: An Update.. <i>Annals of the American Thoracic Society</i> , 2022, , .	1.5	5
2199	Reflux-related symptoms reflect poor asthma control and the presence of airway neuronal dysfunction. <i>Allergy International</i> , 2022, 71, 318-324.	1.4	5
2200	Missing sputum samples are common in asthma intervention studies and successful collection at follow-up is related to improvement in clinical outcomes. <i>ERJ Open Research</i> , 2022, 8, 00612-2021.	1.1	0
2202	Deprescribing montelukast in children with asthma: a systematic review. <i>BMJ Open</i> , 2022, 12, e053112.	0.8	3
2204	When one plus one means more than two: the blockade of both IL-4 and IL-13 inflammatory pathways with dupilumab in a case of severe refractory T2-high asthma. <i>BMJ Case Reports</i> , 2022, 15, e244503.	0.2	1
2205	Mepolizumab improves work productivity, activity limitation, symptoms, and rescue medication use in severe eosinophilic asthma. <i>Clinical Respiratory Journal</i> , 2022, , .	0.6	6
2206	Eosinophilic asthma. , 2022, , 73-99.		2
2207	Biomarkers of eosinophilic inflammation. , 2022, , 37-50.		2
2208	Moving beyond medication: Assessment and interventions on environmental and social determinants are needed to reduce severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 535-537.	1.5	1

#	ARTICLE	IF	CITATIONS
2209	Recent advances in the immunopathogenesis of severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 455-465.	1.5	22
2210	Mucus Plugs Persist in Asthma, and Changes in Mucus Plugs Associate with Changes in Airflow over Time. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 1036-1045.	2.5	39
2211	TH17 cells and corticosteroid insensitivity in severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 467-479.	1.5	31
2212	Considering biomarkers in asthma disease severity. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 480-487.	1.5	12
2213	Role of Th17 Cytokines in Airway Remodeling in Asthma and Therapy Perspectives. <i>Frontiers in Allergy</i> , 2022, 3, 806391.	1.2	8
2214	Low-dose oral corticosteroids in asthma associates with increased morbidity and mortality. <i>European Respiratory Journal</i> , 2022, 60, 2103054.	3.1	20
2215	Patient-reported outcome measures (PROMs) using the MASK <sup>air</sup> app in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1600-1602.	2.7	11
2216	Rhinovirus infection of bronchial epithelium induces specific bronchial smooth muscle cell migration of severe asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 104-113.	1.5	7
2218	The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 397-408.	2.0	14
2219	Phenotypic clusters on computed tomography reflects asthma heterogeneity and severity. <i>World Allergy Organization Journal</i> , 2022, 15, 100628.	1.6	1
2220	Predicting the course of asthma from childhood until early adulthood. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2022, 22, 115-122.	1.1	9
2221	Asthma, from mild to severe, is an independent prognostic factor for mild to severe Coronavirus disease 2019 (COVID-19). <i>Clinical Respiratory Journal</i> , 2022, 16, 293-300.	0.6	11
2222	Baseline type 2 biomarker levels and response to tezepelumab in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1786-1796.	2.7	49
2223	Clinical Characteristics of Patients and Factors Associated with Switching Biologics in Asthma. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 187-195.	1.5	3
2224	Early effectiveness of type-2 severe asthma treatment with dupilumab in a real-life setting; a FeNO-driven choice that leads to winning management. <i>Multidisciplinary Respiratory Medicine</i> , 2022, 17, 797.	0.6	10
2225	Difficult-to-Control Asthma Management in Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 378-384.	2.0	7
2226	Inflammatory phenotypes of severe asthma in India. <i>Lung India</i> , 2019, 36, 267.	0.3	3
2227	Investigation of Janus Kinase (JAK) Inhibitors for Lung Delivery and the Importance of Aldehyde Oxidase Metabolism. <i>Journal of Medicinal Chemistry</i> , 2022, 65, 633-664.	2.9	6

#	ARTICLE	IF	CITATIONS
2228	Dupilumab in Children with Uncontrolled Moderate-to-Severe Asthma. <i>New England Journal of Medicine</i> , 2021, 385, 2230-2240.	13.9	121
2229	Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review. <i>Journal of Asthma</i> , 2022, 59, 2201-2217.	0.9	18
2230	2. Pathophysiology of Severe Asthma and Its Latest Treatment. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2021, 110, 66a-70a.	0.0	0
2231	Use of FeNO to Predict Anti-IL-5 and IL-5R Biologics Efficacy in a Real-World Cohort of Adults with Severe Eosinophilic Asthma. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
2232	Histone deacetylase-2 inducer like theophylline has a potential to improve glucocorticoid responsiveness in severe uncontrolled asthma by reducing P-glycoprotein/MRP-1. <i>Indian Journal of Rheumatology</i> , 2022, 17, 47.	0.2	0
2233	Mucus Plugs and Small Airway Dysfunction in Asthma, COPD, and Asthma-COPD Overlap. <i>Allergy, Asthma and Immunology Research</i> , 2022, 14, 196.	1.1	12
2234	Nrf2 regulates downstream genes by targeting miR-29b in severe asthma and the role of grape seed proanthocyanidin extract in a murine model of steroid-insensitive asthma. <i>Pharmaceutical Biology</i> , 2022, 60, 347-358.	1.3	6
2236	Characterization of Italian severe uncontrolled Asthmatic patients Key features when receiving Benralizumab in a real-life setting: the observational retrospective ANANKE study. <i>Respiratory Research</i> , 2022, 23, 36.	1.4	14
2237	Prevalence of eosinophilic, atopic, and overlap phenotypes among patients with severe asthma in Saudi Arabia: a cross-sectional study. <i>BMC Pulmonary Medicine</i> , 2022, 22, 67.	0.8	6
2238	Clinical and Lung Function Outcomes After Anti-IgE or Anti-IL5 Therapy in Severe Asthma. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 209-217.	1.5	7
2239	Severe eosinophilic asthma in Chinese BIOIPRED asthma cohort. <i>Clinical and Translational Medicine</i> , 2022, 12, e710.	1.7	4
2240	Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1545-1553.e2.	2.0	28
2241	Identifying Bacterial Airways Infection in Stable Severe Asthma Using Oxford Nanopore Sequencing Technologies. <i>Microbiology Spectrum</i> , 2022, 10, e0227921.	1.2	5
2242	Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma. <i>Respiratory Research</i> , 2022, 23, 45.	1.4	2
2243	Plethysmography-derived gas trapping lacks utility in predicting response to bronchial thermoplasty. <i>ERJ Open Research</i> , 2022, 8, 00690-2021.	1.1	1
2244	MicroRNAs: A Promising Tool for Asthma Diagnosis and Severity Assessment: A Systematic Review. <i>Journal of Personalized Medicine</i> , 2022, 12, 543.	1.1	12
2245	Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis. <i>Clinical and Experimental Allergy</i> , 2022, 52, 616-627.	1.4	33
2246	Clinical Remission in Severe Asthma: A Pooled Post Hoc Analysis of the Patient Journey with Benralizumab. <i>Advances in Therapy</i> , 2022, 39, 2065-2084.	1.3	47

#	ARTICLE	IF	CITATIONS
2247	Clinical Characteristics of Irritant-Induced Occupational Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1554-1561.e7.	2.0	6
2248	Expression of LINC00847 in Peripheral Blood Mononuclear Cells of Children with Asthma and Its Prediction between Asthma Exacerbation and Remission. <i>Genetical Research</i> , 2022, 2022, 1-9.	0.3	1
2249	A study of nasal epithelial cell gene expression in a sample of mild to severe asthmatic children and healthy controls. <i>Egyptian Journal of Medical Human Genetics</i> , 2022, 23, .	0.5	1
2250	Severe asthma in children: Description of a large multidisciplinary clinical cohort. <i>Pediatric Pulmonology</i> , 2022, 57, 1447-1455.	1.0	2
2251	Omalizumab and IgE in the Control of Severe Allergic Asthma. <i>Frontiers in Pharmacology</i> , 2022, 13, 839011.	1.6	9
2252	Maintenance of Asthma Control in Adolescents with Severe Asthma After Transitioning to a Specialist Adult Centre: A French Cohort Experience. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 327-340.	1.5	3
2253	Reducing Tolerance for SABA and OCS towards the Extreme Ends of Asthma Severity. <i>Journal of Personalized Medicine</i> , 2022, 12, 504.	1.1	3
2254	Bronchial asthma: an update. <i>Minerva Medica</i> , 2022, 113, .	0.3	1
2255	Asthmatic bronchial smooth muscle increases rhinovirus replication within the bronchial epithelium. <i>Cell Reports</i> , 2022, 38, 110571.	2.9	11
2256	The impact of identifying laryngeal obstruction syndromes on reducing treatment of pediatric asthma: a systematic review. <i>Pediatric Pulmonology</i> , 2022, , .	1.0	5
2257	Modern Understanding of Severe Bronchial Asthma. <i>Russian Archives of Internal Medicine</i> , 2022, 12, 113-122.	0.0	0
2258	Pulmonary <sc>MRI</sc> and Cluster Analysis Help Identify Novel Asthma Phenotypes. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 56, 1475-1486.	1.9	4
2259	The Korean Severe Asthma Registry (KoSAR): real world research in severe asthma. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 249-260.	0.7	6
2260	Recent advances in bronchial thermoplasty for severe asthma: a narrative review. <i>Annals of Translational Medicine</i> , 2022, 10, 370-370.	0.7	4
2261	Therapeutic Potential of Combining IL-6 and TNF Blockade in a Mouse Model of Allergic Asthma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 3521.	1.8	8
2262	Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 169-180.	0.5	28
2263	Asthma Control, Airway Mucus, and 129Xe MRI Ventilation After a Single Benralizumab Dose. <i>Chest</i> , 2022, 162, 520-533.	0.4	25
2264	Efficacy of anti-IL-5 therapy with mepolizumab for severe bronchial asthma and concomitant inflammatory nasal diseases in real clinical practice. <i>Russian Journal of Allergy</i> , 0, , .	0.1	1



#	ARTICLE	IF	CITATIONS
2265	Eosinophil-derived neurotoxin: An asthma exacerbation biomarker in children. <i>Allergy and Asthma Proceedings</i> , 2022, 43, 133-139.	1.0	6
2266	Specific Therapy for T2 Asthma. <i>Journal of Personalized Medicine</i> , 2022, 12, 593.	1.1	7
2267	Home-based intravenous treatment with reslizumab for severe asthma in the Netherlands â€œ An evaluation. <i>Respiratory Medicine</i> , 2022, 194, 106776.	1.3	1
2268	Characterization of Asthma by Age of Onset: A Multi-Database Cohort Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1825-1834.e8.	2.0	19
2269	Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1835-1843.	2.0	4
2270	Eosinophil-mediated suppression and antiâ€œIL-5 enhancement of plasmacytoid dendritic cell interferon responses in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 150, 666-675.	1.5	11
2271	Leukocyte redistribution as immunological biomarker of corticosteroid resistance in severe asthma. <i>Clinical and Experimental Allergy</i> , 2022, 52, 1183-1194.	1.4	5
2272	A whole genome sequencing study of moderate to severe asthma identifies a lung function locus associated with asthma risk. <i>Scientific Reports</i> , 2022, 12, 5574.	1.6	9
2273	Correlation of Activation Site and Number with the Clinical Response to Bronchial Thermoplasty. <i>Journal of Asthma and Allergy</i> , 2022, Volume 15, 437-452.	1.5	3
2274	The German severe asthma patient: Baseline characteristics of patients in the German Severe Asthma Registry, and relationship with exacerbations and control. <i>Respiratory Medicine</i> , 2022, 195, 106793.	1.3	9
2275	STIM1 is the key that unlocks airway smooth muscle remodeling and hyperresponsiveness during asthma. <i>Cell Calcium</i> , 2022, 104, 102589.	1.1	4
2276	Exploring the efficacy and contribution of Dupilumab in asthma management. <i>Molecular Immunology</i> , 2022, 146, 9-17.	1.0	2
2277	Pharmacological approaches to target type 2 cytokines in asthma. , 2022, 237, 108167.		8
2278	Asthma Control during COVID-19 Lockdown in Patients with Severe Asthma under Biological Drug Treatment. <i>Applied Sciences (Switzerland)</i> , 2021, 11, 12089.	1.3	1
2279	A pragmatic guide to choosing biologic therapies in severe asthma. <i>Breathe</i> , 2021, 17, 210144.	0.6	20
2280	Saudi Arabian real-life experience with biologic therapy in severe asthma. <i>Multidisciplinary Respiratory Medicine</i> , 2021, 16, 807.	0.6	0
2281	Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) in Pediatric Severe Allergic Asthmaâ€œA Romanian Perspective. <i>Children</i> , 2021, 8, 1141.	0.6	3
2282	Case Report: Self-Administration of Omalizumab in an Adolescent With Severe Asthma During SARS-CoV-2 Infection. <i>Frontiers in Pediatrics</i> , 2021, 9, 675281.	0.9	2

#	ARTICLE	IF	CITATIONS
2284	Association of IL33, IL1RL1, IL1RAP Polymorphisms and Asthma in Chinese Han Children. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 759542.	1.8	4
2285	STIM1 is a core trigger of airway smooth muscle remodeling and hyperresponsiveness in asthma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	21
2286	Switch from Omalizumab to Benralizumab in Allergic Patients with Severe Eosinophilic Asthma: A Real-Life Experience from Southern Italy. <i>Biomedicines</i> , 2021, 9, 1822.	1.4	13
2287	Impact of gentrification on asthma visits to the emergency department. <i>SN Social Sciences</i> , 2022, 2, 1.	0.4	2
2288	Multiomics analysis identifies BIRC3 as a novel glucocorticoid response-associated gene. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1981-1991.	1.5	6
2289	Asthma and obesity: endotoxin another insult to add to injury?. <i>Clinical Science</i> , 2021, 135, 2729-2748.	1.8	9
2290	Understanding and Managing Severe Asthma in the Context of COVID-19. <i>ImmunoTargets and Therapy</i> , 2021, Volume 10, 419-430.	2.7	1
2291	Phenotype and severity of asthma determines bronchial epithelial immune responses to a viral mimic. <i>European Respiratory Journal</i> , 2022, 60, 2102333.	3.1	8
2292	2021 Brazilian Thoracic Association recommendations for the management of severe asthma. <i>Jornal Brasileiro De Pneumologia</i> , 2021, 47, e20210273.	0.4	9
2293	Bronchial Thermoplasty Global Registry (BTGR): 2-year results. <i>BMJ Open</i> , 2021, 11, e053854.	0.8	9
2294	Advances and Challenges of Antibody Therapeutics for Severe Bronchial Asthma. <i>International Journal of Molecular Sciences</i> , 2022, 23, 83.	1.8	8
2295	The Experience of Living with Severe Asthma, Depression and Anxiety: A Qualitative Art-Based Study. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 1527-1537.	1.5	0
2296	Real-world impact of mepolizumab in patients with life-threatening asthma: US insurance claims database analysis. <i>Clinical Therapeutics</i> , 2021, 43, 2064-2073.	1.1	5
2297	Challenges and recommendations for the management of asthma in the Middle East and Africa. <i>Annals of Thoracic Medicine</i> , 2022, 17, 71.	0.7	8
2298	Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice. <i>Terapevticheski Arkhiv</i> , 2022, 94, 413-419.	0.2	2
2299	Severe asthma as the initial clinical manifestation of IgG4-related disease: a retrospective clinical study. <i>BMC Pulmonary Medicine</i> , 2022, 22, 141.	0.8	4
2300	Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts. <i>Frontiers in Pharmacology</i> , 2022, 13, 836635.	1.6	4
2301	Severe asthma in children. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2022, 43, 329-340.	0.5	1

#	ARTICLE	IF	CITATIONS
2305	Patients with Severe Uncontrolled Asthma: Perception of Asthma Control and its Management. <i>Pulmonary Therapy</i> , 2022, 8, 209-223.	1.1	2
2306	Primary Care Severe Asthma Registry and Education Project (PCSAR-EDU): Phase 1 â€œ an e-Delphi for registry definitions and indices of clinician behaviour. <i>BMJ Open</i> , 2022, 12, e055958.	0.8	0
2311	A prospective study exploring the predictors of response to benralizumab in patients with refractory bronchial asthma.. , 2022, 8, 13-16.		0
2315	Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma. <i>Farmacia Hospitalaria</i> , 2019, 43, 187-193.	0.6	3
2316	Epithelial immune regulation of inflammatory airway diseases: Chronic rhinosinusitis with nasal polyps (CRSwNP). <i>Allergologie Select</i> , 2022, 6, 148-166.	1.6	4
2317	Characteristics of the European Thoracic Society/American Thoracic Society severe asthma definition as a determinant of future use of biologics/bronchial thermoplasty. <i>Asia Pacific Allergy</i> , 2022, 12, e13.	0.6	2
2318	Exercise effects in adults with asthma. , 2022, , 117-130.		0
2319	Real-World Effectiveness of Reslizumab in Patients With Severe Eosinophilic Asthma â€œ First Initiators and Switchers. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2099-2108.e6.	2.0	12
2320	Budget Impact Analysis of Mepolizumab for Eligible Patients in the Setting of a Severe Asthma Clinic Within Dubai Health Authority (DHA). <i>ClinicoEconomics and Outcomes Research</i> , 2022, Volume 14, 265-279.	0.7	0
2321	Predictive Response to Immunotherapy Score: A Useful Tool for Identifying Eligible Patients for Allergen Immunotherapy. <i>Biomedicines</i> , 2022, 10, 971.	1.4	4
2322	Clinical and transcriptomic features of persistent exacerbationâ€”prone severe asthma in Uâ€œBIOPRED cohort. <i>Clinical and Translational Medicine</i> , 2022, 12, e816.	1.7	11
2323	Clinical response to biologics for severe asthma: any relevance for sex in different age ranges?. <i>ERJ Open Research</i> , 2022, 8, 00670-2021.	1.1	2
2324	Novel Biological Therapies for Severe Asthma Endotypes. <i>Biomedicines</i> , 2022, 10, 1064.	1.4	10
2325	Stressed out - The role of oxidative stress in airway smooth muscle dysfunction in asthma and COPD. <i>Free Radical Biology and Medicine</i> , 2022, 185, 97-119.	1.3	11
2327	Exacerbation Profile and Risk Factors in a Type-2â€œLow Enriched Severe Asthma Cohort: A Clinical Trial to Assess Asthma Exacerbation Phenotypes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 545-553.	2.5	14
2328	Regional variation in intensity of inhaled asthma medication and oral corticosteroid use in Denmark, Finland, and Sweden. <i>European Clinical Respiratory Journal</i> , 2022, 9, 2066815.	0.7	2
2329	Identification of ANXA2 on epithelial cells as a new receptor for secretory IgA using immunoprecipitation and mass spectrometry. <i>Clinical and Experimental Immunology</i> , 2022, 208, 351-360.	1.1	3
2330	The Role of Access and Cost-Effectiveness in Managing Asthma: A Systematic Review. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2109-2116.	2.0	7

#	ARTICLE	IF	CITATIONS
2331	Prescription Patterns of Oral Corticosteroids for Asthma Treatment and Related Asthma Phenotypes in University Hospitals in Korea. <i>Allergy, Asthma and Immunology Research</i> , 2022, 14, 300.	1.1	2
2332	Tezepelumab compared with other biologics for the treatment of severe asthma: a systematic review and indirect treatment comparison. <i>Journal of Medical Economics</i> , 2022, 25, 679-690.	1.0	23
2333	*Neonatal Pulmonology: "Year in Review" for the Pediatric Pulmonologist. <i>Pediatric Pulmonology</i> , 2022, , .	1.0	0
2334	Breathing Exercises for Patients with Asthma in Specialist Care: A Multicenter Randomized Clinical Trial. <i>Annals of the American Thoracic Society</i> , 2022, 19, 1498-1506.	1.5	2
2335	The Clinical Efficacy of Type 2 Inflammation-Specific Agents Targeting Interleukins in Reducing Exacerbations in Severe Asthma: A Meta-Analysis. <i>Yonsei Medical Journal</i> , 2022, 63, 511.	0.9	2
2336	Paucigranulocytic Asthma: Potential Pathogenetic Mechanisms, Clinical Features and Therapeutic Management. <i>Journal of Personalized Medicine</i> , 2022, 12, 850.	1.1	8
2338	Benralizumab in Patients With Severe Eosinophilic Asthma With and Without Chronic Rhinosinusitis With Nasal Polyps: An ANANKE Study post-hoc Analysis. <i>Frontiers in Allergy</i> , 2022, 3, .	1.2	9
2339	The new era of add-on asthma treatments: where do we stand?. <i>Allergy, Asthma and Clinical Immunology</i> , 2022, 18, .	0.9	12
2340	IgA <sup>+</sup> memory B-cells are significantly increased in patients with asthma and small airway dysfunction. <i>European Respiratory Journal</i> , 2022, 60, 2102130.	3.1	8
2341	A Pilot Randomized Trial of As-Needed Budesonide-Formoterol for Stepping Down Controller Treatment in Moderate Asthma with Complete Remission. <i>Tuberculosis and Respiratory Diseases</i> , 2022, 85, 227-236.	0.7	1
2342	Effectiveness of Switching to Benralizumab in Severe Refractory Eosinophilic Asthma. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 727-735.	1.5	9
2343	Characteristics, phenotypes, mechanisms and management of severe asthma. <i>Chinese Medical Journal</i> , 2022, 135, 1141-1155.	0.9	12
2344	Antibiotic use among admitted pediatric patients in the United States with status asthmaticus before and during the COVID-19 pandemic. <i>Journal of Asthma</i> , 0, , 1-11.	0.9	1
2345	Primary care referral patterns for patients with asthma: analysis of real-world data. <i>Journal of Asthma</i> , 2023, 60, 609-615.	0.9	3
2346	Could transthoracic ultrasound be useful to suggest a small airways disease in severe uncontrolled asthma?. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 461-466.	0.5	3
2347	RELIGHT: A two-year REAL-life study of mepolizumab in patients with severe eosinophilic asthma in Greece: Evaluating the multiple components of response. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2848-2852.	2.7	10
2348	Antibiotic resistance in chronic respiratory diseases: from susceptibility testing to the resistome. <i>European Respiratory Review</i> , 2022, 31, 210259.	3.0	10
2349	Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study. <i>Internal Medicine</i> , 2022, 61, 1663-1671.	0.3	2

#	ARTICLE	IF	CITATIONS
2350	One-year safety and tolerability of tezepelumab in Japanese patients with severe uncontrolled asthma: results of the NOZOMI study. <i>Journal of Asthma</i> , 2023, 60, 616-624.	0.9	8
2351	Severe asthma phenotyping: does the definition of different phenotypes matter?. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20220176.	0.4	0
2352	Biologic use and outcomes among adults with severe asthma treated by US subspecialists. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 467-474.e3.	0.5	7
2353	REALITI-A Study: Real-World Oral Corticosteroid-Sparing Effect of Mepolizumab in Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2646-2656.	2.0	24
2354	Association of corticosteroid use and attention deficit/hyperactivity disorder in asthmatic children varies by age. <i>Journal of Asthma</i> , 2023, 60, 698-707.	0.9	1
2355	The Impact of Insulin Resistance on Loss of Lung Function and Response to Treatment in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 206, 1096-1106.	2.5	28
2356	Reduction in asthma exacerbation rate after mepolizumab treatment initiation in patients with severe asthma: A real-world database study in Japan. <i>Pulmonary Pharmacology and Therapeutics</i> , 2022, 75, 102130.	1.1	3
2357	Improving Medication Adherence in Asthma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 0, , .	0.8	0
2358	Multidisciplinary care in chronic airway diseases: the Newcastle model. <i>ERJ Open Research</i> , 2022, 8, 00215-2022.	1.1	18
2359	Molecular Allergen-Specific IgE Recognition Profiles and Cumulative Specific IgE Levels Associated with Phenotypes of Cat Allergy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6984.	1.8	5
2360	Pathways linked to unresolved inflammation and airway remodelling characterize the transcriptome in two independent severe asthma cohorts. <i>Respirology</i> , 2022, 27, 730-738.	1.3	3
2361	Association of longitudinal changes in quality of life with comorbidities and exacerbations in patients with severe asthma. <i>Allergology International</i> , 2022, 71, 481-489.	1.4	4
2362	Comorbid allergic rhinitis and asthma: important clinical considerations. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 747-758.	1.3	12
2363	Extracellular Traps: A Novel Therapeutic Target for Severe Asthma. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 803-810.	1.5	5
2364	Biologic Therapies in Pediatric Asthma. <i>Journal of Personalized Medicine</i> , 2022, 12, 999.	1.1	12
2365	â€œBreathing Fireâ€™: Impact of Prolonged Bushfire Smoke Exposure in People with Severe Asthma. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 7419.	1.2	14
2366	SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2588-2595.	2.0	9
2367	Biological Therapy of Severe Asthma and Nasal Polyps. <i>Journal of Personalized Medicine</i> , 2022, 12, 976.	1.1	14

#	ARTICLE	IF	CITATIONS
2368	Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management. <i>BioDrugs</i> , 2022, 36, 443-458.	2.2	20
2369	Clinical Characteristics and Disease Burden of Severe Asthma According to Oral Corticosteroid Dependence: Real-World Assessment From the Korean Severe Asthma Registry (KoSAR). <i>Allergy, Asthma and Immunology Research</i> , 2022, 14, 412.	1.1	4
2370	Direct Visualization and Quantitative Imaging of Small Airway Anatomy Using Deep Learning Assisted Diffractive OCT. <i>IEEE Transactions on Biomedical Engineering</i> , 2023, 70, 238-246.	2.5	7
2371	Is the unrealistic expectation of getting cured related to poor treatment adherence among Indian Asthma patients? A hospital based mixed methods study from central India. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 3178.	0.3	2
2372	Continuous positive airway pressure therapy suppresses inflammatory cytokines and improves glucocorticoid responsiveness in patients with obstructive sleep apnea and asthma: A case-control study. <i>Annals of Thoracic Medicine</i> , 2022, 17, 166.	0.7	3
2373	Efficacy and Safety of Mepolizumab in Corticosteroid-Dependent Severe Asthma: A Randomized Placebo-Controlled Trial. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 737-747.	1.5	13
2374	Effects of obesity on CC16 and their potential role in overweight/obese asthma. <i>Respiratory Research</i> , 2022, 23, .	1.4	6
2375	Biologics in severe asthma: the role of real-world evidence from registries. <i>European Respiratory Review</i> , 2022, 31, 210278.	3.0	13
2377	DNA methylation signatures in airway cells from adult children of asthmatic mothers reflect subtypes of severe asthma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	11
2378	Eosinophilic Asthma, Phenotypes-Endotypes and Current Biomarkers of Choice. <i>Journal of Personalized Medicine</i> , 2022, 12, 1093.	1.1	12
2379	Prevalence of Patients with Uncontrolled Asthma Despite NVL/GINA Step 4/5 Treatment in Germany. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 897-906.	1.5	8
2380	The airway smooth muscle sodium/calcium exchanger NCLX is critical for airway remodeling and hyperresponsiveness in asthma. <i>Journal of Biological Chemistry</i> , 2022, 298, 102259.	1.6	5
2381	Factors associated with 6-minute walk distance in severe asthma: A cross-sectional study. <i>Respirology</i> , 2022, 27, 1025-1033.	1.3	3
2382	Classifications of moderate to severe asthma phenotypes in Japan and analysis of serum biomarkers: A Nationwide Cohort Study in Japan (NHOM Asthma Study). <i>Allergology International</i> , 2023, 72, 63-74.	1.4	6
2383	Severe Pediatric Asthma Therapy: Mepolizumab. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	6
2384	Federal guidelines on diagnosis and treatment of bronchial asthma. <i>Pulmonologiya</i> , 2022, 32, 393-447.	0.2	9
2385	Expert Opinion for the Management of Severe Asthma in Adults in the Gulf region. <i>Current Respiratory Medicine Reviews</i> , 2022, 18, .	0.1	0
2386	Investigational approaches for unmet need in severe asthma. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 661-678.	1.0	2

#	ARTICLE	IF	CITATIONS
2387	Frontiers Review: Severe Asthma in Adolescents. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	1
2388	Neuromedin U promotes human type 2 immune responses. <i>Mucosal Immunology</i> , 2022, 15, 990-999.	2.7	5
2389	The Therapeutic Potential for Targeting Group 2 Innate Lymphoid Cells in Asthma. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
2391	Benefits of specialist severe asthma management: demographic and geographic disparities. <i>European Respiratory Journal</i> , 2022, 60, 2200660.	3.1	13
2392	IL-17 Cytokines and Chronic Lung Diseases. <i>Cells</i> , 2022, 11, 2132.	1.8	27
2393	Regional variation in prevalence of difficult-to-treat asthma and oral corticosteroid use for patients in Australia: heat map analysis. <i>Journal of Asthma</i> , 2023, 60, 727-736.	0.9	1
2394	Relationship between inflammatory status and microbial composition in severe asthma and during exacerbation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3362-3376.	2.7	7
2395	Impact of mepolizumab in patients with high-burden severe asthma within a managed care population. <i>Journal of Asthma</i> , 0, , 1-13.	0.9	6
2396	Nebulized budesonide combined with systemic corticosteroid vs systemic corticosteroid alone in acute severe asthma managed in the emergency department: a randomized controlled trial. <i>BMC Emergency Medicine</i> , 2022, 22, .	0.7	2
2397	The effectiveness of anti-IgE therapy for allergic rhinitis in patients with severe atopic bronchial asthma and concomitant allergic rhinitis in real clinical practice. <i>Russian Journal of Allergy</i> , 0, , .	0.1	0
2398	Asthma and Tobacco Smoking. <i>Journal of Personalized Medicine</i> , 2022, 12, 1231.	1.1	5
2399	Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study. <i>European Respiratory Journal</i> , 2022, 60, 2103226.	3.1	7
2400	Severe non-atopic asthma: omalizumab can reduce severe asthma exacerbations. <i>Journal of Asthma</i> , 0, , 1-10.	0.9	0
2401	Overall Response to Anti-IL-5/Anti-IL5-R $\alpha$ Treatment in Severe Asthma Does Not Depend on Initial Bronchodilator Responsiveness. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 3174-3183.	2.0	12
2402	A machine learning approach to characterize patients with asthma exacerbation attending an acute care setting. <i>European Journal of Internal Medicine</i> , 2022, 104, 66-72.	1.0	2
2403	Type 2 inflammation in asthma and other airway diseases. <i>ERJ Open Research</i> , 2022, 8, 00576-2021.	1.1	62
2404	Safety of omalizumab in the treatment of moderate-to-severe bronchial asthma. <i>Rossiiskii Meditsinskii Zhurnal: Organ Ministerstva Zdravookhraneniia RSFSR</i> , 2022, 28, 89-98.	0.1	0
2405	Eosinophilic cationic protein as marker for response to antibody therapy in severe asthma. <i>ERJ Open Research</i> , 2022, 8, 00138-2022.	1.1	3

#	ARTICLE	IF	CITATIONS
2406	Increasing physical activity in severe asthma: a systematic review and meta-analysis. <i>European Respiratory Journal</i> , 2022, 60, 2200546.	3.1	8
2407	Spray-Dried and Spray-Freeze-Dried Powder Formulations of an Anti-Interleukin-4R $\beta$ Antibody for Pulmonary Delivery. <i>Pharmaceutical Research</i> , 2022, 39, 2291-2304.	1.7	8
2408	CEBPD modulates the airway smooth muscle transcriptomic response to glucocorticoids. <i>Respiratory Research</i> , 2022, 23, .	1.4	1
2409	T-cell responses in asthma exacerbations. <i>Annals of Allergy, Asthma and Immunology</i> , 2022, 129, 709-718.	0.5	5
2410	Treatment of allergic eosinophilic asthma through engineered IL-5-anchored chimeric antigen receptor T cells. <i>Cell Discovery</i> , 2022, 8, .	3.1	9
2411	Microarray-Based Analyses of Rhinovirus Species-Specific Antibody Responses in Exacerbated Pediatric Asthma in a German Pediatric Cohort. <i>Viruses</i> , 2022, 14, 1857.	1.5	2
2412	Differences Between Early- and Late-Onset Asthma: Role of Comorbidities in Symptom Control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 3196-3203.	2.0	14
2413	Healthcare utilization and health-related quality of life of severe asthma patients in Singapore. <i>Journal of Asthma</i> , 2023, 60, 969-980.	0.9	3
2414	Data from the Russian Severe Asthma Registry (RSAR). <i>Terapevticheskii Arkhiv</i> , 2022, 94, 865-871.	0.2	2
2415	Mobilisation of HLA-DR on the surface of bronchial epithelial cells and platelets in asthmatic patients. <i>Hla</i> , 2022, 100, 491-499.	0.4	4
2416	Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 4702.	1.0	5
2417	Relaxing Responses of Isolated Rat Airways to Hydrocotyle umbellata Extract. <i>Revista Brasileira De Farmacognosia</i> , 2022, 32, 636-644.	0.6	0
2418	Biologics and airway remodeling in severe asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3538-3552.	2.7	65
2419	Assessment of Real-World Escalation to Biologics in US Patients With Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2941-2948.	2.0	7
2420	IL-33 receptor inhibition in subjects with uncontrolled asthma: A randomized, placebo-controlled trial. , 2022, 1, 198-208.		3
2421	A Pragmatic Primary Practice Approach to Using Specific IgE in Allergy Testing in Asthma Diagnosis, Management, and Referral. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 1069-1080.	1.5	4
2422	Efficacy and safety of treatment with benralizumab for eosinophilic asthma. <i>International Immunopharmacology</i> , 2022, 111, 109131.	1.7	6
2423	EPI-ASTHMA study protocol: a population-based multicentre stepwise study on the prevalence and characterisation of patients with asthma according to disease severity in Portugal. <i>BMJ Open</i> , 2022, 12, e064538.	0.8	1



#	ARTICLE	IF	CITATIONS
2424	Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma. <i>Biomedicines</i> , 2022, 10, 2181.	1.4	10
2426	Perioperative management of the child with asthma. <i>BJA Education</i> , 2022, 22, 402-410.	0.6	1
2427	Evolving Concept of Severe Asthma: Transition From Diagnosis to Treatable Traits. <i>Allergy, Asthma and Immunology Research</i> , 2022, 14, 447.	1.1	8
2428	Question 9. , 2022, , 21-22.		0
2429	Oral corticosteroid-sparing effects of mepolizumab in severe eosinophilic asthma: evidence from randomized controlled trials and real-world studies. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211073.	1.0	3
2430	Steroid resistance of severe asthma " mechanisms and therapeutic targets. <i>Folia Pharmacologica Japonica</i> , 2022, 157, 293-298.	0.1	0
2431	A retrospective observational study on pheno-endotypes of severe asthma among adults attending asthma clinic in a tertiary care centre in India. <i>Lung India</i> , 2022, 39, 393.	0.3	0
2432	Multiple Choice Questions with explanations. , 2022, , 1-267.		0
2433	Prevalence of the eosinophilic phenotype among severe asthma patients in Brazil: the BRAEOS study. <i>Jornal Brasileiro De Pneumologia</i> , 0, , e20210367.	0.4	3
2434	Impact of the COVID-19 Pandemic on Incidence of Asthma Exacerbations and Hospitalizations in US Subspecialist-Treated Patients with Severe Asthma: Results from the CHRONICLE Study. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 1195-1203.	1.5	7
2435	Multimorbidity in Difficult Asthma: The Need for Personalised and Non-Pharmacological Approaches to Address a Difficult Breathing Syndrome. <i>Journal of Personalized Medicine</i> , 2022, 12, 1435.	1.1	4
2436	Determinants of lung function across childhood in the Severe Asthma Research Program (SARP) 3. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 138-146.e9.	1.5	10
2437	Pulmonary rehabilitation versus usual care for adults with asthma. <i>The Cochrane Library</i> , 2022, 2022, .	1.5	4
2438	Social dimensions of chronic respiratory disease: stigma, isolation, and loneliness. <i>Current Opinion in Supportive and Palliative Care</i> , 2022, 16, 195-202.	0.5	9
2439	Peripheral blood transcriptomic clusters uncovered immune phenotypes of asthma. <i>Respiratory Research</i> , 2022, 23, .	1.4	4
2440	Characteristics of different asthma phenotypes associated with cough: a prospective, multicenter survey in China. <i>Respiratory Research</i> , 2022, 23, .	1.4	6
2441	Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. <i>Scientific Reports</i> , 2022, 12, .	1.6	0
2442	Adult Asthma Management in the Emergency Department during COVID-19 Pandemic: An Expert Opinion Survey. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 9460.	1.3	0

#	ARTICLE	IF	CITATIONS
2444	Urinary total conjugated 3-bromotyrosine, asthma severity, and exacerbation risk. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2022, 323, L548-L557.	1.3	2
2445	Low CC16 mRNA Expression Levels in Bronchial Epithelial Cells Are Associated with Asthma Severity. American Journal of Respiratory and Critical Care Medicine, 2023, 207, 438-451.	2.5	15
2446	Functional gastrointestinal disorders are associated with capsaicin cough sensitivity in severe asthma. Allergology International, 2022, , .	1.4	2
2447	Managing food allergy: GA2LEN guideline 2022. World Allergy Organization Journal, 2022, 15, 100687.	1.6	58
2448	Influence of sex, cigarette smoking and airway inflammation on treatable traits in CBIOPRED severe asthma. Clinical and Translational Allergy, 2022, 12, .	1.4	0
2449	Heterogeneity in the use of biologics for severe asthma in Europe: a SHARP ERS study. ERJ Open Research, 2022, 8, 00273-2022.	1.1	8
2450	Bronchial smooth muscle cell in asthma: where does it fit?. BMJ Open Respiratory Research, 2022, 9, e001351.	1.2	2
2451	Narrative review to capture patients's™ perceptions and opinions about non-response and response to biological therapy for severe asthma. European Respiratory Journal, 2023, 61, 2200837.	3.1	11
2452	Applicability of the MASK-Air® App to Severe Asthma Treated with Biologic Molecules: A Pilot Study. International Journal of Molecular Sciences, 2022, 23, 11470.	1.8	4
2453	Ketone body augmentation decreases methacholine hyperresponsiveness in mouse models of allergic asthma. , 2022, 1, 282-298.		0
2454	Switching from one biologic to benralizumab in patients with severe eosinophilic asthma: An ANANKE study post hoc analysis. Frontiers in Medicine, 0, 9, .	1.2	7
2455	Neisseria species as pathobionts in bronchiectasis. Cell Host and Microbe, 2022, 30, 1311-1327.e8.	5.1	17
2456	Cumulative IgE-levels specific for respiratory allergens as biomarker to predict efficacy of anti-IgE-based treatment of severe asthma. Frontiers in Immunology, 0, 13, .	2.2	3
2457	Investigational Treatments in Phase I and II Clinical Trials: A Systematic Review in Asthma. Biomedicines, 2022, 10, 2330.	1.4	6
2458	Long-term cardiac pathology in individuals with mild initial COVID-19 illness. Nature Medicine, 2022, 28, 2117-2123.	15.2	63
2459	Obesity affects pulmonary function in Japanese adult patients with asthma, but not those without asthma. Scientific Reports, 2022, 12, .	1.6	5
2460	Immunomodulatory potential of apolipoproteins and their mimetic peptides in asthma: Current perspective. Respiratory Medicine, 2022, , 107007.	1.3	3
2461	PrimaryCare Settingto Care Asthma. International Journal of Pharmaceutical and Bio-medical Science, 0, , .	0.0	0

#	ARTICLE	IF	CITATIONS
2462	Biologics for chronic severe asthma: a network meta-analysis. The Cochrane Library, 2022, 2022, .	1.5	1
2464	2. Pathophysiology of Severe Asthma and Its Latest Treatment. The Journal of the Japanese Society of Internal Medicine, 2021, 110, 1763-1770.	0.0	0
2465	Role of mepolizumab in severe allergic asthma with vocal cord polyp. Lung India, 2022, 39, 578.	0.3	0
2466	A correlational study on neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in bronchial asthma. Advances in Human Biology, 2022, .	0.1	0
2467	Pharmacometabolomics of Asthma as a Road Map to Precision Medicine. Handbook of Experimental Pharmacology, 2022, , .	0.9	0
2468	Is immunotherapy safe for treatment of severe asthma. Current Opinion in Allergy and Clinical Immunology, 2022, 22, 396-401.	1.1	1
2469	Critical evaluation of asthma biomarkers in clinical practice. Frontiers in Medicine, 0, 9, .	1.2	19
2470	Current Limitations and Recent Advances in the Management of Asthma. Disease-a-Month, 2023, 69, 101483.	0.4	3
2471	Ālinical and allergological characteristics of chronic inflammatory diseases of the nose in patients with severe bronchial asthma receiving immunobiological therapy in the Sverdlovsk region. Meditsinskiy Sovet, 2022, 16, 11-19.	0.1	0
2472	Measurement of Exhaled Volatile Organic Compounds as a Biomarker for Personalised Medicine: Assessment of Short-Term Repeatability in Severe Asthma. Journal of Personalized Medicine, 2022, 12, 1635.	1.1	2
2473	Development of Core Outcome Measures sets for paediatric and adult Severe Asthma (COMSA). European Respiratory Journal, 2023, 61, 2200606.	3.1	20
2474	Dual activation of estrogen receptor alpha and glucocorticoid receptor upregulate CRTh2-mediated type 2 inflammation; mechanism driving asthma severity in women?. Allergy: European Journal of Allergy and Clinical Immunology, 0, , .	2.7	4
2475	Real-Life Performance of Mepolizumab in T2-High Severe Refractory Asthma with the Overlapping Eosinophilic-Allergic Phenotype. Biomedicines, 2022, 10, 2635.	1.4	5
2476	Daily Physical Activity in Asthma and the Effect of Mepolizumab Therapy. Journal of Personalized Medicine, 2022, 12, 1692.	1.1	1
2477	Is Omalizumab Related to Ear and Labyrinth Disorders? A Disproportionality Analysis Based on a Global Pharmacovigilance Database. Diagnostics, 2022, 12, 2434.	1.3	2
2478	NOD2 Signaling Circuitry during Allergen Sensitization Does Not Worsen Experimental Neutrophilic Asthma but Promotes a Th2/Th17 Profile in Asthma Patients but Not Healthy Subjects. International Journal of Molecular Sciences, 2022, 23, 11894.	1.8	1
2479	The CRTh2 polymorphism rs533116 G &gt; A associates with asthma severity in older females. Frontiers in Medicine, 0, 9, .	1.2	1
2480	Correct treatment regimen and inhalation technique are the components of success in bronchial asthma in the era of COVID-19. Meditsinskiy Sovet, 2022, 16, 122-130.	0.1	0

#	ARTICLE	IF	CITATIONS
2481	Prevalence and Characterisation of Patients with Asthma According to Disease Severity in Portugal: Findings from the EPI-ASTHMA Pilot Study. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 1441-1453.	1.5	3
2482	Pyrroloquinoline Quinone Administration Alleviates Allergic Airway Inflammation in Mice by Regulating the JAK-STAT Signaling Pathway. <i>Mediators of Inflammation</i> , 2022, 2022, 1-18.	1.4	1
2483	Selective Inhibition of ERK1/2: When Less Is More. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 0, , .	1.4	0
2484	A Renewed Charter: Key Principles to Improve Patient Care in Severe Asthma. <i>Advances in Therapy</i> , 2022, 39, 5307-5326.	1.3	7
2485	Distribution of type 2 biomarkers and association with severity, clinical characteristics and comorbidities in the BREATHE real-life asthma population. <i>ERJ Open Research</i> , 2023, 9, 00483-2022.	1.1	3
2486	The Italian severe/uncontrolled asthma registry (RItA): A 12-month clinical follow-up. <i>Respiratory Medicine</i> , 2022, 205, 107030.	1.3	1
2487	Determinants of Severe Asthma – A Long-Term Cohort Study in Northern Sweden. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 1429-1439.	1.5	4
2488	Clusters based on immune markers in a Lithuanian asthma cohort study. <i>Journal of Asthma</i> , 2023, 60, 1123-1130.	0.9	0
2489	Impact of mepolizumab on exacerbations in the US Medicare population. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	2.0	1
2490	Breaking the vicious circle – the Asthma Referral Identifier (ReferID) tool. <i>Npj Primary Care Respiratory Medicine</i> , 2022, 32, .	1.1	5
2491	Use of FeNO to predict anti-IL-5 and IL-5R biologics efficacy in a real-world cohort of adults with severe eosinophilic asthma. <i>Journal of Asthma</i> , 2023, 60, 1162-1170.	0.9	5
2492	Documentation of smoking in scheduled asthma contacts in primary health care: a 12-year follow-up study. <i>Npj Primary Care Respiratory Medicine</i> , 2022, 32, .	1.1	1
2493	Monoclonal antibodies targeting small airways: a new perspective for biological therapies in severe asthma. <i>Asthma Research and Practice</i> , 2022, 8, .	1.2	5
2494	New options for severe asthma. <i>Meditinskii Sovet</i> , 2022, 16, 20-28.	0.1	0
2495	Advances in Evaluation and Treatment of Severe Asthma (Part One). <i>Medical Clinics of North America</i> , 2022, 106, 971-986.	1.1	0
2496	Risk of serious COVID-19 outcomes among adults and children with moderate-to-severe asthma: a systematic review and meta-analysis. <i>European Respiratory Review</i> , 2022, 31, 220066.	3.0	13
2497	Clinical impact and management of comorbidities in severe asthma. <i>Alergologia</i> , 2022, 3, 129.	0.1	0
2498	Epidemiology, treatment and health care resource use of patients with severe asthma in Germany – a retrospective claims data analysis. <i>Journal of Asthma</i> , 2023, 60, 1280-1289.	0.9	1

#	ARTICLE	IF	CITATIONS
2499	Clinical Features and Efficacy of Benralizumab in Patients with Blood Eosinophil Count Between 300 and 450 Cells/mm <sup>3</sup> : A Post Hoc Analysis from the ANANKE Study. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 1593-1604.	1.5	2
2500	Differential role of mucus plugs in asthma: Effects of smoking and association with airway inflammation. <i>Allergology International</i> , 2023, 72, 262-270.	1.4	4
2501	Therapeutic response to bronchial thermoplasty: toward feasibility of patient selection based on modeling predictions. <i>Journal of Applied Physiology</i> , 2022, 133, 1341-1348.	1.2	2
2502	Extrapolating Evidence-Based Medicine of AIT Into Clinical Practice in the United States. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 1100-1115.	2.0	3
2503	Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach. <i>Frontiers in Allergy</i> , 0, 3, .	1.2	2
2504	Asthma Management in Children. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 9-18.	2.0	10
2505	Efficacy and safety of tezepelumab in patients with uncontrolled disease while receiving maintenance therapy for moderate or severe asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 943-945.e2.	2.0	1
2506	Paroxysmal dyspnoea in asthma: Wheeze, ILO or dysfunctional breathing?. <i>Frontiers in Allergy</i> , 0, 3, .	1.2	2
2507	Pharmacokinetic equivalence of CTâ€³39 and reference omalizumab in healthy individuals: A randomised, double-blind, parallel-group, Phase 1 trial. <i>Clinical and Translational Allergy</i> , 2022, 12, .	1.4	2
2508	Leveraging genetic ancestry to study severe asthma exacerbations in an admixed population. <i>Thorax</i> , 2023, 78, 220-221.	2.7	0
2509	â€œLife-changingâ€ the experience of super-responders to biologics in severe asthma. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	4
2510	Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia. <i>BMC Pulmonary Medicine</i> , 2022, 22, .	0.8	2
2511	Asthma Exacerbations and Glucagon-Like Peptide-1 Receptor Agonists: a Review of the Current Evidence. <i>Pulmonary Therapy</i> , 2022, 8, 343-358.	1.1	2
2512	Exhaled nitric oxide in asthma: from diagnosis to management. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2023, 23, 29-35.	1.1	7
2513	Comparison between clinical trials and real-world evidence studies on biologics for severe asthma. <i>Journal of International Medical Research</i> , 2022, 50, 030006052211336.	0.4	4
2514	Bronchiectasis in severe asthma is associated with eosinophilic airway inflammation and activation. , 2022, , .		2
2515	Associations of symptoms of anxiety and depression with health-status, asthma control, dyspnoea, dysfunction breathing and obesity in people with severe asthma. <i>Respiratory Research</i> , 2022, 23, .	1.4	17
2516	Benralizumab therapy rapidly improved the quality of life in a woman with adult-onset non-allergic eosinophilic asthma. <i>Minerva Respiratory Medicine</i> , 2022, 61, .	0.1	0

#	ARTICLE	IF	CITATIONS
2517	Staphylococcal Enterotoxins sensitization is not associated with Omalizumab effectiveness. <i>Respiratory Medicine and Research</i> , 2022, , 100986.	0.4	0
2518	Consequences of severe asthma exacerbations. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2023, 23, 44-50.	1.1	3
2519	Association Between Blood Eosinophils and Neutrophils With Clinical Features in Adult-Onset Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 811-821.e5.	2.0	9
2520	Identifying and appraising outcome measures for severe asthma: a systematic review. <i>European Respiratory Journal</i> , 0, , 2201231.	3.1	8
2521	Long-Term Use of Maintenance Systemic Corticosteroids is Associated with Multiple Adverse Conditions in a Large, Real-World Cohort of US Adults with Severe Asthma. <i>Journal of Asthma and Allergy</i> , 0, Volume 15, 1753-1761.	1.5	2
2522	Bronchial eosinophils, neutrophils, and CD8 <sup>+</sup> T cells influence asthma control and lung function in schoolchildren and adolescents with severe treatment-resistant asthma. <i>Respiratory Research</i> , 2022, 23, .	1.4	3
2523	Protocol, rationale and design of the PHOLLOW cross-sectional and retrospective chart review study to assess the prevalence and characterize the patient profile, clinical features and disease burden of type-2 low severe asthma in routine care settings in Greece. <i>Pneumon</i> , 2022, 35, 1-13.	0.6	0
2524	Unmet Need for Oral Corticosteroids Use and Exacerbations of Asthma in Primary Care in Taiwan. <i>Biomedicines</i> , 2022, 10, 3253.	1.4	0
2525	Self-reported insufficient sleep is associated with clinical and inflammatory features of asthma: a prospective cohort study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, , .	2.0	3
2526	Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 885-895.e13.	2.0	6
2527	Systemic corticosteroids in asthma: A call to action from World Allergy Organization and Respiratory Effectiveness Group. <i>World Allergy Organization Journal</i> , 2022, 15, 100726.	1.6	10
2528	Efficacy of anti-IL4R,13 therapy in patients with severe bronchial asthma with concomitant chronic inflammatory nasal diseases. <i>Russian Journal of Allergy</i> , 0, , .	0.1	0
2529	Responsiveness of Inhaled Corticosteroid Treatment in Children with Asthma: The Role of rs242941 Polymorphism of CRHR1 Gene. <i>Pulmonary Therapy</i> , 2023, 9, 127-137.	1.1	2
2530	Diagnosis and treatment of adult asthma patients in Serbia: a 2022 experts group position statement. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 1133-1144.	1.0	0
2531	Using induced sputum method in clinical practice in patients with bronchial asthma. <i>Acta Biomedica Scientifica</i> , 2022, 7, 42-55.	0.1	0
2532	Dyslipidemia Is Associated With Worse Asthma Clinical Outcomes: A Prospective Cohort Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 863-872.e8.	2.0	6
2533	Test-retest reliability, construct validity and determinants of 6-minute walk test performance in adult patients with asthma. <i>Pulmonology</i> , 2022, , .	1.0	1
2534	Roles of real-world evidence in severe asthma treatment: challenges and opportunities. <i>ERJ Open Research</i> , 2023, 9, 00248-2022.	1.1	2

#	ARTICLE	IF	CITATIONS
2536	Prognostic Importance of Th1:Th2 (IL-1 $\beta$ /IL-10) Cytokine Ratio in Adult Onset-Bronchial Asthma. , 2023, , 176-187.		0
2537	Relevance of Smoking Habit in Severe Asthma Patients: Evidence from the Severe Asthma Network in Italy (SANI) Registry. Journal of Clinical Medicine, 2022, 11, 7465.	1.0	1
2538	Validation of the CaReQoL asthma: a patient reported outcome measure for monitoring the perceived effects of pulmonary rehabilitation in adult patients with severe refractory asthma. Respiratory Research, 2023, 24, .	1.4	0
2539	A parametric model to jointly characterize rate, duration, and severity of exacerbations in episodic diseases. BMC Medical Informatics and Decision Making, 2023, 23, .	1.5	0
2540	Geographical differences in the use of oral corticosteroids in patients with severe asthma in Spain: heat map based on existing databases analyses. BMC Pulmonary Medicine, 2023, 23, .	0.8	2
2541	High Level of Blood Eosinophils and Localization of Bronchiectasis in Patients with Severe Asthma: A Pilot Study. Journal of Clinical Medicine, 2023, 12, 380.	1.0	3
2542	Does the severity of asthma affect exercise capacity and daily physical activity?. Journal of Asthma, 2023, 60, 1622-1631.	0.9	2
2543	Factors to Consider in Prescribing Asthma Biologic Therapies to Children. Journal of Allergy and Clinical Immunology: in Practice, 2023, , .	2.0	6
2544	Analysis of Differentially Expressed MicroRNAs in Serum and Lung Tissues from Individuals with Severe Asthma Treated with Oral Glucocorticoids. International Journal of Molecular Sciences, 2023, 24, 1611.	1.8	5
2545	Periostin as an important biomarker of inflammatory phenotype T2 in Brazilian asthma patients. Jornal Brasileiro De Pneumologia, 0, , e20220040.	0.4	0
2546	Respiratory comorbidities in severe asthma: focus on the pediatric age. Expert Review of Respiratory Medicine, 0, , 1-13.	1.0	2
2547	Biomarkers in severe asthma: Identifying the treatable trait. Lung India, 2023, 40, 59.	0.3	1
2548	Oxidative Stress, Environmental Pollution, and Lifestyle as Determinants of Asthma in Children. Biology, 2023, 12, 133.	1.3	5
2550	Severe Fungal Asthma: A Role for Biologics and Inhaled Antifungals. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 TFS	1.5	4
2551	Pediatric obesity and severe asthma: Targeting pathways driving inflammation. Pharmacological Research, 2023, 188, 106658.	3.1	7
2552	Epidermal growth factor receptor in asthma: A promising therapeutic target?. Respiratory Medicine, 2023, 207, 107117.	1.3	1
2554	Ketamine Attenuates Airway Inflammation via Inducing Inflammatory Cells Apoptosis and Activating Nrf2 Pathway in a Mixed-Granulocytic Murine Asthma Model. Drug Design, Development and Therapy, 0, Volume 16, 4411-4428.	2.0	3
2555	IRAK-M Regulates Proliferative and Invasive Phenotypes of Lung Fibroblasts. Inflammation, 2023, 46, 763-778.	1.7	1

#	ARTICLE	IF	CITATIONS
2556	Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting. <i>Journal of Clinical Medicine</i> , 2023, 12, 985.	1.0	4
2557	A Multi-Center Study of the Prevalence and Characteristics of Eosinophilic Phenotype and High IgE Levels Among Chinese Patients with Severe Asthma. <i>Journal of Asthma and Allergy</i> , 0, Volume 16, 173-182.	1.5	1
2558	<i>Asthma and Allergy</i> , 2023, , 47-122.		0
2560	Clinical response to benralizumab can be predicted by combining clinical outcomes at 3â€¦months with baseline characteristics. <i>ERJ Open Research</i> , 0, , 00559-2022.	1.1	1
2561	Definitions of non-response and response to biological therapy for severe asthma: a systematic review. <i>ERJ Open Research</i> , 2023, 9, 00444-2022.	1.1	7
2562	Impact of Anti-IL5 Therapies on Patients with Severe Uncontrolled Asthma and Possible Predictive Biomarkers of Response: A Real-Life Study. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2011.	1.8	2
2563	Exploring the Interaction between Fractional Exhaled Nitric Oxide and Biologic Treatment in Severe Asthma: A Systematic Review. <i>Antioxidants</i> , 2023, 12, 400.	2.2	4
2564	Real-Life Effectiveness of Mepolizumab in Refractory Chronic Rhinosinusitis with Nasal Polyps. <i>Biomedicines</i> , 2023, 11, 485.	1.4	5
2565	Association of the Toll-like receptor 4 and NOX4 gene and protein levels in asthmatic patients with metabolic syndrome: A caseâ€”control study. <i>Journal of Research in Medical Sciences</i> , 2023, 28, 11.	0.4	0
2566	Toward a better understanding of severe asthma phenotypes in Latin America: results from the PREPARE study. <i>Current Medical Research and Opinion</i> , 2023, 39, 627-638.	0.9	0
2567	Prevalence and management of severe asthma in the Nordic countries: findings from the NORDSTAR cohort. <i>ERJ Open Research</i> , 2023, 9, 00687-2022.	1.1	6
2568	Evaluation of real-world mepolizumab use in severe asthma across Europe: the SHARP experience with privacy-preserving federated analysis. <i>ERJ Open Research</i> , 2023, 9, 00745-2022.	1.1	3
2569	Validation of Diagnostic Coding for Asthma in an Electronic Health Record System in Hong Kong. <i>Journal of Asthma and Allergy</i> , 0, Volume 16, 315-321.	1.5	3
2570	Number of patient-reported asthma triggers predicts uncontrolled disease among specialist-treated patients with severe asthma. <i>Annals of Allergy, Asthma and Immunology</i> , 2023, 130, 784-790.e5.	0.5	1
2571	A hierarchical cluster analysis of the psychological impact of the COVID-19 pandemic on Italian severe asthma patients. <i>Journal of Asthma</i> , 2023, 60, 1809-1815.	0.9	0
2572	Clinical Manifestations of Human Exposure to Fungi. <i>Journal of Fungi (Basel, Switzerland)</i> , 2023, 9, 381.	1.5	5
2573	Blockade of neutrophil extracellular traps ameliorates toluene diisocyanate-induced steroid-resistant asthma. <i>International Immunopharmacology</i> , 2023, 117, 109719.	1.7	2
2574	Transport and deposition of beclomethasone dipropionate drug aerosols with varying ethanol concentration in severe asthmatic subjects. <i>International Journal of Pharmaceutics</i> , 2023, 636, 122805.	2.6	4



#	ARTICLE	IF	CITATIONS
2575	Physiological estrogen levels are dispensable for the sex difference in immune responses during allergen-induced airway inflammation. <i>Immunobiology</i> , 2023, 228, 152360.	0.8	4
2576	Sputum Type 2 Markers Could Predict Remission in Severe Asthma Treated With Anti-IL-5. <i>Chest</i> , 2023, 163, 1368-1379.	0.4	15
2577	Asthma with recurrent middle lobe syndrome in children: Clinical features and lung function patterns. <i>Frontiers in Pediatrics</i> , 0, 11, .	0.9	0
2578	Asthma and Fixed Airways Obstruction: Real Life Aspects. <i>Advances in Respiratory Medicine</i> , 2023, 91, 66-73.	0.5	0
2579	Fixed-dose combination fluticasone/formoterol for asthma treatment in a real-world setting: meta-analysis of exacerbation rates and asthma control. <i>European Clinical Respiratory Journal</i> , 2023, 10, .	0.7	1
2580	Minimal clinically important difference for impulse oscillometry in adults with asthma. <i>European Respiratory Journal</i> , 2023, 61, 2201793.	3.1	6
2583	Bronchial epithelial cell transcriptional responses to inhaled corticosteroids dictate severe asthmatic outcomes. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 1513-1524.	1.5	3
2584	Validation of the Asthma Severity Scoring System (ASSESS) in the ALLIANCE Cohort. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 151, 1525-1535.e4.	1.5	1
2585	A real-life comparison of pulmonary and nasal outcomes in patients with severe asthma and nasal polyposis treated with T2-biologics. <i>World Allergy Organization Journal</i> , 2023, 16, 100746.	1.6	7
2586	Association between Exposure to Selected Heavy Metals and Blood Eosinophil Counts in Asthmatic Adults: Results from NHANES 2011â€“2018. <i>Journal of Clinical Medicine</i> , 2023, 12, 1543.	1.0	2
2589	Association between serum folate levels and blood eosinophil counts in American adults with asthma: Results from NHANES 2011â€“2018. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
2590	Incremental net monetary benefit of biologic therapies in moderate to severe asthma: a systematic review and meta-analysis of economic evaluation studies. <i>Journal of Asthma</i> , 2023, 60, 1702-1714.	0.9	4
2591	Patient characteristics and eligibility for biologics in severe asthma: Results from the Greek cohort of the RECOGNISE â€œreal worldâ€•study. <i>Respiratory Medicine</i> , 2023, 210, 107170.	1.3	0
2592	Safety, tolerability, and pharmacokinetics of a single ascending subcutaneous dose of <sc>GSK3772847</sc> in healthy participants. <i>Pharmacology Research and Perspectives</i> , 2023, 11, .	1.1	2
2593	Benralizumab Efficacy in Late Non-Responders to Mepolizumab and Variables Associated with Occurrence of Switching: A Real-Word Perspective. <i>Journal of Clinical Medicine</i> , 2023, 12, 1836.	1.0	4
2594	Clinical Implications of Longitudinal Blood Eosinophil Counts in Patients With Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 1805-1813.	2.0	2
2595	WAO consensus on DEfinition of Food Allergy SEverity (DEFASE). <i>World Allergy Organization Journal</i> , 2023, 16, 100753.	1.6	7
2596	Severe pediatric asthma therapy: Omalizumabâ€•A systematic review and meta-analysis of efficacy and safety profile. <i>Frontiers in Pediatrics</i> , 0, 10, .	0.9	2

#	ARTICLE	IF	CITATIONS
2598	International consensus statement on allergy and rhinology: Allergic rhinitis â€œ 2023. International Forum of Allergy and Rhinology, 2023, 13, 293-859.	1.5	60
2599	CCL5 is a potential bridge between type 1 and type 2 inflammation in asthma. Journal of Allergy and Clinical Immunology, 2023, 152, 94-106.e12.	1.5	8
2600	Poor Translatability of Biomedical Research Using Animals â€œ A Narrative Review. ATLA Alternatives To Laboratory Animals, 2023, 51, 102-135.	0.7	14
2601	Individualised risk prediction model for exacerbations in patients with severe asthma: protocol for a multicentre real-world risk modelling study. BMJ Open, 2023, 13, e070459.	0.8	0
2602	The Role of Neutrophils in the Occurrence and Development of Asthma. Advances in Clinical Medicine, 2023, 13, 3194-3199.	0.0	0
2603	Sphingosine-1-Phosphate Receptor 4 Attenuates Neutrophilic Airway Inflammation in Experimental Asthma via Repressing Proinflammatory Macrophage Activation. International Journal of Biological Sciences, 2023, 19, 1597-1615.	2.6	1
2604	Evaluation of lung function in a German single center cohort of young patients with sickle cell disease using EIT and standard techniques. Frontiers in Medicine, 0, 10, .	1.2	0
2605	Management of difficult-to-treat asthma in adolescence and young adults. Breathe, 2023, 19, 220025.	0.6	1
2606	Precision Medicine Intervention in Severe Asthma (PRISM) study: molecular phenotyping of patients with severe asthma and response to biologics. ERJ Open Research, 2023, 9, 00485-2022.	1.1	5
2607	Identifying the asthma research priorities of people with asthma, their carers and other stakeholders. Respiriology, 2023, 28, 636-648.	1.3	4
2608	The impact of anti-eosinophilic therapy on exercise capacity and inspiratory muscle strength in patients with severe asthma. ERJ Open Research, 2023, 9, 00341-2022.	1.1	0
2609	Reassessment of the Need for Asthmatic Patients for Biologic Treatment in a Tertiary Care Hospital. Cureus, 2023, , .	0.2	0
2610	Severe asthma guidelines in children and adolescents: A practical document for physicians. Pediatric Pulmonology, 0, , .	1.0	0
2611	Investigations of a combination of atopic status and age of asthma onset identify asthma subphenotypes. Journal of Asthma, 2023, 60, 1843-1852.	0.9	1
2612	Trait profiles in difficultâ€œtoâ€œtreat asthma: Clinical impact and response to systematic assessment. Allergy: European Journal of Allergy and Clinical Immunology, 2023, 78, 2418-2427.	2.7	2
2613	Trends of therapy in the treatment of asthma. Therapeutic Advances in Respiratory Disease, 2023, 17, 175346662311557.	1.0	6
2614	Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. Lancet Respiratory Medicine,the, 2023, 11, 591-601.	5.2	12
2615	Digital health in difficult-to-treat severe asthma. Lancet Respiratory Medicine,the, 2023, , .	5.2	0

#	ARTICLE	IF	CITATIONS
2617	Executive summary: Japanese guidelines for adult asthma (JGL) 2021. <i>Allergology International</i> , 2023, 72, 207-226.	1.4	10
2618	Peripheral blood eosinophilia in adult asthmatic patients and its association with the severity of asthma. <i>BMC Pulmonary Medicine</i> , 2023, 23, .	0.8	4
2620	What bothers severe asthma patients most? A paired patientâ€“clinician study across seven European countries. <i>ERJ Open Research</i> , 2023, 9, 00717-2022.	1.1	4
2621	miR-146a-3p as a potential novel therapeutic by targeting MBD2 to mediate Th17 differentiation in Th17 predominant neutrophilic severe asthma. <i>Clinical and Experimental Medicine</i> , 2023, 23, 2839-2854.	1.9	7
2622	Incidence rates of childhood asthma with recurrent exacerbations in the US Environmental influences on Child Health Outcomes (ECHO) program. <i>Journal of Allergy and Clinical Immunology</i> , 2023, 152, 84-93.	1.5	5
2623	Management of Chronic Asthma in Adults. <i>Primary Care - Clinics in Office Practice</i> , 2023, , .	0.7	0
2624	Delivery technology of inhaled therapy for asthma and COPD. <i>Advances in Pharmacology</i> , 2023, , .	1.2	0
2625	The Comorbid Patient in the Spotlight: Efficacy of Benralizumab on Chronic Rhinosinusitis with Nasal Polyp Outcomes in Presence of Severe Asthma. <i>Current Allergy and Asthma Reports</i> , 0, , .	2.4	0
2626	Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	18
2627	The use of systemic corticosteroids in asthma management in Latin American countries. <i>World Allergy Organization Journal</i> , 2023, 16, 100760.	1.6	1
2628	Relationships Between High-Resolution Computed Tomographic Features and Lung Function Trajectory in Patients With Asthma. <i>Allergy, Asthma and Immunology Research</i> , 2023, 15, 174.	1.1	0
2629	Characteristics of severe asthma patients on biologics: a real-life European registry study. <i>ERJ Open Research</i> , 2023, 9, 00586-2022.	1.1	1
2631	One-day systemic corticosteroid administration for asthma and future â€œshort burstsâ€“risk in real clinical practice. <i>Journal of Asthma</i> , 2023, 60, 1951-1959.	0.9	0
2632	A Real-World Study of Achievement Rate and Predictive Factors of Clinical and Deep Remission to Biologics in Patients with Severe Asthma. <i>Journal of Clinical Medicine</i> , 2023, 12, 2900.	1.0	13
2633	Cytokine-targeted therapies for asthma and COPD. <i>European Respiratory Review</i> , 2023, 32, 220193.	3.0	7
2684	<i>Chlamydia pneumoniae</i> and Childhood Asthma. <i>Infectious Diseases</i> , 0, , .	4.0	0
2707	Definition, Phenotyping of Severe Asthma, Including Cluster Analysis. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 239-252.	0.8	1
2708	Systems Biology in Asthma. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 215-235.	0.8	2

#	ARTICLE	IF	CITATIONS
2709	Heterogeneity of Treatment Response to Asthma. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 143-161.	0.8	1
2716	Approaches to Management of Asthma: Guidelines for Stepped Care and Self-Monitoring. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 355-375.	0.8	0
2717	Epidemiology of Asthma: Prevalence and Burden of Disease. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 3-23.	0.8	2
2764	Asthma and COPD: A Focus on Î²-Agonists â€œ Past, Present and Future. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	0.9	0
2767	Eosinophilic Lung Diseases. , 2023, , 1-26.		0
2773	Pediatric Asthma. , 2023, , 1-14.		0